Document:

exv10w13

 

Exhibit 10.13

LICENSE AGREEMENT

     THIS LICENSE AGREEMENT (this “Agreement”), dated as of October ___, 2003 (the “Effective
Date”), is entered into between Archemix Corp., a Delaware corporation, having a place of business
at 1 Hampshire Street, Cambridge, MA 02139 (“Archemix”), and Regado Biosciences, Inc., a Delaware
corporation, having a place of business at                                                             , (“Regado”).

     WHEREAS, Archemix owns or has rights in certain technology regarding aptamers and their
modifications; and

     WHEREAS, Regado desires to obtain a worldwide license under Archemix’s rights in such
technology to develop and commercialize Licensed Products for use in therapeutics.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained, the parties agree as follows:

	1	 	DEFINITIONS

	 	1.1	 	“Affiliate” shall mean, with respect to any Person, any other Person
which directly or indirectly controls, is controlled by, or is under common control
with, such Person. A Person shall be regarded as in control of another Person if it
owns, or directly or indirectly controls, at least fifty percent (50%) of the voting
stock or other ownership interest of the other Person, or if it directly or indirectly
possesses the power to direct or cause the direction of the management and policies of
the other Person by any means whatsoever.
	 
	 	1.2	 	“Anti-Fibrin Activity” shall mean the elimination or modulation of
fibrin deposition, platelet adhesion and/or platelet aggregation in humans.
	 
	 	1.3	 	“Anti-Fibrin Antidote Activity” shall mean the termination or
modulation of Anti-Fibrin Activity.
	 
	 	1.4	 	“Aptamers” shall mean oligonucleotides, including any structural
variations and modifications, derivatives, homologs, analogs and/or mimetics thereof,
identified through the SELEX Process.
	 
	 	1.5	 	“Commercial License” shall have the definition set forth in Section
2.1(b).
	 
	 	1.6	 	“Controlled” shall mean, with respect to a particular item of
information or intellectual property right, that the applicable Party owns or has a
license to such item or right and has the ability to grant to the other Party access to
and a license or sublicense (as applicable) under such item or rights as provided for
in this Agreement without violating the terms of any agreement or other arrangement
with any Third Party.
	 
	 	1.7	 	“Damages” shall mean any and all costs, losses, claims, liabilities,
fines, penalties, damages and expenses, court costs, and reasonable fees and

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

 

 

	 	 	 	disbursements of counsel, consultants and expert witnesses incurred by a Party
hereto (including any interest payments which may be imposed in connection
therewith).
	 
	 	1.8	 	“Excluded Aptamers” shall mean (a) [***], (b) [***], and (c) any
Aptamer directed to a target for use outside the Field and (d) the following targets:

	 	i.	 	[***];
	 
	 	ii.	 	[***];
	 
	 	iii.	 	[***];
	 
	 	iv.	 	[***];
	 
	 	v.	 	[***];
	 
	 	vi.	 	[***];
	 
	 	vii.	 	[***];
	 
	 	viii.	 	[***]; and
	 
	 	ix.	 	[***].

	 	1.9	 	“Field” shall mean the use of a Licensed Product for the treatment of
diseases or conditions in humans caused or characterized by factors involved in, and
the modulation of, fibrin deposition, platelet adhesion and/or platelet aggregation;
provided, however, that the Field shall not include the treatment of
any conditions or diseases of the [***] and [***], the [***] or the [***]. The Field
shall not include the diagnosis of any diseases or conditions nor any uses relating to
the [***].
	 
	 	1.10	 	“First Commercial Sale” shall mean, with respect to any Licensed
Product, the first sale for use or consumption by the general public of such Licensed
Product.
	 
	 	1.11	 	“Gilead-Archemix License Agreement” shall mean the License Agreement
Between Gilead Sciences, Inc. and Archemix Corp. dated October 21, 2001.
	 
	 	1.12	 	“Interested Party” shall mean Regado, Archemix or Gilead and
“Interested Parties” shall mean Regado, Archemix and Gilead.
	 
	 	1.13	 	“In Vitro Diagnostics” shall mean the use of the SELEX Process or
Aptamers identified through the use of the SELEX process in the assay, testing or
determination outside of a living organism, of a substance in a test material.
	 
	 	1.14	 	"In Vivo Diagnostic Agent” shall mean any Licensed Product containing
one or more Aptamers that is used for any human in vivo diagnostic purpose related to,

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

2

 

	 	 	 	inter alia, the identification, quantification or monitoring of the propensity
toward, or actual existence of, any disease state.
	 
	 	1.15	 	“Licensed IP Rights” shall mean, collectively, the Licensed Patent
Rights and the Licensed Know-How Rights.
	 
	 	1.16	 	“Licensed Know-How Rights” shall mean all trade secrets, know-how,
information and data Controlled by Archemix during the Term that is not generally known
(including, but not limited to, information and data regarding formulae, procedures,
protocols, techniques and results of experimentation and testing), which is necessary
or useful for Regado to practice within the Field any invention, composition of matter,
method or process claimed or disclosed in any issued patent or pending patent
application within the Licensed Patent Rights.
	 
	 	1.17	 	“Licensed Patent Rights” shall mean any and all patents or patent
applications Controlled during the Term by Archemix that are necessary or useful for
the performance of the SELEX Process or the manufacture, sale, offer for sale,
importation or use of Aptamers, excluding the Excluded Aptamers, within the Field,
including, without limitation, the Licensed SELEX Patent Rights; provided,
however, that patents and patent applications claiming the composition or use
of specific Aptamers shall not be included within the definition of “Licensed Patent
Rights” except to the extent they are included within the Licensed SELEX Patent Rights.
	 
	 	1.18	 	“Licensed Product” shall mean a product that contains an Aptamer, other
than an Excluded Aptamer, with Anti-Fibrin Activity, and that has, as another
component, a nucleic acid that has Anti-Fibrin Antidote Activity, wherein the
discovery, development, manufacture, use, sale or importation of such product would
infringe a Valid Claim within the Licensed Patent Rights but for the grant and
continuing validity of the license granted by Archemix to Regado in Section 2.1 hereof.
In addition, if Regado manufactures, uses, sells, offers for sale, has sold or imports
a product that would constitute a Licensed Product but for the fact that Regado did not
discover or develop the Aptamer contained within such product, then, that product shall
be deemed to be within the definition of the term “Licensed Product” for all purposes
hereunder. For avoidance of doubt, in addition to the foregoing requirements, a
product must have therapeutically significant levels of both Anti-Fibrin Activity and
Anti-Fibrin Antidote Activity in order to be a “Licensed Product.”
	 
	 	1.19	 	“Licensed SELEX Patent Rights” shall mean (a) those certain patent
applications and patents listed on Schedule A hereto and any patent or patent
application claiming priority therefrom; (b) all patents that have issued or in the
future issue from such patent applications, including utility, model and design patents
and certificates of invention; and (c) all divisionals, continuations,
continuations-in-part, reissues, renewals, extensions or foreign counterparts or
additions to any such patent applications and patents.

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

3

 

	 	1.20	 	“NDA” shall mean a New Drug Application, as defined in the United
States Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any
successor application thereto.
	 
	 	1.21	 	“Net Sales” shall mean, with respect to any Licensed Product, the
invoiced sales price of such Licensed Product billed to independent customers by Regado
and its Affiliates, less (a) credits, allowances, discounts and rebates to, and
chargebacks from the account of, such independent customers for spoiled, damaged,
out-dated, rejected or returned Licensed Product or bad debts; (b) actual freight and
insurance costs incurred by Regado in transporting such Licensed Product to such
customers; (c) cash, quantity and trade discounts and other price reductions; (d)
sales, use, value-added and other direct taxes incurred; and (e) customs duties,
surcharges and other governmental charges incurred by Regado in connection with the
exportation or importation of such Licensed Product.
	 
	 	1.22	 	“Party” shall mean Regado or Archemix and “Parties” shall mean
Regado and Archemix.
	 
	 	1.23	 	“Person” shall mean an individual, corporation, partnership, limited
liability company, trust, business trust, association, joint stock company, joint
venture, pool, syndicate, sole proprietorship, unincorporated organization,
governmental authority or any other form of entity not specifically listed herein.
	 
	 	1.24	 	“Phase III Trial” shall mean a clinical trial designed to demonstrate
the safety and efficacy of a Licensed Product as more fully defined in 21 CFR 312.21(c)
or any successor regulation thereto.
	 
	 	1.25	 	“Proprietary Information” shall mean, subject to the limitations set
forth in Section 9.1 hereof, any confidential information of a Party disclosed by such
Party to the other Party in the course of negotiating or performing under this
Agreement that is identified as confidential by the disclosing party at the time of its
disclosure.
	 
	 	1.26	 	“Radio Therapeutic” shall mean any Licensed Product for human
therapeutic use that contains one or more Aptamers that target specifically any
diseased tissue, cells or disease-specific molecules or any tissue or cells which are
affected by a disease or located in the close neighborhood of a disease process and
linked to or incorporates (a) radionucleotides or (b) any structure or elements which
develop therapeutic effects similar to the effect of linking or incorporating
radionucleotides after submission of any kind of radiation.
	 
	 	1.27	 	“Regado Improvements” shall mean any inventions, patentable or not,
information and/or data Controlled by Regado after the Effective Date and during the
term of this Agreement, that were derived from the practice of the Licensed IP Rights,
and that relate to (a) improvements in the SELEX Process and (b) improvements made to
the Licensed IP Rights.

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

4

 

	 	1.28	 	“Regado SELEX Technology” shall mean any know-how, technology,
inventions, information or data Controlled by Regado as of the Effective Date of this
Agreement or during the Term, that constitute a modification or improvement to the
SELEX Process.
	 
	 	1.29	 	“Research License” shall have the definition set forth in Section
2.1(a).
	 
	 	1.30	 	“Royalty Term” shall mean, as determined on a Licensed
Product-by-Licensed Product and country-by-country basis, the period of time commencing
on the date of the First Commercial Sale of such Licensed Product in such country, and
ending upon the expiration or termination of the last Valid Claim within the Licensed
Patent Rights that covers the development, manufacture, use, sale or importation into
such country of such Licensed Product.
	 
	 	1.31	 	“SELEX Process” means any process for the identification of a nucleic
acid, which process is disclosed in or falls within the claimed scope of the Licensed
SELEX Patent Rights.
	 
	 	1.32	 	“Sublicense Income” shall mean the consideration payable to Regado in
connection with a sublicense of any or all of the rights granted hereunder to Regado by
Archemix, including without limitation, any and all upfront payments, annual fees,
milestone payments, royalties but excluding (a) payment for research or development to
be conducted by Regado or its Affiliates for the benefit of the Sublicensee to the
extent not in excess of the actual direct cost of performing such research and
development, and (b) proceeds from the sale and issuance of Regado securities to a
Sublicensee to the extent not in excess of the fair market value of said securities.
	 
	 	1.33	 	“Sublicensee” shall mean a Third Party to whom Regado grants a
sublicense of any or all of the rights granted hereunder to Regado by Archemix
	 
	 	1.34	 	“Territory” shall mean the world.
	 
	 	1.35	 	“Third Party” shall mean any Person other than Archemix, Regado and
their respective Affiliates.
	 
	 	1.36	 	“URC License Agreement” shall mean the Restated Assignment and License
Agreement, dated July 17, 1991, by and between University Research Corporation and
Gilead as successor in interest to NeXstar.
	 
	 	1.37	 	“UTC” shall mean University Technology Corporation, the successor to
the University Research Corporation.
	 
	 	1.38	 	“Valid Claim” shall mean (a) a claim of an issued and unexpired patent
within the Licensed Patent Rights, which has not been held permanently revoked, found
unenforceable or invalid by a decision of a court or other governmental agency of
competent jurisdiction, unappealable or unappealed within the time allowed for appeal,
and which has not been admitted to be invalid or unenforceable through

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

5

 

reissue or disclaimer or otherwise, or (b) a claim of a pending patent application
so long as there exists an issued and unexpired patent meeting the criteria of
clause (a) above that includes a claim covering the discovery, development,
manufacture, use, sale or importation into the country of the Licensed Product.

	2	 	LICENSE GRANT

	 	2.1	 	License Grants to Regado. Subject to the terms and conditions set
forth herein (including Section 2.5), Archemix hereby grants to Regado the following
licenses during the term of this Agreement (a) a non-exclusive, non-sublicenseable
license under the Licensed IP Rights, to use the SELEX Process, for the purpose of
identifying and developing anti-protein Aptamers for use solely as part of a Licensed
Product (the “Research License”) and (b) an exclusive, worldwide license under the
Licensed IP Rights, with the right to grant Sublicenses as set forth in Section 2.2, to
develop, manufacture, use, sell, offer for sale, have sold, and import Licensed
Products solely for use in the Field (the “Commercial License”). For the avoidance of
doubt the Research License shall include the right to test potential Licensed Products
in animal.
	 
	 	2.2	 	Sublicense Rights. Subject to Archemix’s rights under Article 8,
Regado shall have the right to grant sublicenses solely under the Commercial License.
Regado shall give Archemix prompt written notice of each sublicense under this
Agreement along with a copy of such sublicense. Any such sublicense shall contain
provisions for the assignment to Archemix of Regado’s interest therein upon termination
of this Agreement, subject to the last sentence of this Section 2.2, unless the
termination of this Agreement arises out of the action or inaction of such Sublicensee
or the Sublicensee is then in breach of its obligations under such sublicense, in which
case Archemix, at its option, may terminate such sublicense. Notwithstanding this, if
in Regado’s opinion, sublicensee did not materially breach the agreement, Regado may
challenge the termination under the provisions of Section 8.3. Each sublicense shall
also contain provisions which obligate such Sublicensee to comply with terms,
conditions, agreements and obligations that are consistent with the terms, conditions,
agreements and obligations to which Regado is subject under this Agreement. Archemix
hereby agrees to accept such assignment and that such sublicense, as assigned, will
remain in full force and effect, provided that Archemix shall have no obligation
thereunder except to maintain the continued effectiveness of the sublicense.
	 
	 	2.3	 	Negative Covenants.

	 	2.3.1	 	Without limiting any of the other terms, conditions and
limitations contained herein, Regado shall not (a) use the SELEX Process or
otherwise select Aptamers against targets for use outside the Field, (b)
perform any research or development on any Aptamer for use outside the Field
(c) provide Aptamers for use outside the Field to any party that does not
possess a valid license to the Licensed SELEX Patent Rights for the intended
use of the Aptamer, except for evaluation of the aptamer as a

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

6

 

	 	 	 	therapeutic; (d) make, use, sell, offer for sale, import or export any
Licensed Products containing any Excluded Aptamers, (e) make, use, sell,
offer for sale, import or export any Excluded Aptamers, or (f) make, use,
sell, offer for sale, import or export any Aptamers for In Vitro
Diagnostics, as In Vivo Diagnostic Agents or as Radio Therapeutics.
	 
	 	2.3.2	 	Subject to the terms and conditions set forth herein, Archemix
hereby agrees not to develop, or grant to any Third Party the right, under the
Licensed IP Rights, to develop therapeutic aptamers to modulate the Factor
[***] or the Factor [***] [***]. The foregoing restriction shall terminate on
the first to occur of the following events: (a) the [***] anniversary of the
Effective Date; (b) at any time after the [***] anniversary of the Effective
Date upon [***] months prior written notice from Archemix to Regado, or (c) on
a target-by-target basis, if Regado discontinues active development of Licensed
Products against aptamers used to modulate Factor [***] or the Factor [***].

	 	2.4	 	License Grants to Archemix.

	 	2.4.1	 	Subject to the terms and conditions hereof, Regado hereby
grants to Archemix, a royalty-free, paid-up, and non-exclusive nontransferable
license under Regado’s intellectual property rights relating to the Regado
Improvements (a) to conduct internal research solely within Archemix.
	 
	 	2.4.2	 	Subject to the terms and conditions set forth herein
(including Section 2.5), Regado hereby grants to Archemix a royalty-free,
paid-up, non-exclusive license, with the right to grant sublicenses solely as
provided in this Section 2.4.2, under intellectual property rights Controlled
by Regado, as of the Effective Date and during the Term, that relate to Regado
SELEX Technology, for any and all uses outside of the Field. The license
granted under this Section 2.4.2 shall remain in effect following the
expiration or termination of this Agreement for any reason other than a
termination by Regado under Section 11.2 due to a material breach by Archemix.

	 	2.5	 	Third Party Agreements. The Parties each hereby acknowledge that
certain of the intellectual property rights which are subject to the licenses granted
herein may be Controlled by the Party granting such license (the “Licensor” and the
other Party under such circumstances is the “Licensee”) by virtue of a license (a
“Third Party Agreement”) granted to the Licensor by a Third Party. Except as otherwise
set forth in this Section 2.5, the Parties hereby agree to pay, either to the Licensor
or directly to such Third Party as the Licensor shall determine, any and all
incremental costs (including without limitation, milestones and royalties) required to
be paid under a Third Party Agreement due to the grant of the license of such rights to
the Licensee or the exercise of those rights by the Licensee (such amounts are “Third
Party Royalties”). Notwithstanding the foregoing, and subject to the terms and
conditions set forth herein, Archemix shall be responsible for all

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

7

 

amounts payable to Third Parties for the rights to the Licensed SELEX Patent Rights
and Regado shall be responsible for all amounts payable to Third Parties for the
rights to the intellectual property licensed to Regado by Duke University (or any of
its Affiliates or agents). The Parties further agree (a) to provide notice and
copies to each other of all Third Party Agreements that require the payment of Third
Party Royalties (with terms and conditions that are not relevant to the Licensee
redacted), (b) to refrain from breaching, or causing the Licensor to breach, any
Third Party Agreements, and (c) when acting as Licensor, to refrain from charging or
attempting to charge any fee or royalty to the Licensee in connection with the grant
or exercise of such license, other than Third Party Royalties, or the amounts due
under Section 3 of this Agreement. The Parties further acknowledge and agree that
either of them, when acting as Licensee, may, by notice to the Licensor, reject or
terminate the licenses granted to them hereunder with respect to rights under any
Third Party Agreement(s), at any time during the term, without effecting the ongoing
effectiveness of this Agreement.

	3	 	TECHNOLOGY ACCESS FEE; ROYALTIES; MILESTONES

	 	3.1	 	Technology Access Fee. In consideration of the licenses and rights
granted to Regado herein, Regado shall, as of the date immediately preceding the
closing (the “Closing”) of the first equity financing of Regado in which Regado is
assigned a pre-money valuation of not less than [***] dollars ($[***]), issue to
Archemix fully-paid and non-assessable shares of common stock of Regado equal to [***]
percent ([***]%) of the total number of equity shares of Regado, on a fully diluted
basis, immediately prior to the issuance of shares at the Closing. Regado shall
deliver written notice of the Closing to Archemix at least [***] business days prior to
such Closing in accordance with the notice provisions contained in Section 14.1 of this
Agreement. Archemix and Regado shall enter into such agreements relating to the
issuance of the common stock as are customary under such circumstances.
	 
	 	 	 	For the purpose of this Agreement, “fully diluted basis” shall mean the aggregate of
(a) the number of shares of common stock issued and outstanding on the determination
date, (b) the number of shares of common stock issuable upon exercise, exchange or
conversion of all exercisable, exchangeable or convertible securities outstanding on
the determination date, assuming such securities were exercised, exchanged or
converted on the determination date (without regard to whether such securities are
actually exercisable, exchangeable or convertible on the determination date) and (c)
the number of shares of common stock issuable pursuant to any other obligation or
agreement of, or right granted by, Regado, whether vested or unvested, contingent or
otherwise.
	 
	 	3.2	 	Royalty Payments. In consideration for the licenses granted to Regado
herein, Regado shall pay royalties to Archemix equal to [***] percent ([***]%) of Net
Sales of Licensed Products beginning with the First Commercial Sale by Regado or its
Affiliates and continuing during the Royalty Term, and (ii) [***] percent

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

8

 

([***]%) of all Sublicense Income received by Regado or its Affiliates during the
Term.

If Regado grants a sublicense to a Third Party to develop therapeutic aptamers that
modulate the Factor [***] or the Factor [***], then Regado shall pay to Archemix, an
additional [***] percent ([***]%) of all Sublicense Income received by Regado in
connection with that sublicense, for a total of [***] percent ([***]%) of such
Sublicense Income. However, if Regado grants this sublicense after the completion
of a [***], or if Archemix terminates the period described under Section 2.3.2 prior
to [***] anniversary of the Effective Date by notice to Regado, then such additional
[***] percent ([***]%) will not be payable hereunder.

As further consideration for the term of exclusivity granted in Section 2.3.2,
Regado shall provide Archemix with an additional [***] percent ([***]%) of all
Sublicense Income. If Archemix terminates the period described under Section 2.3.2
prior to [***] of the Effective Date by notice to Regado, then such additional [***]
percent ([***]%) will not be payable hereunder.

	 	3.3	 	Milestones. In consideration for the licenses granted to Regado
herein, Regado shall pay the amounts indicated below to Archemix within [***] days
following the achievement of each of the events indicated below for Licensed Products
developed by Regado to achieve each such event:

	 	 	 
	Event	 	Milestone Payment Amount
	[***]*

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]

*[***] is [***] upon [***] of the [***] in such [***].

Regado shall provide no less than [***] days prior written notice to Archemix of the
anticipated achievement of each of the above-described milestone events with respect
to each Licensed Product and written notice of the actual achievement of each of the
above milestone events with respect to each Licensed Product no later than [***]
days following each such achievement.

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

9

 

	4	 	ROYALTY REPORTS AND ACCOUNTING

	 	4.1	 	Royalty Reports. Following the First Commercial Sale of a Licensed
Product and continuing throughout the term, Regado shall furnish to Archemix a [***]
written report showing in reasonably specific detail the calculation of royalties owing
with respect to the sale of Licensed Products by Regado and its Affiliates for the
prior quarter. With respect to sales of Licensed Products invoiced in United States
dollars, all amounts shall be expressed in United States dollars. With respect to
sales of Licensed Products invoiced in a currency other than United States dollars, all
amounts shall be expressed in the domestic currency of the party making the sale
together with the United States dollar equivalent. The United States dollar equivalent
shall be calculated using the average of the exchange rate (local currency per US$1)
published in The Wall Street Journal, Eastern Edition, under the heading “Currency
Trading” on the last business day of each month during the applicable calendar quarter.
Reports shall be due on the [***] day following the close of each [***]. Regado shall
also furnish to Archemix a report promptly upon receipt of any Sublicense Income,
showing in reasonably specific detail the calculation of Sublicense Income (including
any deductions from the gross amount received from the Sublicensee) and the amounts
owing with respect to such Sublicense Income. Regado shall keep complete and accurate
records in sufficient detail to enable the royalties payable hereunder to be
determined.
	 
	 	4.2	 	Audits.

	 	4.2.1	 	Upon the written request of Archemix and not more than [***]
in each [***], Regado shall permit an independent certified public accounting
firm of nationally recognized standing selected by Archemix and reasonably
acceptable to Regado, at Archemix’ expense, to have access during normal
business hours to such of the records of Regado as may be reasonably necessary
to verify the accuracy of the royalty reports for any year ending not more than
[***] months prior to the date of such request. The accounting firm shall
disclose to Archemix only whether or not the reports are correct and the amount
of any discrepancies. No other information shall be shared.
	 
	 	4.2.2	 	If such accounting firm concludes that additional royalties
were owed during such period, Regado shall pay the additional royalties within
[***] days of the date Archemix delivers to Regado such accounting firm’s
written report so concluding. The fees charged by such accounting firm shall
be paid by Archemix; provided, however, if the audit discloses
that the royalties payable by Regado for the audited period are more than [***]
percent ([***]%) of the royalties actually paid for such period, then Regado
shall, in addition to paying the overdue amounts, pay the reasonable fees and
expenses charged by such accounting firm.

	 	4.3	 	Confidential Financial Information. Archemix shall treat all financial
information subject to review under this Section 5 as confidential, and shall cause its

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

10

 

accounting firm to retain all such financial information in confidence under Section
9 below.

	5	 	PAYMENT TERMS

	 	5.1	 	Payment Terms. Royalties shown to have accrued by each royalty report
provided for under Section 5.1 above shall be due on the date such royalty report is
due. Payment of royalties in whole or in part may be made in advance of such due date.
Overdue amounts shall bear interest at the rate of [***] percent ([***]%) per month.
Acceptance of overdue amounts plus interest shall not constitute a waiver by Archemix
of any other remedies it may have hereunder or otherwise.
	 
	 	5.2	 	Exchange Control. If at any time legal restrictions prevent the prompt
remittance of part or all royalties with respect to any country where a Licensed
Product is sold, Regado shall promptly notify Archemix of such fact and shall make such
payments by depositing the amount thereof in local currency in a bank or other
depository institution in such country indicated by Archemix.
	 
	 	5.3	 	Withholding Taxes. Regado shall be entitled to deduct the amount of
any withholding taxes, value-added taxes or other taxes, levies or charges with respect
to such amounts, payable by Regado, its Affiliates or Sublicensees, or any taxes
required to be withheld by Regado, its Affiliates or Sublicensees, to the extent
Regado, its Affiliates or Sublicensees pay to the appropriate governmental authority on
behalf of Archemix such taxes, levies or charges. Regado shall use reasonable efforts
to minimize any such taxes, levies or charges required to be withheld on behalf of
Archemix by Regado, its Affiliates or Sublicensees. Regado promptly shall deliver to
Archemix proof of payment of all such taxes, levies and other charges, together with
copies of all communications from or with such governmental authority with respect
thereto.
	 
	 	5.4	 	Limitations Imposed by Law. If any amount payable under Section 3 or
Section 5.1 are limited by any applicable laws, regulations or government order, then
the amount payable shall be deemed to be the highest amount payable under such law,
regulation or government order.

	6	 	FUNDING REQUIREMENT

	 	6.1	 	Funding Requirement. Regado shall close an equity financing, or series
of financings, having aggregate proceeds of at least [***] dollars ($[***]) on or
before the first anniversary of the Effective Date. Failure of Regado to close such a
financing in accordance with this Section 6.1 will constitute a material breach of this
Agreement.

	7	 	PROGRESS REPORT AND COMMERCIAL APPLICATION

	 	7.1	 	Progress Report. On or before February 28 and August 30 of each year,
commencing as of February 28, 2004 and ending on August 30 of the calendar

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

11

 

	 	 	 	year following the calendar year in which Regado, its Affiliates or Sublicensees
first begins to market any Licensed Product, Regado shall provide a semi-annual
progress report to Archemix, each report covering the [***] month period preceding
the due date of the report. Thereafter, Regado shall provide such reports on an
annual basis covering the [***] month period preceding the due date of the report.
Each report shall describe any Regado Improvements, notice of any patents filed by
Regado in connection with any Regado Improvements and the progress made by Regado,
its Affiliates or Sublicensees toward the commercial development of any Licensed
Products or services utilizing the Licensed IP Rights. Such report shall include at
a minimum, information reasonably sufficient to enable Archemix to satisfy its
reporting obligations to Gilead under the Gilead-Archemix License Agreement with
respect to this Agreement, including any reporting obligations of the U.S.
Government, and to assess the progress made by Regado toward meeting the diligence
requirements of Section 7.2 below.
	 
	 	7.2	 	Commercial Application. Regado, either directly or with and through
the efforts of its Affiliates and Sublicensees, shall at all times use commercially
reasonable efforts to proceed with the development, manufacture and sale of Licensed
Products, including, without limitation, maintaining sufficient facilities, resources
and personnel to fulfill its obligations under this Agreement. In the event that
Regado, its Affiliates and Sublicensees cease reasonable efforts to develop the
commercial applications of the Licensed Products for a period of at least [***] months
Archemix will have the option, at its sole discretion, to terminate this Agreement
pursuant to Section 11.2 below. In such event, Archemix may exercise its option;
provided, however, that (a) Archemix delivers advance written notice of
its decision to exercise such option to force a reversion of the technology to
Archemix, and (b) for a period of [***] months following Regado’s receipt of such
notice, Regado, its Affiliates, and Sublicensees, shall have the right and opportunity
to cure the alleged cessation of such reasonable commercial development. Further, if
Regado or its sublicensee disagrees that it has ceased reasonable efforts to
commercialize a Licensed Product, or disagrees that it has not sufficiently cured a
cessation of reasonable efforts, it can request arbitration of the termination decision
under the terms of Section 8.3 by written notice to Archemix within [***] month of a
written notice of termination. Regado acknowledges and agrees that under the URC
License Agreement and the Gilead-Archemix License Agreement, Archemix rights in the
Licensed IP Rights may revert to Gilead or the UTC if Archemix, its Affiliates and all
assignees and sublicensees cease reasonable efforts to develop the commercial
applications of the Licensed Products and services utilizing the Licensed IP Rights.
	 
	 	 	 	Regado further acknowledges and agrees that, in the event of any termination of the
URC License Agreement, the licenses granted to Regado hereunder shall remain in full
force and effect in accordance with Section 3.4 of the URC License Agreement,
provided that Regado is not then in breach of this Agreement and Regado agrees to be
bound to UTC as the licensor under the terms and conditions of this Agreement.

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

12

 

Regado further acknowledges and agrees that, in the event of any termination of the
Gilead-Archemix License Agreement, the licenses granted to Regado hereunder shall
remain in full force and effect in accordance with Section 2.3 of the
Gilead-Archemix License Agreement provided that Regado agrees to be bound to Gilead
as the licensor under the terms and conditions of this Agreement and provided that
if the termination of the Gilead-Archemix License Agreement arises out of the action
or inaction of Regado, Gilead, at its option, may terminate such license.

	8	 	ARCHEMIX RIGHT OF FIRST REFUSAL

	 	8.1	 	Partnering Rights. Regado shall have the sole and exclusive right to
develop and commercialize the Licensed Products worldwide and to enter into such
agreements with respect to the transfer of such rights as it deems appropriate in its
sole discretion. However, if and to the extent that Regado finalizes the terms of a
collaboration agreement with one or more Third Parties (a “Partnering Agreement”)
concerning part or all of the development and commercialization of one (1) or more
Licensed Products (each a “Partnered Product”), Regado shall, prior to entering into a
binding agreement, give written notice (a “Collaboration Agreement Notice”) to Archemix
that shall include a description of the other party and a statement of the proposed,
material terms for the Partnering Agreement (the “Proposed Terms”).
	 
	 	8.2	 	Good Faith Determination and Exercise of Rights. Upon receipt of the
Collaboration Agreement Notice, Archemix shall have [***] days to determine in good
faith, subject to due diligence, whether the Proposed Terms are in keeping with terms
that are customary in the industry at that time for similar deals between
similarly-situated parties. If Archemix makes such a determination, then Archemix
shall provide prompt written notice to Regado of that determination and Regardo shall
be free, for the next [***] months, to enter into a Partnering Agreement with the party
identified in the Collaboration Agreement Notice on the Proposed Terms. In the event
that Archemix determines that the Proposed Terms are not in keeping with terms that are
customary in the industry at that time for similar deals between similarly-situated
parties, then Archemix shall provide prompt written notice of that determination to
Regado and Regado shall have a period of [***] days to agree with such determination or
to initiate arbitration of that dispute as set forth in Section 8.3. If either (a)
Regado agrees with Archemix’ determination that the Proposed Terms are not in keeping
with terms that are customary in the industry at that time for similar deals between
similarly-situated parties, or (b) the arbitrator makes such a determination in
accordance with Section 8.3, then Archemix shall have the option, to be exercised
within [***] days, to either enter into a Partnering Agreement with Regado on the
Proposed Terms or Archemix may waive such right and allow Regado to enter into a
Partnering Agreement with the party identified in the Collaboration Agreement Notice on
the Proposed Terms at any time within the next [***] months. If the arbitrator
determines pursuant to Section 8.3 that the Proposed Terms are in keeping with terms
that are customary in the industry at that time for

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

13

 

	 	 	 	similar deals between similarly-situated parties, then Regado shall be free to enter
into a Partnering Agreement with the party identified in the Collaboration Agreement
Notice on the Proposed Terms at any time within the next [***] month period. If, in
the event that Regado is permitted by the terms of this Section 8.2 to enter into a
Partnering Agreement with a Third Party within a [***] month period, and Regado and
such Third Party fail to both execute and deliver a Partnering Agreement containing
the Proposed Terms within such [***] month period, then Regado’s right to enter into
such an agreement shall expire and the proposed Partnered Products shall again
become subject to Archemix’s rights as described herein. Any Partnering Agreement
entered into in violation of Section 8.1 or this Section 8.2 shall be deemed a
material breach of this agreement.
	 
	 	8.3	 	Arbitration. If Regado seeks arbitration of a dispute under Section
8.2 or either Archemix or Regado seeks arbitration under any other section of this
agreement that provides for arbitration of a dispute, the arbitration shall be
conducted in accordance with the rules of the American Arbitration Association in
effect at that time. The arbitration shall be conducted so as to be concluded within
[***] days from the initiation of the proceeding. The arbitration shall be overseen by
a panel of [***] arbitrators with experience in the bio-pharmaceutical field. Each
Party shall choose [***] arbitrator and the [***] so chosen shall choose the [***]
arbitrator. The Parties shall bear their own internal costs (including their
respective legal fees) in connection with the arbitration and shall share equally the
fees and expenses of the arbitration. The arbitration shall take place in New York.

	9	 	CONFIDENTIALITY AND PUBLICITY

	 	9.1	 	Proprietary Information, Exceptions. Each Party will maintain all
Proprietary Information of the other Party received by it under this Agreement in trust
and confidence and will not disclose any such Proprietary Information of the other
Party to any Third Party or use any such Proprietary Information of the other Party for
any purposes other than those necessary or permitted for performance under this
Agreement without the express prior written permission of the other Party. Neither
Party shall use Proprietary Information of the other Party for any purpose or in any
manner that would constitute a violation of any laws or regulations, including without
limitation the export control laws of the United States. Neither Party shall disclose
Proprietary Information of the other Party to any employee, agent, consultant,
Affiliate, or sublicensee who does not have a need for such information. To the extent
that disclosure is authorized by this Agreement, the disclosing Party will obtain prior
agreement, from its employees, directors, agents, consultants, Affiliates, sublicensees
or clinical investigators to whom disclosure is permitted to be made, to obligations to
hold in confidence and not make use of such Proprietary Information of the other Party
for any purpose other than those permitted by this Agreement, that are at least as
restrictive as those of this Section 9.1. Each Party will use at least the same
standard of care as it uses to protect its own Proprietary Information of a similar
nature to ensure that such employees, agents, consultants and clinical investigators do
not disclose or make any unauthorized use of Proprietary Information of the other
Party, but no

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

14

 

less than reasonable care. Each Party will notify the other Party promptly upon
discovery of any unauthorized use or disclosure of the Proprietary Information of
the other Party. Notwithstanding the above, the parties hereby grant to each other
permission to make reasonable disclosures to potential investors or collaborators to
facilitate business discussions subject to such investor or collaborator entering
into a confidentiality agreement of similar scope to this Section 9.

Proprietary Information shall not include any information that the receiving Party
can demonstrate by competent written evidence:

	 	i.	 	is now, or hereafter becomes, through no act or
failure to act on the part of the receiving Party, its employees or
contractors in breach hereof, generally known or available;
	 
	 	ii.	 	is known by the receiving Party at the time of
receiving such information, as evidenced by its contemporaneous written
records;
	 
	 	iii.	 	is hereafter furnished to the receiving Party
by a Third Party, as a matter of right and without restriction on
disclosure; or
	 
	 	iv.	 	is independently developed by the receiving
Party without any breach of this Agreement, as shown by independent,
contemporaneous, written records.

	 	9.2	 	Authorized Disclosure. Notwithstanding any other provision of this
Agreement, each Party may disclose Proprietary Information if such disclosure:

	 	i.	 	is in response to a valid order of a court or
other governmental body of the United States or a foreign country, or
any political subdivision thereof; provided, however,
that the receiving Party shall first have given notice to the other
Party hereto to allow the other Party the opportunity to obtain a
protective order, with the reasonable cooperation of the receiving
Party as necessary, requiring that the Proprietary Information so
disclosed be used only for the purposes for which the order was issued;
	 
	 	ii.	 	is otherwise required by governmental law, rule
or regulation, including without limitation rules or regulations of the
U.S. Securities and Exchange Commission, or by rules of the National
Association of Securities Dealers; provided, however,
that the receiving Party shall first have given notice to the other
Party hereto in order to allow such Party the opportunity to seek
confidential treatment of the Proprietary Information; or
	 
	 	iii.	 	is otherwise necessary to prosecute or defend
litigation or comply with applicable governmental regulations or
otherwise enforce obligations under this Agreement, but only to the
extent that any such disclosure is necessary for such enforcement.

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

15

 

	 	9.3	 	Return of Proprietary Information. Upon the termination or expiration
of this Agreement, each Party shall, at the other Party’s option, promptly return or
destroy all Proprietary Information received by it from such other Party and shall
certify in writing to such other Party the completion thereof.
	 
	 	9.4	 	Publicity. Neither Party shall make a public announcement of this
Agreement or the relationship between the Parties or Interested Parties without the
other Party’s prior written consent. The Parties intend to issue a mutually agreed
upon press release within thirty (30) days after the Effective Date.

	10	 	PATENTS

	 	10.1	 	Prosecution and Maintenance. Archemix shall be solely responsible for
and shall control, at its sole cost, the preparation, filing, prosecution and
maintenance of the Licensed Patent Rights.
	 
	 	10.2	 	Enforcement.

	 	10.2.1	 	Notice. Each Party shall promptly notify the other in writing upon
becoming aware of any actual or potential infringement or misappropriation of
any Licensed IP Rights by Third Parties within the Territory and shall provide
any information available to that Party relating to such actual or potential
infringement or misappropriation. Regado shall have no rights with respect to
any infringement or misappropriation of Licensed IP Rights that occurs outside
of the Field except the right to receive notice pursuant to this Section
10.2.1; provided however, that, to the extent within the
control of Archemix, Archemix shall not enter into any settlement, consent
judgment or other voluntary final disposition with respect to any such
infringement or misappropriation if it would have a material adverse effect on
any Licensed IP Rights within the Field without the prior consent of Regado,
which consent shall not be unreasonably withheld.
	 
	 	10.2.2	 	Enforcement of Licensed Patent Rights. Within 60 days of receipt of
notice under Section 10.2.1 of any infringement of Licensed Patent Rights
within the Field or with respect to any Licensed Products within the Field, the
Parties shall confer to determine whether to bring suit (or take other
appropriate legal action) and what actions to take (including which patents
will be asserted) against the actual, alleged or threatened infringement. If
the Parties can not agree on how to proceed, no suit shall be brought by either
Party pending submission of the matter to arbitration under the provisions of
Section 8.3. Regado shall have the primary right, but not the obligation, to
initiate, prosecute and control any action with respect to such infringement,
by counsel of its own choice, to secure the cessation of the infringement or to
enter suit against the infringer; provided, however, that in
the event the validity or enforceability of any Licensed Patent Right is
challenged, or is otherwise at issue in such an action, then Archemix

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

16

 

shall have the right, at its discretion, to assume control of this part of
action, including without limitation, all aspects of claim construction,
with counsel of its own choice.. In any case controlled by Regado, Archemix
and/or Gilead shall have the right to participate in any such action and to
be represented by counsel of its own choice and at its own expense. If
Regado fails to exercise its right to bring an action or proceeding to so
enforce a Licensed Patent Right within a period of [***] days after receipt
of written notice of infringement of such Licensed Patent Right, then
Archemix and/or Gilead (as they shall determine) shall have the right to
bring and control any such action by counsel of their own choice and at its
own expense. In such an event, Gilead shall have the right to extend the
right to participate in and control, as applicable, any such action to its
Affiliates and sublicensees, as Gilead in its sole discretion deems
necessary to satisfy its obligations to such other sublicensees of the
Licensed Patent Rights. If any such action or proceeding is brought by an
Interested Party hereunder, the other Interested Parties agree to be joined
as necessary as party plaintiffs and to give the Interested Party bringing
suit reasonable assistance and authority to control, file and prosecute the
suit as necessary, at the sole expense of the Interested Party bringing
suit. The costs and expenses of the Interested Party bringing suit under
this Section 10.2.2 (including the internal costs and expenses specifically
attributable to such suit) shall be reimbursed first out of any damages or
other monetary awards recovered in favor of the Interested Parties, and any
remaining damages shall be paid to the Interested Party that controlled such
action. No settlement or consent judgment or other voluntary final
disposition of a suit under this Section 10.2.2 relating to a Licensed
Patent Right may be entered into without the consent of the Interested
Parties not controlling such action, such consent not to be unreasonably
withheld, delayed or conditioned. If either of the Interested Parties not
controlling the action do not consent to the proposed settlement, consent
judgement or other voluntary final disposition, the Interested Party
controlling the disposition can request expedited arbitration of the failure
to consent under the terms of Section 8.3. The Interested Party(ies) not
prevailing in the arbitration shall pay the cost of the arbitration.

	 	10.3	 	Infringement of Third Party Rights.

	 	10.3.1	 	Notice of Claim. If the practice of the Licensed IP Rights by
Regado, its Affiliates or Sublicensees, in accordance with the licenses granted
under Section 2 hereof, results in a claim of patent infringement against
Regado, its Affiliates or Sublicensees, the Party to this Agreement first
having notice of that claim shall promptly notify the other Party and Gilead in
writing. The notice shall set forth the facts of the claim in reasonable
detail.
	 
	 	10.3.2	 	Resolution of Claims. If a Third Party asserts that a patent or
other right owned by or licensed to it is infringed within a country by the
practice of

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

17

 

the Licensed IP Rights by Regado, its Affiliates or Sublicensees, in
accordance with the licenses granted under Section 2 hereof, Regado may
attempt to resolve the asserted infringement; provided,
however that Archemix and/or Gilead shall have the right, as they
shall determine in their sole discretion, to participate in any such
resolution and to be represented by counsel of their own choice and at their
own expense. Regado shall control the process to resolve any such
infringement. The matter shall be deemed resolved if Regado obtains (i) a
license permitting Regado to manufacture, use, import, offer for sale and
sell Licensed Products in that country on a royalty-free basis (ii) a
legally binding statement or representation from the Third Party that (A)
no action will be taken against Regado, its Affiliates or its Sublicensees,
or (B) that the patent or other right is not infringed by the practice of
the Licensed IP Rights by Regado, its Affiliates or its Sublicensees in such
country or (iii) a final judgment by a court of competent jurisdiction from
which no appeal has or can be taken that the Third Party’s patent(s) alleged
to be infringed is invalid, or the Third Party’s patent(s) or other right(s)
are unenforceable or not infringed by the practice of the Licensed IP Rights
by Regado, its Affiliates or Sublicensees. Regado shall have the primary
right to defend any such claim. Archemix and/or Gilead shall have the
right, but not the obligation, to participate in any such suit at its sole
option and at its own expense. Each Interested Party shall reasonably
cooperate with the Interested Parties conducting the defense of the claim.
The Interested Party conducting the defense shall not enter into any
settlement that affects the other Interested Parties’ rights or interests
without such other Interested Parties’ prior written consent, not to be
unreasonably withheld, delayed or conditioned. . If either of the
Interested Parties not conducting the defense do not consent to the proposed
settlement or other voluntary final disposition, the Interested Party
controlling the defense can request expedited arbitration of the failure to
consent under the terms of Section 8.3. The Interested Party(ies) not
prevailing in the arbitration shall pay the cost of the arbitration.

	11	 	TERMINATION

	 	11.1	 	Expiration. Subject to the provisions of Sections 11.2, 11.3 and 11.4
below, this Agreement shall expire on the expiration of the last Valid Claim within the
Licensed IP Rights.
	 
	 	11.2	 	Termination for Cause. A Party may terminate this Agreement upon or
after the material breach of this Agreement by the other Party if the other Party has
not cured such material breach within [***] days after written notice thereof by the
non-breaching Party.
	 
	 	11.3	 	Effect of Expiration or Termination. Upon expiration of this Agreement
under Section 11.1, Regado shall have a paid up, exclusive, worldwide license under the
Licensed Know-How Rights for use in the Field. Expiration or termination of this

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

18

 

Agreement shall not relieve the Parties of any obligation accruing prior to or upon
such expiration or termination, and, in addition to any provisions of this Agreement
which by their terms are to continue after expiration or termination of this
Agreement, the provisions of Sections 2.2, 2.4, 2.5, 3.1, 4.2, 9, 10, 11, 12, 13 and
14.3 shall survive the expiration or termination of this Agreement. Without
limiting the foregoing, in the event of a termination by Archemix for cause or
termination by Regado without cause, Regado shall continue to pay amounts that would
have become due and payable hereunder in connection with manufacture, use, sale,
offer for sale, having sold or importing products that would have been Licensed
Products had the Agreement not terminated, and such Sublicense Income as would have
become due and payable in connection with the grant of rights relating to any such
products.

	 	11.4	 	Rights Upon Termination. In the event of termination of this Agreement
under Section 11.2 or Section 11.3, the license granted by Archemix to Regado under
Section 2.1 shall immediately terminate and Regado shall cease all activities relating
to the manufacture, use or sale of any and all Licensed Products after such a
termination.
	 
	 	11.5	 	Termination at Will. Regado can terminate this Agreement at will on [***] days
written notice to Archemix.

	12	 	INDEMNIFICATION

	 	12.1	 	Indemnification by Regado. Regado shall indemnify, defend and hold
harmless Gilead, its Affiliates and UTC and any of their respective directors,
officers, employees and agents (each, a “Gilead Indemnitee”), and Archemix, and its
respective directors, officers, employees and agents (each, a “Archemix Indemnitee”)
from and against any Damages that are incurred by a Gilead Indemnitee or Archemix
Indemnitee as a result of Third Party claims, demands, actions or proceedings
(collectively, the “Claims”) to the extent such Claims arise out of:

	 	i.	 	the breach or alleged breach of any
representation or warranty by Regado hereunder;
	 
	 	ii.	 	failure to perform duly and punctually any of
Regado’s covenants or undertakings under this Agreement, including,
without limitation Regado’s covenants in Section 13 hereof;
	 
	 	iii.	 	the possession, research, development,
manufacture, use, offer for sale, sale or other commercialization,
distribution, administration, storage or transport, by Regado or its
Affiliates or Sublicensees of (A) any Aptamers or Licensed Products or
(B) any other Licensed Products, services and activities developed by
Regado relating to the Licensed IP Rights, including any Licensed
Products or Aptamers; and

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

19

 

	 	iv.	 	any negligence or intentional act by Regado
pertaining to this Agreement that Damages Archemix.

	 	12.2	 	Procedure. Archemix promptly shall notify Regado of any claim, demand,
action or other proceeding for which Archemix intends to claim indemnification. Regado
shall have the right to participate in, and to the extent Archemix so desires jointly
with any other indemnitor similarly noticed, to assume the defense thereof with counsel
selected by Regado; provided, however, that Archemix shall have the
right to retain its own counsel, with the fees and expenses to be paid by Archemix.
The indemnity obligations under this Section 12 shall not apply to amounts paid in
settlement of any claim, demand, action or other proceeding if such settlement is
effected without the prior express written consent of Regado, which consent shall not
be unreasonably withheld or delayed. The failure to deliver notice to Regado within a
reasonable time after notice of any such claim or demand, or the commencement of any
such action or other proceeding, if prejudicial to its ability to defend such claim,
demand, action or other proceeding, shall relieve such Indemnitor of any liability to
Archemix under this Section 12 with respect thereto, but the omission so to deliver
notice to Regado shall not relieve it of any liability that it may have to Archemix
other than under this Section 12. Regado may not settle or otherwise consent to an
adverse judgment in any such claim, demand, action or other proceeding, that diminishes
the rights or interests of Archemix without the prior express written consent of
Archemix, which consent shall not be unreasonably withheld or delayed. Archemix, its
employees and agents, shall reasonably cooperate with Regado and its legal
representatives in the investigation of any claim, demand, action or other proceeding
covered by this Section 12.
	 
	 	12.3	 	Insurance. Regado shall maintain insurance with respect to the
research, development and commercialization of Licensed Products by Regado in such
amount as U.S-based bio-pharmaceutical companies customarily maintain with respect to
the research, development and commercialization of similar products. Regado shall
maintain such insurance for so long as it continues to research, develop or
commercialize any Licensed Products, and thereafter for a period of [***] years.
	 
	 	12.4	 	Indemnification by Archemix. Archemix shall indemnify, defend and hold
harmless Regado and any of its respective directors, officers, employees and agents
(each, a “Regado Indemnitee”), from and against any Damages that are incurred by a
Regado Indemnitee as a result of Third Party claims, demands, actions or proceedings
(collectively, the “Claims”) to the extent such Claims arise out of:

	 	i.	 	the breach or alleged breach of any representation or
warranty by Archemix hereunder;
	 
	 	ii.	 	failure to perform duly and punctually any of
Archemix’s covenants or undertakings under this Agreement; and

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

20

 

	 	iii.	 	any negligence or intentional act by Archemix
pertaining to this Agreement that Damages Regado.

	 	12.5	 	Procedure. Regado promptly shall notify Archemix of any claim, demand,
action or other proceeding for which Regado intends to claim indemnification. Archemix
shall have the right to participate in, and to the extent Regado so desires jointly
with any other indemnitor similarly noticed, to assume the defense thereof with counsel
selected by Archemix; provided, however, that Regado shall have the
right to retain its own counsel, with the fees and expenses to be paid by Regado. The
indemnity obligations under this Section 12 shall not apply to amounts paid in
settlement of any claim, demand, action or other proceeding if such settlement is
effected without the prior express written consent of Archemix, which consent shall not
be unreasonably withheld or delayed. The failure to deliver notice to Archemix within
a reasonable time after notice of any such claim or demand, or the commencement of any
such action or other proceeding, if prejudicial to its ability to defend such claim,
demand, action or other proceeding, shall relieve such Indemnitor of any liability to
Regado under this Section 12 with respect thereto, but the omission so to deliver
notice to Archemix shall not relieve it of any liability that it may have to Regado
other than under this Section 12. Archemix may not settle or otherwise consent to an
adverse judgment in any such claim, demand, action or other proceeding, that diminishes
the rights or interests of Regado without the prior express written consent of Regado,
which consent shall not be unreasonably withheld or delayed. Regado, its employees and
agents, shall reasonably cooperate with Archemix and its legal representatives in the
investigation of any claim, demand, action or other proceeding covered by this Section
12.

	13	 	REPRESENTATIONS AND WARRANTIES

	 	13.1	 	Mutual Representations and Warranties. Each Party hereby represents
and warrants to the other Party as follows:

	 	13.1.1	 	Corporate Existence. Such Party is a corporation duly organized,
validly existing and in good standing under the laws of the state in which it
is incorporated.
	 
	 	13.1.2	 	Authorization and Enforcement of Obligations. Such Party (a) has the
corporate power and authority and the legal right to enter into this Agreement
and to perform its obligations hereunder, and (b) has taken all necessary
corporate action on its part to authorize the execution and delivery of this
Agreement and the performance of its obligations hereunder. This Agreement has
been duly executed and delivered on behalf of such Party, and constitutes a
legal, valid, binding obligation, enforceable against such party in accordance
with its terms.

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

21

 

	 	13.1.3	 	Consents. All necessary consents, approvals and authorizations of
all governmental authorities and other Persons required to be obtained by such
Party in connection with this Agreement have been obtained.
	 
	 	13.1.4	 	No Conflict. The execution and delivery of this Agreement and the
performance of such Party’s obligations hereunder (a) do not conflict with or
violate any requirement of applicable laws or regulations, and (b) do not
conflict with, or constitute a default under, any contractual obligation of it.

	 	13.2	 	Regado Representations and Warranties. Regado acknowledges and agrees
that it has been provided a copy of the documents listed in Schedule B. Regado
represents and warrants that it has read and understands the contents of such
documents.
	 
	 	13.3	 	Warranty Disclaimer. Except as expressly provided in this Section
13, neither party makes any representation or warranty as to any licensed intellectual
property rights, express or implied, either in fact or by operation of law, by statute
or otherwise, including without limitation any implied warranty of merchantability,
fitness for a particular purpose, non-infringement of third party rights, or warranty
against infringement, or otherwise, and each party specifically disclaims any and all
implied or statutory warranties. without limiting the generality of the foregoing,
archemix makes no warranties as to the validity or enforceability of any licensed ip
rights. Without limiting the foregoing, each Party acknowledges that it has not
and is not relying upon any implied warranty of merchantability, fitness for a
particular purpose, non-infringement of third party rights, or warranty against
infringement, or otherwise, or upon any representation or warranty whatsoever as to the
prospects (financial, regulatory or otherwise), or the validity or likelihood of
success, of any Licensed Products or services based on the Licensed IP Rights or any
Archemix intellectual property after the Effective Date.

	14	 	MISCELLANEOUS

	 	14.1	 	Notices. Any consent, notice or report required or permitted to be
given or made under this Agreement by one of the Parties to the other shall be in
writing and addressed to such other Party at its address indicated below, or to such
other address as the addressee shall have last furnished in writing to the addressor,
and shall be effective upon receipt by the addressee.

	 	 	 
	If to Archemix:

	 	1 Hampshire St
	 

	 	Cambridge, MA 02139
	 

	 	Attention: EVP, Corporate Development

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

22

 

	 	 	 	 	 	 	 
	If to Regado:
	 	 	 	 	 	 
	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Attention:	 	 	 	 
	 

	 	 	 	 	 

	 	14.2	 	Assignment. Except as otherwise expressly provided under this
Agreement neither this Agreement nor any right or obligation hereunder may be assigned
or otherwise transferred (whether voluntarily, by operation of law or otherwise),
without the prior express written consent of the other Party; provided, however, that
either Party may, without such consent, assign this Agreement and its rights and
obligations hereunder in connection with the transfer or sale of all or substantially
all of its business, or in the event of its merger, consolidation, change in control or
similar transaction or in the case of Regado in connection with any sale or transfer of
rights to any of the Licensed Products. Any permitted assignee shall assume all
obligations of its assignor under this Agreement. Any purported assignment or transfer
in violation of this Section 14.2 shall be void.
	 
	 	14.3	 	Applicable Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, without regard to the conflicts of
law principles thereof.
	 
	 	14.4	 	Entire Agreement. This Agreement contains the entire understanding of
the Parties with respect to the subject matter hereof. All express or implied
representations, agreements and understandings, either oral or written, heretofore made
are expressly superseded by this Agreement.
	 
	 	14.5	 	Independent Contractors. Each Party hereby acknowledges that the
Parties shall be independent contractors and that the relationship between the parties
shall not constitute a partnership, joint venture or agency. Neither Party shall have
the authority to make any statements, representations or commitments of any kind, or to
take any action, which shall be binding on the other Party, without the prior consent
of the other Party to do so.
	 
	 	14.6	 	Waiver. The waiver by a Party of any right hereunder, or of any
failure to perform or breach by the other Party hereunder, shall not be deemed a waiver
of any other right hereunder or of any other breach or failure by the other party
hereunder whether of a similar nature or otherwise.
	 
	 	14.7	 	Force Majeure. Neither Party shall be held liable or responsible to the
other Party nor be deemed to have defaulted under or breached this Agreement for
failure or delay in fulfilling or performing any term of this Agreement to the extent,
and for so long as, such failure or delay is caused by or results from causes beyond
the reasonable control of the affected Party including but not limited to fire, floods,
embargoes, war, acts of war (whether war be declared or not), insurrections, riots,
civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts,
omissions or delays in acting by any governmental authority or the other Party.

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

23

 

	 	14.8	 	Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

     IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

	 	 	 	 	 	 	 
	 	 	Archemix Corp.	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Title	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Regado Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Title	 	 	 	 
	 

	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

24

 

Schedule A. Archemix Patents and Patent Applications 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

25

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

26

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

27

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

28

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

29

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

30

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

31

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

32

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

33

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

34

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

35

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

36

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

37

 

	 	 	 	 	 	 	 	 	 	 	 
	MATTER NO	 	CTRY	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

38

 

Schedule B. List of [***]

MISCELLANEOUS [***] I

[***]

[***]

[***]

[***]

      [***]

[***]

US Patent No. [***] — available on the Patents Referenced in Misc. [***] CDROM

[***]

Reexamination Certificate – US Patent No. [***] (dated April 7, 1998)

US Patent No. [***] (dated August 11, 1998)

US Patent No. [***] (dated November 14, 1995)

US Patent No. [***] (dated November 11, 1997)

US Patent No. [***] (dated February 8, 2000)

[***]

US Patent No. [***] — available on the Patents Referenced in Misc. [***] CDROM

[***]

[***];

      [***]

[***];

      [***]

[***] [***]

[***]

     [***]

[***]

[***]

     [***]

US Patents [***]; [***] [***] and [***] are available on the

     Patents Referenced in Misc. [***] CDROM

[***]

[***]

US Patents [***]; [***]; [***]; [***] and [***] are available on the

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

39

 

     Patents Referenced in Misc. [***] CDROM

[***]

[***]

[***]

[***]

      [***]

[***]

      [***]

[***]

European Patent No. [***] in both German and English (Application dated September 14, 1993)

[***]

WO
[***] (EP Patent Application No. [***]) is available on the Patents Referenced in Misc. [***] CDROM

[***]

[***]

[***]

[***].

[***].

MISCELLANEOUS [***] 2

[***]

Third New Divisional Application

[***]

[***]

January 22, 2001

March 27, 2000

January 26, 2000

March 9, 1999

January 19, 1999

February 18, 1998

October 2, 1997

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

40

 

September 12, 1997

July 28, 1997

July 17, 1997

February 19, 1997

February 9, 1996

February 8, 1996

January 26, 1996

[***]

[***]

[***]

List of 6 pages

Portions of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

41exv10w14

 

Exhibit 10.14

EXECUTION COPY

COLLABORATIVE RESEARCH AND LICENSE AGREEMENT

between

ARCHEMIX CORP.

and

TAKEDA PHARMACEUTICAL COMPANY LIMITED

June 11, 2007

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 
	 	 	 	 	Page
	1.

	 	DEFINITIONS
	 	 	1	 
	2.

	 	ADMINISTRATION OF THE COLLABORATION
	 	 	19	 
	 

	 	2.1 Joint Steering Committee
	 	 	19	 
	 

	 	2.2 Joint Project Team
	 	 	21	 
	3.

	 	RESEARCH PROGRAM
	 	 	24	 
	 

	 	3.1 Objectives of the Research Program
	 	 	24	 
	 

	 	3.2 Annual Research Plans
	 	 	24	 
	 

	 	3.3 Conduct of Research Program
	 	 	25	 
	 

	 	3.4 Records
	 	 	26	 
	 

	 	3.5 Selection of Program Targets
	 	 	27	 
	 

	 	3.6 Identification of Optimized Lead Compounds
	 	 	28	 
	 

	 	3.7 Supply of Proprietary Materials
	 	 	29	 
	 

	 	3.8 Research Program Term
	 	 	29	 
	 

	 	3.9 Evaluation of Program Aptamers for Satisfaction of OLSC Prior to Expiration of Research Program Term
	 	 	29	 
	 

	 	3.10 Evaluation of Program Aptamers for Satisfaction of OLSC After Expiration of Research Program Term
	 	 	29	 
	4.

	 	DEVELOPMENT PROGRAM; COMMERCIALIZATION OF PRODUCTS
	 	 	29	 
	 

	 	4.1 Objectives of the Development Program
	 	 	30	 
	 

	 	4.2 Responsibility for Development and Commercialization of Products
	 	 	30	 
	 

	 	4.3 Technical Assistance
	 	 	30	 
	 

	 	4.4 Development and Commercialization Obligations
	 	 	30	 
	 

	 	4.5 Cooperation
	 	 	31	 
	 

	 	4.6 Exchange of Reports; Information; Updates
	 	 	31	 
	 

	 	4.7 Product Recalls
	 	 	32	 
	5.

	 	PAYMENTS
	 	 	33	 
	 

	 	5.1 Upfront Technology Access and License Fee
	 	 	33	 
	 

	 	5.2 R&D Funding
	 	 	33	 
	 

	 	5.3 Milestone Payments
	 	 	34	 
	 

	 	5.4 Payment of Royalties; Royalty Rates; Accounting and Records
	 	 	36	 
	6.

	 	TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY; NON-SOLICITATION.
	 	 	40	 
	 

	 	6.1 Confidentiality
	 	 	40	 
	 

	 	6.2 Publicity
	 	 	41	 
	 

	 	6.3 Publications and Presentations
	 	 	41	 
	 

	 	6.4 Prohibition on Solicitation
	 	 	42	 
	7.

	 	LICENSE GRANTS; ASSIGNMENT; EXCLUSIVITY
	 	 	42	 

 

Portions
of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 406 of
the Securities Act.

i

 

	 	 	 	 	 	 	 
	 	 	 	 	Page
	 

	 	7.1 Research and Development Licenses
	 	 	42	 
	 

	 	7.2 Commercialization License
	 	 	47	 
	 

	 	7.3 Right to Sublicense
	 	 	48	 
	 

	 	7.4 Right to Subcontract
	 	 	48	 
	 

	 	7.5 No Other Rights
	 	 	48	 
	 

	 	7.6 Exclusivity
	 	 	48	 
	8.

	 	INTELLECTUAL PROPERTY RIGHTS
	 	 	49	 
	 

	 	8.1 ARCHEMIX Intellectual Property Rights
	 	 	50	 
	 

	 	8.2 Program Generic Patent Rights
	 	 	50	 
	 

	 	8.3 TAKEDA Intellectual Property Rights
	 	 	50	 
	 

	 	8.4 Program Aptamer-Specific Patent Rights
	 	 	50	 
	 

	 	8.5 Joint Technology Rights
	 	 	50	 
	 

	 	8.6 Patent Coordinators
	 	 	50	 
	 

	 	8.7 Inventorship
	 	 	51	 
	 

	 	8.8 Technology Disputes
	 	 	51	 
	 

	 	8.9 Cooperation
	 	 	51	 
	9.

	 	FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS
	 	 	51	 
	 

	 	9.1 Patent Filing, Prosecution and Maintenance
	 	 	51	 
	 

	 	9.2 Legal Actions
	 	 	54	 
	10.

	 	TERM AND TERMINATION
	 	 	59	 
	 

	 	10.1 Term
	 	 	59	 
	 

	 	10.2 Termination
	 	 	59	 
	 

	 	10.3 Consequences of Termination of Agreement
	 	 	60	 
	 

	 	10.4 Surviving Provisions
	 	 	63	 
	11.

	 	REPRESENTATIONS AND WARRANTIES
	 	 	63	 
	 

	 	11.1 Mutual Representations and Warranties
	 	 	63	 
	 

	 	11.2 Acknowledgment and Covenants of TAKEDA
	 	 	63	 
	 

	 	11.3 Representations and Warranties of ARCHEMIX
	 	 	64	 
	12.

	 	INDEMNIFICATION
	 	 	65	 
	 

	 	12.1 Indemnification of TAKEDA by ARCHEMIX
	 	 	65	 
	 

	 	12.2 Indemnification of ARCHEMIX by TAKEDA
	 	 	65	 
	 

	 	12.3 Indemnification of [***] and [***] by TAKEDA
	 	 	66	 
	 

	 	12.4 Conditions to Indemnification
	 	 	66	 
	 

	 	12.5 Warranty Disclaimer
	 	 	66	 
	 

	 	12.6 No Warranty of Success
	 	 	67	 
	 

	 	12.7 Limited Liability
	 	 	67	 
	13.

	 	MISCELLANEOUS
	 	 	67	 
	 

	 	13.1 Dispute Resolution
	 	 	67	 
	 

	 	13.2 Litigation; Jurisdiction
	 	 	67	 
	 

	 	13.3 Notices
	 	 	67	 
	 

	 	13.4 Governing Law
	 	 	68	 
	 
	 	 	 	 	 	 
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

ii

 

	 	 	 	 	 	 	 
	 	 	 	 	Page
	 
	 	 	 	 	 	 
	 

	 	13.5 Binding Effect
	 	 	68	 
	 

	 	13.6 Headings
	 	 	68	 
	 

	 	13.7 Counterparts
	 	 	68	 
	 

	 	13.8 Amendment; Waiver
	 	 	68	 
	 

	 	13.9 No Third Party Beneficiaries
	 	 	69	 
	 

	 	13.10 Purposes and Scope
	 	 	69	 
	 

	 	13.11 Assignment and Successors
	 	 	69	 
	 

	 	13.12 Force Majeure
	 	 	69	 
	 

	 	13.13 Interpretation
	 	 	69	 
	 

	 	13.14 Integration; Severability
	 	 	69	 
	 

	 	13.15 Further Assurances
	 	 	70	 
	 
	 	 	 	 	 	 
	List of Schedules	 	 	 	 
	 
	 	 	 	 	 	 
	Schedule 1       Optimized Lead Compound Selection Criteria	 	 	 	 
	Schedule 2A    Program Targets	 	 	 	 
	Schedule 2B    Target Replacement List	 	 	 	 
	Schedule 3       Licensed Patent Rights	 	 	 	 
	Schedule 4       Excluded Aptamers	 	 	 	 
	Schedule 5       Form of Press Release	 	 	 	 
	Schedule 6       Program Chemistry	 	 	 	 
	Schedule 7       Ligands to Program Targets/Pre-approved Replacement Targets	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

iii

 

COLLABORATIVE RESEARCH AND LICENSE AGREEMENT

     This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of
June 11, 2007, by and between Archemix Corp., a Delaware corporation with offices at 300 Third
Street, Cambridge, MA 02142 (“ARCHEMIX”), and Takeda Pharmaceutical Company Limited, a Japanese
corporation with a principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645,
Japan (“TAKEDA”). Each of TAKEDA and ARCHEMIX is sometimes referred to individually herein as a
“Party” and collectively as the “Parties.”

     WHEREAS, ARCHEMIX has developed and controls certain technology, patent rights and proprietary
materials related to (a) the identification and optimization of aptamers using its proprietary
SELEX Process and SELEX Technology (each as defined herein), and (b) the use of such aptamers for
treating, preventing or delaying the onset or progression of human diseases or conditions; and

     WHEREAS, TAKEDA is engaged in the research, development and commercialization of human
therapeutics; and

     WHEREAS, the Parties desire to enter into a collaboration for the purposes of identifying
aptamers against certain identified targets, and developing and commercializing human therapeutic
products Derived (as defined herein) from such aptamers.

     NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as
follows:

1. DEFINITIONS

     Whenever used in this Agreement with an initial capital letter, the terms defined in this
Section 1 shall have the meanings specified.

     1.1 “Adverse Event” means any event temporally related to the administration of a
Product that results in any of the following outcomes: death, a life-threatening adverse drug
experience, inpatient hospitalization, prolongation of existing hospitalization, a persistent or
significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events
that may not result in death, be life-threatening, or require hospitalization may be considered an
Adverse Event when, based upon appropriate medical judgment, they may jeopardize the patient or
subject and may require medical or surgical intervention to prevent one of the outcomes listed in
this definition.

     1.2 “Affiliate” means, with respect to any Person, any other Person that, directly or
indirectly through one or more affiliates, controls, or is controlled by, or is under common
control with, such Person. For purposes of this definition, “control” means (a) ownership of fifty
percent (50%) or more of the shares of stock entitled to vote for the election of directors in the
case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, (b) status as a general
partner in any partnership, or (c) any other arrangement

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

 

 

whereby a Person controls or has the right to control the board of directors of a corporation
or equivalent governing body of an entity other than a corporation.

     1.3 “Annual Net Sales” means, with respect to any Fiscal Year, the aggregate amount of
the Net Sales for such Fiscal Year.

     1.4 Annual Research Plan” means, with respect to the Program Targets, the written plan
describing the research activities to be carried out by each Party during each Fiscal Year of the
Research Program Term in conducting the Research Program pursuant to this Agreement with respect to
such Program Targets, as such written plan may be amended, modified or updated, as further
described in Section 3.2.

     1.5 “Applicable Laws” means Federal, state, local, national and supra-national laws,
statutes, rules and regulations, including any rules, regulations, guidance, guidelines or
requirements of Regulatory Authorities, national securities exchanges or securities listing
organizations, that are in effect from time to time during the Term and apply to a particular
activity hereunder.

     1.6 “Aptamer” means (a) any naturally or non-naturally occurring oligonucleotide
identified by ARCHEMIX that binds to a Target with high specificity and affinity and (b) any
oligonucleotide Derived from any such oligonucleotide that has such high specificity and affinity.

     1.7 “Aptamer-Antidote Combination Product” means [***] of the [***] of (a) [***]
aptamer [***], or [***] and (b) a [***] the [***] of such[***].

     1.8 “ARCHEMIX Additional Activities” means any activities, other than ARCHEMIX
Research Activities, that (a) TAKEDA reasonably requests in writing that ARCHEMIX perform and (b)
ARCHEMIX is reasonably capable of providing. For purposes of clarity, such ARCHEMIX Additional
Activities shall include, and unless otherwise agreed by the Parties in writing, be limited to: (i)
the use by TAKEDA of certain ARCHEMIX employees and/or long-term consultants of ARCHEMIX to provide
advice with respect to issues with respect to which ARCHEMIX has expertise or experience [***],
without [***] with[***]and/or [***] and (ii) the transfer by ARCHEMIX to TAKEDA of methods and
protocols Controlled by ARCHEMIX that may reasonably assist TAKEDA in the Development and/or
Commercialization of Products.

     1.9 “ARCHEMIX Background Technology” means any Technology that is used by
ARCHEMIX, or provided by ARCHEMIX for use, in the Research Program and/or the
Development Program that is (a) Controlled by ARCHEMIX as of the Effective Date or (b)
conceived or first reduced to practice by employees of, or consultants to, ARCHEMIX
after the Effective Date other than in the conduct of ARCHEMIX Research Activities
and/or ARCHEMIX Additional Activities. For purposes of clarity, (i) ARCHEMIX
Background Technology shall include any Technology described in (a) and
(b) of this Section 1.9 that is an improvement upon the SELEX Process
and/or SELEX Technology and (ii) ARCHEMIX Program Technology or ARCHEMIX’s
interest in Joint Technology shall not include ARCHEMIX Background
Technology.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

2

 

     1.10 “ARCHEMIX Decision” means a decision with respect to the following issues:
(a) the manner by which ARCHEMIX conducts the [***] against [***]; (b) whether ARCHEMIX is to incur
any [***] under the Research Program except for [***] that are included in any Annual Research Plan
by mutual agreement of the Parties and without TAKEDA exercising the deciding vote under Section
2.1.6 to cause its inclusion; (c) whether ARCHEMIX is [***] any ARCHEMIX Additional Activities; (d)
whether ARCHEMIX is to incur any [***] in the performance of [***] and/or ARCHEMIX Additional
Activities except for [***] that are included in the Annual Research Plan by mutual agreement of
the Parties and without TAKEDA exercising the deciding vote under Section 2.1.6 to cause its
inclusion; and (e) the number of FTEs to be provided by ARCHEMIX in each Annual Research Plan to
the extent such number of FTEs exceeds [***] FTEs per Fiscal Year.

     1.11 “ARCHEMIX-Gilead License Agreement” means the License Agreement between Gilead
Sciences, Inc. and ARCHEMIX dated October 21, 2001, as amended.

     1.12 “ARCHEMIX Patent Rights” means any Patent Rights Controlled by ARCHEMIX that
contain one or more claims that cover ARCHEMIX Technology.

     1.13 “ARCHEMIX Program Technology” means (a) any oligonucleotide of an Enriched Pool
that is not a Program Aptamer; (b) any Program Technology, other than Program Aptamer-Specific
Technology, that is conceived or first reduced to practice by employees of, or consultants to,
ARCHEMIX, alone or jointly with any Third Party; and (c) any Program Technology, regardless of
whether conceived or first reduced to practice by employees of, or consultants to, ARCHEMIX,
TAKEDA, or both Parties, alone or jointly with any Third Party, that is an improvement to the SELEX
Process or SELEX Technology.

     1.14 “ARCHEMIX Research Activities” means all activities specified to be conducted by
ARCHEMIX in any Annual Research Plan (or amendment thereto) that are (a) approved by the JPT and
the JSC and (b) to the extent involving matters that are ARCHEMIX Decisions, approved by ARCHEMIX
in accordance with Section 2.1.6.

     1.15 “ARCHEMIX Technology” means, collectively, ARCHEMIX Background Technology and
ARCHEMIX Program Technology.

     1.16 “Challenge” means any formal written filing with a government patent
agency or court of law in any country made independent of and not in response to a
material breach of this Agreement where such filing calls into question the validity
or enforceability of any Royalty Triggering Patent Rights scheduled according to
Section 9.2.4, including without limitation by (a) filing a declaratory judgment
action in which any Royalty Triggering Patent Rights are alleged to be invalid or
unenforceable; (b) citing prior art pursuant to 35 U.S.C. §301, filing a request for re-examination of any Royalty
Triggering Patent Rights pursuant to 35 U.S.C. §302 and/or §311, or
provoking or becoming party to an interference with an application for
Licensed Patent Rights pursuant to 35 U.S.C. §135; or (c) filing or
commencing any re-examination, opposition, cancellation, nullity or
similar proceedings against any Royalty Triggering Patent Right in any
country. Notwithstanding the foregoing, any action with respect to the
Prosecution of Patent Rights taken by a Party in accordance with Section
9.1 shall not be deemed to be a Challenge for purposes of this Agreement.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

3

 

     1.17 “Change of Control” means, with respect to a Party, (a) a merger,
consolidation, share exchange or other similar transaction involving such Party and any Third Party
which results in the holders of the outstanding voting securities of such Party immediately prior
to such merger, consolidation, share exchange or other similar transaction ceasing to hold more
than fifty percent (50%) of the combined voting power of the surviving, purchasing or continuing
entity immediately after such merger, consolidation, share exchange or other similar transaction,
(b) any transaction or series of related transactions (other than an investment transaction by an
entity not engaged in the pharmaceutical or biotechnology business, the purpose of which is to
raise capital for a Party) in which a Third Party, together with its Affiliates, becomes the
beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding
securities of such Party, or (c) the sale or other transfer to a Third Party of all or
substantially all of such Party’s assets which relate to this Agreement.

     1.18 “Collaboration” means the alliance of ARCHEMIX and TAKEDA established pursuant to
this Agreement for the purposes of identifying, researching, Developing and Commercializing
Products in the Field in the Territory.

     1.19 “Collaboration Aptamer” means, collectively, all Program Aptamers and Optimized
Lead Compounds.

     1.20 “Combination Product” means a combination or bundled product that is sold
together in a single package or as a unit at a single price by TAKEDA, its Affiliates or
Sublicensees and that includes: (a) a Product; and (b) a Supplemental Product.

     1.21 “Commercialization” or “Commercialize” means any and all activities
directed to the commercialization of a Product after Commercialization Regulatory Approval has been
obtained, including marketing, manufacturing for commercial sale, promoting, detailing,
distributing, offering to sell and selling a Product, importing a Product for sale, conducting
post-marketing human clinical studies and interacting with Regulatory Authorities regarding the
foregoing. When used as a verb, “to Commercialize” and “Commercializing” means to engage in
Commercialization and “Commercialized” has a corresponding meaning.

     1.22 “Commercialization Regulatory Approval” means, with respect to any
Product, the Regulatory Approval required by Applicable Laws to sell such Product for
use in the Field in a country or region in the Territory. “Commercialization
Regulatory Approval” shall include, without limitation, the approval of any Drug
Approval Application. For purposes of clarity, “Commercialization Regulatory
Approval” in the United States shall mean final approval of an NDA for the first
Indication or sNDA for an additional Indication permitting marketing of the applicable
Product in interstate commerce in the United States, “Commercialization Regulatory
Approval” in the European Union shall mean marketing authorization for the applicable Product pursuant to
Council Directive 2001/83/EC, as amended, or Council Regulation
2309/93/EEC, as amended and “Commercialization Regulatory Approval” in
Japan shall mean final approval of an application submitted to the
Ministry of Health, Labor and Welfare and the publication of a New Drug
Approval Information Package permitting marketing of the applicable
Product in Japan, as any of the foregoing may be supplemented or amended
from time to time.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

4

 

     1.23 “Commercially Reasonable Efforts” or “Commercially Reasonable” means
(a) with respect to the manner by which ARCHEMIX performs (i) the activities assigned to ARCHEMIX
in the Research Program and (ii) ARCHEMIX Additional Activities, if any, efforts and resources that
are comparable to those undertaken by ARCHEMIX in pursuing the research, discovery, development and
intellectual property protection of proprietary materials and the development of product
candidates, as applicable, that are not subject to the Collaboration and that are at an equivalent
stage of research, development or commercialization and have similar market potential and are at a
similar stage in their lifecycle, and (b) with respect to activities of TAKEDA in the Research
Program, and the Development and/or Commercialization of a particular Product, the efforts and
resources comparable to those undertaken by TAKEDA in pursuing intellectual property protection,
development and commercialization of similar products that are not subject to the Collaboration,
taking into account the product’s stage of development and/or commercialization, risks and
probabilities of success, market potential, and stage in their lifecycle. For purposes of (a) and
(b) above, all relevant factors as measured by the facts and circumstances at the time such efforts
are due shall be taken into account, including, as applicable and without limitation, mechanism of
action; efficacy and safety; product profile; actual or anticipated Regulatory Authority approved
labelling; and the nature and extent of market exclusivity (including patent coverage, proprietary
position and regulatory exclusivity; cost, time required for and likelihood of obtaining
Commercialization Regulatory Approval; competitiveness of alternative products and market
conditions; actual or projected profitability and availability of capacity to manufacture and
supply for commercial sale).

     1.24 “Competitive Program” means any research, development or commercialization
activity that involves an aptamer that targets a Program Target for use in the Field.

     1.25 “Confidential Information” means all information, Technology and Proprietary
Materials disclosed or provided by or on behalf of one Party (the “disclosing Party”) to the other
Party (the “receiving Party”) or to any of the receiving Party’s employees, consultants, Affiliates
or sublicensees (or Sublicensees, as the case may be); provided, that, none of the foregoing shall
be Confidential Information if: (A) as of the date of disclosure, it is known to the receiving
Party or its Affiliates as demonstrated by contemporaneous credible written documentation, other
than by virtue of a prior confidential disclosure to such receiving Party; (B) as of the date of
disclosure it is in the public domain, or it subsequently enters the public domain through no fault
of the receiving Party or its Affiliates; (C) it is obtained by the receiving Party from a Third
Party having a lawful right to make such disclosure free from any obligation of confidentiality to
the disclosing Party or its Affiliates; or (D) it is independently developed by or for the
receiving Party or its Affiliates without reference to or use of any Confidential Information of
the disclosing Party as demonstrated by contemporaneous credible written documentation. The
foregoing notwithstanding (i) all tangible embodiments of ARCHEMIX Technology shall be ARCHEMIX
Confidential Information, (ii) all tangible embodiments of TAKEDA Technology shall be TAKEDA
Confidential Information, and (iii) all tangible embodiments of Joint Technology shall be
ARCHEMIX Confidential Information and TAKEDA Confidential Information. Notwithstanding anything
herein to the contrary, the terms of this Agreement shall constitute Confidential Information of
each Party.

     1.26 “Control” or “Controlled” means (a) with respect to
Technology or Patent Rights, the possession by a Party of the right to grant a license
or sublicense to such Technology or Patent

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

5

 

Rights as provided herein without the payment of additional consideration to, and without
violating the terms of any agreement or arrangement with, any Third Party and without violating any
Applicable Laws and (b) with respect to Proprietary Materials, the possession by a Party of the
right to supply such Proprietary Materials to the other Party as provided herein without the
payment of additional consideration to, and without violating the terms of, any agreement or
arrangement with any Third Party, and without violating any Applicable Laws.

     1.27 “CTN” means the notification submitted to the Japanese Ministry of Health, Labor
and Welfare prior to the Initiation of a clinical trial in Japan.

     1.28 “Derived” means identified, obtained, developed, created, synthesized, generated,
designed or resulting from, based upon, containing or incorporating; conjugated to or complexed
with (whether directly or indirectly, or in whole or in part).

     1.29 “Development” or “Develop” means, with respect to each Product on or
after the selection of the Optimized Lead Compound from which such Product is Derived, all
non-clinical and clinical activities performed in order to obtain Regulatory Approval of such
Product, in accordance with this Agreement up to and including the obtaining of Commercialization
Regulatory Approval of such Product. For purposes of clarity, these activities include, without
limitation, in vivo animal efficacy testing, preclinical safety testing, test method development
and stability testing, regulatory toxicology studies, formulation, process development,
manufacturing, manufacturing scale-up, development-stage manufacturing, quality assurance/quality
control development, statistical analysis and report writing, clinical trial design and operations,
preparing and filing Drug Approval Applications, and all regulatory affairs related to the
foregoing. When used as a verb, “Developing” means to engage in Development and “Developed” has a
corresponding meaning.

     1.30 “Development Program” means the Development activities to be conducted during the
Term with respect to each Product on or after the selection of the Optimized Lead Compound from
which such Product is Derived with the objective of developing such Product.

     1.31 “Diagnosis” means (a) the determination or monitoring of (i) the presence or
absence of a disease, (ii) the stage, progression or severity of a disease or (iii) the effect on a
disease of a particular treatment; and/or (b) the selection of patients for a particular treatment
with respect to a disease.

     1.32 “Diagnostic Product” means In Vitro Diagnostics, In Vivo Diagnostic Agents and
any other aptamer product used for Diagnosis. For purposes of clarity, the term Diagnostic Product
shall not include a product used for the delay of onset or progression of, or treatment or
prevention of, an Indication.

     1.33 “Discontinued Competitive Target” means any Program Target so designated by
TAKEDA pursuant to Section 7.6.1(b) following a Change of Control of ARCHEMIX.

     1.34 “Drug Approval Application” means, with respect to a Product in a
particular country or region, an application for Commercialization Regulatory Approval
for such Product in such country or region, including, without limitation: (a) an NDA
or sNDA; (b) a counterpart of

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

6

 

an NDA or sNDA in any country or region in the Territory (including, without limitation, a
CTN); and (c) all supplements and amendments to any of the foregoing.

     1.35 “E5 Country” means each of the [***] and [***].

     1.36 “Effective Date” means the date first set forth above.

     1.37 “Enriched Pool” means a pool of oligonucleotides used to perform the SELEX
Process against a Program Target in the performance of the Research Program that (a) has
undergone [***] and (b) wherein, [***] with [***] of [***] (e.g., [***] and [***] of the
applicable Program Target, [***]% of the input pool of [***] is [***] in the [***] by the Program
Target and the [***]fraction of the [***] pool is at least [***] [***]relative to the [***]
fraction for the [***] (i.e., [***]) pool of [***].

     1.38 “Excepted Decision” means any of the following decisions requiring the unanimous
approval of all members of the JSC: (a) any decision as to whether a milestone has been achieved
under this Agreement for which a milestone payment is payable; and (b) any decision as to the
appropriate method of determining royalties for a Combination Product pursuant to the last sentence
of Section 5.4.1(h).

     1.39 “Excluded Aptamer” means any Aptamer listed on Schedule 4 attached
hereto.

     1.40 “Exclusivity Term” means, (a) with respect to each Program Target, the period
commencing on the Effective Date and continuing until the later of (i) the third anniversary of the
Effective Date, and (ii) such date as TAKEDA is no longer either (A) evaluating Collaboration
Aptamers directed to such Program Target pursuant to Section 3.10; (B) Developing and/or
Commercializing a Product directed to such Program Target in any country in the Territory, or (C)
providing the R&D Funding contemplated by Section 5.2 applicable to such Program Target, and (b)
with respect to each Pre-approved Replacement Target, the period commencing on the Effective Date
and continuing until the second anniversary of the Effective Date.

     1.41 “Failed Compound” means any Collaboration Aptamer directed against a Failed
Target.

     1.42 “Failed Target” means any Program Target as to which the JSC determines that
[***] is unable or unlikely to identify an [***] against such Program Target. For purposes of
clarity, a Failed Target shall no longer be considered a Program Target for purposes of this
Agreement once such Program Target becomes a Failed Target.

     1.43 “FDA” means the United States Food and Drug Administration or any successor
agency or authority thereto.

     1.44 “FDCA” means the United States Federal Food, Drug, and Cosmetic Act, as amended.

     1.45 “Field” means the treatment, prevention, cure or delay of onset or
progression of all human therapeutic Indications.

	 	 	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

7

 

     1.46 “First Commercial Sale” means, with respect to a Product in a country in the
Territory, the first sale, transfer or disposition for value to an end user of such Product in such
country. For purposes of clarity, the use of any Product in clinical trials, pre-clinical studies
or other research or development activities, or the disposal or transfer of Products for a bona
fide charitable purpose or a commercially reasonable sampling program, shall not be considered to
be a sale, transfer or disposal for value to an end user.

     1.47 “Fiscal Quarter” means each successive period of three (3) consecutive calendar
months commencing on January 1, April 1, July 1 or October 1, as the case may be, and ending on
March 31, June 30, September 30 or December 31, respectively; provided, that, the initial Fiscal
Quarter shall commence on the Effective Date and end on June 30, 2007.

     1.48 “Fiscal Year” means each successive period of twelve (12) months commencing on
April 1 and ending on March 31; provided, that, the first Fiscal Year shall commence on the
Effective Date and end on March 31, 2008.

     1.49 “Force Majeure” means any occurrence beyond the reasonable control of a Party
that (a) prevents or substantially interferes with the performance by such Party of any of its
obligations hereunder and (b) occurs by reason of any act of God, flood, fire, explosion,
earthquake, strike, lockout, labor dispute, casualty or accident, or war, revolution, civil
commotion, act of terrorism, blockage or embargo, or any injunction, law, order, proclamation,
regulation, ordinance, demand or requirement of any government or of any subdivision, authority or
representative of any such government.

     1.50 “FTE” shall mean [***] hours of work devoted to or in support of the ARCHEMIX
Research Activities and/or the ARCHEMIX Additional Activities that is carried out by one or more
employees of ARCHEMIX, measured in accordance with ARCHEMIX’s time allocation practices as
applicable at the relevant time.

     1.51 “FTE Cost” means, for any period, the FTE Rate multiplied by the applicable
number of FTEs in such period.

     1.52 “FTE Rate” means [***] Dollars (US $[***]). For purposes of clarity, the FTE
Rate does not include any [***] set forth in Section 5.2.4.

     1.53 “GAAP” means United States generally accepted accounting principles, consistently
applied.

     1.54 “Generic Product” means a pharmaceutical product that (i) contains the same
active ingredient as the Product, and (ii) is bioequivalent to such Product.

     1.55 “[***] Study” means a study performed in accordance with the [***].

     1.56 “Hatch-Waxman Act” means the Drug Price Competition and Patent Term Restoration
Act of 1984, as amended.

     1.57 “ICC” means the International Chamber of Commerce.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

8

 

     1.58 “IND” means: (a) an Investigational New Drug Application as defined in the
FDCA and regulations promulgated thereunder or any successor application or procedure required to
initiate clinical testing of a Collaboration Aptamer in humans in the United States; (b) a
counterpart of an Investigational New Drug Application that is required in any other country or
region in the Territory before beginning clinical testing of a Collaboration Aptamer in humans in
such country or region; and (c) all supplements and amendments to any of the foregoing.

     1.59 “Indication” means any human indication, disease or condition, which can be
treated, prevented, cured or the progression of which can be delayed.

     1.60 “Initiation” means, with respect to a human clinical trial, the first date that a
subject or patient is dosed in such clinical trial.

     1.61 “In Vitro Diagnostics” means the use of the SELEX Process or aptamers identified
through the use of the SELEX Process in the assay, testing or determination, outside of a living
organism, of a substance in a test material. In Vitro Diagnostics shall include, among other
things, the use of the SELEX Process or aptamers identified through the use of the SELEX Process in
the assay, testing or determination: (a) outside of a living organism, (i) of a human substance in
a test material, often to identify or follow the progression of a disease or disorder, or to select
a patient for treatment; (ii) of a plant substance, animal substance or other substance in a test
material, often to identify or follow the progression of a disease, process, or disorder in a human
or non-human organism; and (iii) of environmental substances (as in water quality testing); and (b)
of a substance on a test material such as cells (as in FACS analysis or other measurements of
pathogens within biological samples) and (c) any other in vitro diagnostic use of the SELEX Process
or aptamers identified through the use of the SELEX Process in drug development processes,
including target identification, pre-clinical and clinical testing, and the following more specific
examples of uses of aptamer technology: (i) to observe, through protein profiling, protein levels
moving up or down in diseases or models of diseases, and to evaluate whether such proteins are
sensible targets for the development of therapeutic agents; (ii) to observe coordinated expression
of protein pathways in a variety of biological states in various systems; (iii) to study protein or
metabolite levels during pre-clinical drug candidate evaluation in response to putative therapeutic
agents during clinical trials (e.g., as markers of efficacy or response); and (iv) to study human
protein or metabolite levels in response to putative therapeutic agents during clinical trials
(e.g., as markers of efficacy or response). Notwithstanding the above, In Vitro Diagnostics does
not include any of the above-identified activities directed at the discovery or Development of
Aptamers by TAKEDA under and pursuant to the terms of this Agreement.

     1.62 “In Vivo Diagnostic Agent” means any product containing one or more aptamers that
is used for any human in vivo diagnostic purpose related to (inter alia) the identification,
quantification or monitoring of the propensity toward, or actual existence of, any disease state. For purposes of clarity, the use or development of an aptamer for the
treatment of human disease does not constitute In Vivo Diagnostics.

     1.63 “Joint Patent Rights” means Patent Rights that contain one or more
claims that cover Joint Technology.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

9

 

     1.64 “Joint Project Team” or “JPT” means the committee composed of
ARCHEMIX and TAKEDA representatives established pursuant to Section 2.2.

     1.65 “Joint Steering Committee” or “JSC” means the committee composed of
ARCHEMIX and TAKEDA representatives established pursuant to Section 2.1.

     1.66 “Joint Technology” means any Program Technology, other than Program
Aptamer-Specific Technology, that is jointly conceived or reduced to practice by employees of, or
consultants to, TAKEDA and employees of, or consultants to, ARCHEMIX. For purposes of clarity, any
Program Technology that relates to the SELEX Process or to the SELEX Technology shall not be
considered Joint Technology irrespective of which Party conceived or reduced to practice such
Program Technology.

     1.67 “Knowledge” means, with respect to a Party, the actual knowledge of the chief
executive officer or any vice president of such Party.

     1.68 “Licensed Patent Rights” means any ARCHEMIX Patent Rights and ARCHEMIX’s interest
in Joint Patent Rights that (a) contain one or more claims that cover any Collaboration Aptamer,
including its manufacture or formulation or a method of its delivery or use, or (b) are necessary
for TAKEDA to exercise the licenses and rights granted to it pursuant to Article 7. Licensed
Patent Rights existing as of the Effective Date, include, without limitation, those Patent Rights
listed on Schedule 3 attached hereto. For purposes of clarity, Licensed Patent Rights
shall exclude any Patent Rights, on a claim by claim basis, that relate solely to the SELEX Process
and the SELEX Technology.

     1.69 “Licensed Technology” means any ARCHEMIX Technology and ARCHEMIX’s interest in
Joint Technology that (a) relates to any Collaboration Aptamer, including its manufacture or its
formulation or a method of its delivery or of its use, or (b) is necessary for TAKEDA to exercise
the licenses and rights granted to it pursuant to Article 7.

     1.70 “Minimum FTE Funding Commitment” means, on a Fiscal Quarter by Fiscal Quarter
basis, with respect to each Target designated as a Program Target pursuant to Section 3.5.1 during
the Research Program Term and for which an Optimized Lead Compound has not been identified, the
funding of [***] FTE. For purposes of clarity, the Minimum FTE Funding Commitment per
Program Target per Fiscal Quarter set forth in the preceding sentence corresponds to [***] FTEs per
Program Target on an annual basis. To the extent that the first Fiscal Quarter following the
Effective Date of this Agreement is not a full three months, the Minimum FTE Funding Commitment for
such first Fiscal Quarter shall be prorated to account for the ratio between the total days
remaining in such Fiscal Quarter following the Effective Date and the total days in such Fiscal
Quarter.

     1.71 “Minimum Program Target Commitment” means one (1) Program Target upon
the initiation of research by ARCHEMIX on a first Program Target pursuant to Section 3.3.1; two (2) Program Targets
upon the initiation of research by ARCHEMIX on a second Program Target;
and, upon the initiation of research by ARCHEMIX on a third Program
Target, a number of Program Targets [***] to the [***] between (a) [***]
the number of Program Targets for which an

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

10

 

[***] has been [***], and (b) the [***] of the number of Program Targets for which an
[***] has [***] been [***] and the number of [***] Targets listed on [***].

     1.72 “NDA” means a New Drug Application, as defined in the FDCA and regulations
promulgated thereunder or any successor application or procedure required to sell a Product in the
United States.

     1.73 “Net Sales” means the gross amount billed or invoiced by TAKEDA or any of its
Affiliates or Sublicensees to Third Parties throughout the Territory for sales or other
dispositions or transfers for value of Products less, as determined in accordance with GAAP, (a)
allowances for normal and customary trade, quantity and cash discounts actually allowed and taken,
(b) transportation, insurance and postage charges, if prepaid by TAKEDA or any Affiliate or
Sublicensee of TAKEDA and included on any such party’s bill or invoice as a separate item, (c)
credits, rebates, returns (including product recalls) pursuant to agreements (including, without
limitation, managed care agreements) or government regulations, to the extent actually allowed or
implemented, including without limitation, with respect to any Net Sales in Japan, any sales-based
contribution for “Drug Induced Suffering” and any sales-based contribution for “Contribution for
Measure for Drug Safety,” in each case as required by Applicable Laws or any Regulatory Authority,
in the amount determined by and payable to the Pharmaceuticals and Medical Devices Agency
(so-called “KIKO”), (d) sales, use and other consumption taxes similarly incurred to the extent
included on the bill or invoice as a separate item. In addition, Net Sales are subject to the
following:

          (a) If TAKEDA or any of its Affiliates or Sublicensees effects a sale, disposition or transfer
of a Product to a customer in a particular country other than on customary commercial terms or as
part of a package of products and services, the Net Sales of such Product to such customer shall be
deemed to be “the fair market value” of such Product. For purposes of this subsection (a), “fair
market value” shall mean the value that would have been derived had such Product been sold as a
separate product to another customer in the country concerned on customary commercial terms.

          (b) In the case of pharmacy incentive programs, hospital performance incentive program
chargebacks, disease management programs, similar programs or discounts on “bundles” of products,
all discounts and the like shall be allocated among products on the basis on which such discounts
and the like were actually granted or, if such basis cannot be determined, in proportion to the
respective list prices of such products or such other reasonable allocation method as the Parties
shall agree.

          (c) For purposes of clarity, use of any Product in clinical trials, pre-clinical studies or
other research or development activities, or disposal or transfer of Products for a bona fide
charitable purpose or a commercially reasonable sampling program, shall not give rise to any Net
Sales.

     1.74 “Optimized Lead Compound” or “Optimized Lead” means any
Program Aptamer that the JSC accepts as meeting the OLSC for such Program Target and
any Aptamer Derived therefrom. The Parties agree that any Program Aptamer for which
[***] shall be deemed to have been accepted as an Optimized Lead Compound by the JSC.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

11

 

     1.75 “Optimized Lead Compound Selection Criteria” or “OLSC” means the
guideline criteria for selecting Program Aptamers that are sufficiently promising to warrant
further research as an Optimized Lead Compound. The OLSC for the initial three (3) Program Targets
listed in Schedule 2A attached hereto as agreed upon between the Parties is incorporated into
Schedule 1. The OLSC shall be defined by the JSC for Pre-Approved Replacement Target as soon as
practicable after the selection of any Pre-approved Replacement Targets pursuant to Section 3.5.1,
but in any event, prior to the commencement of research activities with respect to any such
Pre-approved Replacement Target.

     1.76 “Patent Rights” means the rights and interests in and to issued patents and
pending patent applications (which, for purposes of this Agreement, include certificates of
invention, applications for certificates of invention and priority rights) in any country or
region, including all provisional applications, substitutions, continuations,
continuations-in-part, divisions, renewals, all letters patent granted thereon, and all reissues,
re-examinations and extensions thereof, and all foreign counterparts of any of the foregoing.

     1.77 “Permitted Activities” means (a) [***] to [***] and [***], any [***] ARCHEMIX
[***] or [***] for ARCHEMIX and/or for [***] for the [***] of [***] to a [***] than such [***] or
[***], as [***], and (b) [***] ARCHEMIX [***] and/or [***] Aptamers [***] and [***]; provided,
that, ARCHEMIX [***] or [***] in the [***] and/or [***] of any [***] Aptamers [***] of the [***]

     1.78 “Person” means an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust,
joint stock company, trust, incorporated association, joint venture or similar entity or
organization, including a government or political subdivision, department or agency of a
government.

     1.79 “Phase I Clinical Trial” means a clinical trial conducted in healthy humans or
patients, which clinical trial is designed to establish the safety, drug-drug interactions and/or
pharmacokinetics of an investigational drug given its intended use, and to support continued
testing of such drug in Phase II Clinical Trials.

     1.80 “Phase II Clinical Trial” means a clinical trial conducted in patients with a
particular disease or condition, which clinical trial is designed to establish the safety,
appropriate dosage and pharmacological activity of an investigational drug given its intended use,
and to initially explore its efficacy for such disease or condition.

     1.81 “Phase III Clinical Trial” means a pivotal clinical trial conducted in patients
with a particular disease or condition, which clinical trial is designed to ascertain efficacy and
safety of an investigational drug for its intended use and to define warnings, precautions and
Adverse Events that are associated with an investigational drug in the dosage range intended to be
prescribed, with the purpose of preparing and submitting applications for Regulatory Approval or
label expansion to the pertinent Regulatory Authority in any country.

     1.82 “Product” means any pharmaceutical or medicinal item, substance or
formulation that contains, incorporates or comprises a Collaboration Aptamer.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

12

 

     1.83 “Product Trademark” means any trademark or trade name, whether or not
registered, or any trademark application or renewal, extension or modification thereof, in the
Territory, or any trade dress and packaging, in each case (a) that are specifically applied to or
used with and obtained for any Product by TAKEDA and (b) together with all goodwill associated
therewith and promotional materials relating thereto.

     1.84 “Program Aptamer” means (a) any [***] oligonucleotide that (i) is an Aptamer that
[***] and (ii) was first identified in the performance of the Research or Development Program, (b)
[***] Aptamers Controlled by ARCHEMIX as of the Effective Date that [***] to the applicable Program
Target, and (c) any [***] any [***] this Section 1.84(a) or (b) where such Aptamer was first
identified in the performance of the Research Program or Development Program and binds to a Program
Target.

     1.85 “Program Aptamer-Specific Patent Rights” means all Patent Rights, on a claim by
claim basis, that contain, as a specific element, Program Aptamer-Specific Technology. Program
Aptamer-Specific Patent Rights where ARCHEMIX is the sole inventor or a joint inventor with TAKEDA
shall be “ARCHEMIX Program Aptamer-Specific Patent Rights” and Program Aptamer-Specific Patent
Rights where TAKEDA is the sole inventor shall be “TAKEDA Program Aptamer-Specific Patent
Rights.“ 

     1.86 “Program Aptamer-Specific Technology” means any Program Technology Controlled by
either Party at any time during the Exclusivity Term for a given Program Target that (a) has as an
element thereof a Collaboration Aptamer, including any Program Technology relating to the
composition, production, manufacture, formulation, delivery or use of a Collaboration Aptamer and
is specific for that Program Target; and/or (b) is specific for that Program Target. For purposes
of illustration with respect to Sections 1.85, 1.86, 1.88 and 1.89, (i) the nucleotide sequence of
an Aptamer that binds a Program Target would be considered Program Aptamer-Specific Technology and
any Patent Rights that specify that nucleotide sequence would be considered Program
Aptamer-Specific Patent Rights and (ii) the composition of the oligonucleotide pool (e.g., deoxy
purines and 2’ O-methyl substituted pyrimidines) from which the specific nucleotide sequence was
obtained would be considered Program Generic Technology and any Patent Rights that encompass the
pool composition but do not specify the particular nucleotide sequence(s) of an Aptamer that bind
to a Program Target would be considered Program Generic Patent Rights.

     1.87 “Program Chemistry” means the proprietary molecules, methods and/or processes
listed on Schedule 6 attached hereto to be used by ARCHEMIX in the conduct of the Research
Program and any proprietary molecules, methods and/or processes generically identified on
Schedule 6.

     1.88 “Program Generic Patent Rights” means all Patent Rights, on a claim by claim
basis, that cover Program Generic Technology but do not contain as a specific element Program
Aptamer-Specific Technology.

     1.89 “Program Generic Technology” means any Program Technology that is not
Program Aptamer-Specific Technology and that relates generally to the composition,
discovery, generation, optimization, manufacture, formulation, delivery or use of
aptamers.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

13

 

     1.90 Program Target” means the Targets listed on Schedule 2A attached
hereto, as amended from time to time in accordance with Section 3.5.

     1.91 “Program Technology” means any Technology (including, without limitation, any new
and useful process, method of manufacture or composition of matter) or Proprietary Materials that
are conceived or first reduced to practice (actively or constructively) by either Party in the
conduct of the Research Program and/or the Development Program and by ARCHEMIX in the conduct of
ARCHEMIX Additional Activities.

     1.92 “Proprietary Materials” means tangible chemical, biological or physical materials
(a) that are furnished by or on behalf of one Party to the other Party in connection with this
Agreement, whether or not specifically designated as proprietary by the Transferring Party or (b)
that are otherwise conceived and reduced to practice in the conduct of the Research Program or the
Development Program.

     1.93 “Prosecution” or “Prosecute” means the preparation, filing, prosecution
and/or maintenance of Patent Rights including any reissue and re-examination proceedings relating
to the foregoing; provided, however, that any interference, opposition or similar proceedings
relating to any Aptamer-Specific Patent Rights shall be classified as an Infringement subject to
Section 9.2.1(b)(ii).

     1.94 “Quarterly FTE Payment” means the amount of R&D Funding payable by TAKEDA to
ARCHEMIX for FTEs for each Fiscal Quarter of the Research Program Term pursuant to Section 5.2,
which shall equal the product of the number of FTEs required by the Minimum FTE Funding Commitment
times the number of Program Targets required by the Minimum Program Target Commitment times the FTE
Rate.

     1.95 “Radio Therapeutic” means any product for human therapeutic use that contains one
or more Aptamers that targets specifically any diseased tissue, cells or disease-specific molecules
or any tissue or cells which are affected by a disease or located in the close neighborhood of a
disease process and is linked to or incorporates (a) radionucleotides or (b) any structure or
elements which develop therapeutic effects similar to the effect of linking or incorporating
radionucleotides after submission of any kind of radiation.

     1.96 “R&D Funding” means the aggregate funding provided by TAKEDA to ARCHEMIX in
connection with the conduct by ARCHEMIX of the ARCHEMIX Research Activities and/or ARCHEMIX
Additional Activities, as the case may be, which shall be equal to the aggregate FTE Cost for all
FTEs expended by ARCHEMIX in connection therewith, based on the FTE Rate.

     1.97 “Regulatory Approval” means, with respect to any country or region in the
Territory, any approval, product and establishment license, registration or authorization of any
Regulatory Authority required for the manufacture, use, storage, importation, exportation, distribution, transport or sale of a Product in the Field in such
country or region.

     1.98 “Regulatory Authority” means the FDA, or any counterpart of the FDA
outside the United States, or any other national, supra-national, regional, state or
local regulatory agency, department, bureau, commission, council or other governmental
entity with authority over the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

14

 

distribution, importation, exportation, manufacture, production, use, storage, transport,
clinical testing or sale of a Product.

     1.99 “Regulatory Filings” means, collectively: (a) all INDs, establishment license
applications, drug master files, applications for designation as an “Orphan Product(s)” under the
Orphan Drug Act, for “Fast Track” status under Section 506 of the FDCA (21 U.S.C. § 356) or for a
Special Protocol Assessment under Section 505(b)(4)(B) and (C) of the FDCA (21 U.S.C. §
355(b)(4)(B)), NDAs and BLAs and all other similar filings (including, without limitation,
counterparts of any of the foregoing in any country or region in the Territory); (b) all
supplements and amendments to any of the foregoing; and (c) all data and other information
contained in, and correspondence relating to, any of the foregoing.

     1.100 “Research Program” means the research program to be conducted by the Parties
during the Research Program Term pursuant to the Annual Research Plan up to and including the
selection of Optimized Lead Compounds. For purposes of clarity, the Research Program does not
include any Development activities performed in the course of the Development Program.

     1.101 “Research Program Term” means the period beginning on the Effective Date and
ending on June 11, 2010, or such later date as the Parties may mutually agree in writing; provided,
that, (a) the Research Program Term ending June 11, 2010, may be extended for up to two (2)
additional periods of one (1) year each upon the mutual agreement of the Parties, subject to
ARCHEMIX’s commitment to continue to provide FTEs, and TAKEDA’s commitment to continue to provide
ARCHEMIX with the R&D Funding applicable thereto pursuant to Section 5.2.1, in order to discover
Optimized Lead Compounds for one or more Program Targets; and (b) if this Agreement is terminated
prior to the end of the Research Program Term, the effective date of such early termination shall
become the last day of the Research Program Term. For purposes of clarity, under no circumstances
shall the Research Program Term be extended beyond the fifth anniversary of the Effective Date.

     1.102 “ROW Territory” means all counties and territories of the world other than the
[***].

     1.103 “Royalty Term” means, on a Product-by-Product and country-by-country basis, the
period beginning on the date of First Commercial Sale of a given Product in a country and ending on
the later to occur of (a) expiration of the last to expire Valid Claim of a Royalty Triggering
Patent Right as to such Product in such country and (b) [***] years from the date of the First
Commercial Sale of such Product in such country. For purposes of clarity, [***] years after the
First Commercial Sale of a Product, the Royalty Term will expire as to a given Product in a given
country if the Product is being manufactured, used, offered for sale or sold without the
infringement of any Valid Claim of any Royalty Triggering Patent Rights as a result of such
activities.

     1.104 “Royalty Triggering Patent Rights” means, on a Product-by-Product
and country-by-country basis, those Valid Claims within the Licensed Patent Rights,
ARCHEMIX Program Aptamer-Specific Patent Rights and Joint Patent Rights, that are
scheduled according to Section 9.2.4, subject to the dispute resolution procedures set
forth in Section 9.2.4, that would be infringed by the manufacture, use, offer for
sale or sale of a Product in a given country absent the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

15

 

license granted under this Agreement. For purposes of clarity, the making, using, offering
for sale and selling activities of a particular Product may be covered by Royalty Triggering Patent
Rights in one country and not be covered by any Royalty Triggering Patent Rights in another
country. Also for purposes of clarity, TAKEDA Program Aptamer-Specific Patent Rights are excluded
from Royalty Triggering Patent Rights.

     1.105 “SELEX Portfolio” means those Patent Rights licensed by Gilead to ARCHEMIX
pursuant to the ARCHEMIX-Gilead License Agreement.

     1.106 “SELEX Process” means any process for the identification or generation of an
oligonucleotide that binds to a Target by means other than Watson-Crick base-pairing including any
process that is covered by, (a) the SELEX Portfolio, including, without limitation, U.S. Patent
Nos. [***] or [***] and any continuations, divisionals, and continuations-in-part, substitutions,
renewals, reissues, re-examinations and extensions thereof, or (b) any other Patent Rights directed
to the SELEX Process Controlled by ARCHEMIX.

     1.107 “SELEX Technology” means (a) oligonucleotides that bind to a Target by means
other than Watson-Crick base-pairing that consist of or incorporate structural elements that are
generally applicable to such oligonucleotides independent of Targets (e.g., a novel nucleoside,
bond or linkage or combination(s) thereof, for example, deoxypurine and 2’O-methyl substituted
prymidine compositions) as used in such oligonucleotides, and (b) any process for modifying,
optimizing and/or stabilizing oligonucleotides that bind to a Target by means other than
Watson-Crick base-pairing that is generally applicable to such oligonucleotides independent of
Targets wherein such modification, optimization or stabilization includes, without limitation,
minimization, truncation, conjugation, pegylation, complexation, substitution, deletion and/or
incorporation of modified nucleotides; provided, however, that SELEX Technology does not include
Program Aptamers.

     1.108 “sNDA” means a Supplemental New Drug Application, as defined in the FDCA and
applicable regulations promulgated thereunder.

     1.109 “Sublicense Agreement” means any agreement entered into by TAKEDA with a
Sublicensee.

     1.110 “Sublicensee” means any Third Party to which TAKEDA grants a sublicense under
the licenses granted to it under Section 7.1 or 7.2.

     1.111 “Supplemental Product” means a therapeutically active ingredient incorporated
into a Combination Product where such therapeutically active ingredient is not a Product.

     1.112 “TAKEDA Background Technology” means any Technology that is used by
TAKEDA, or provided by TAKEDA for use, in the Research Program and/or Development Program that is (a) Controlled by
TAKEDA as of the Effective Date or (b) conceived or first reduced to
practice by employees of, or consultants to, TAKEDA after the Effective
Date other than in the conduct of TAKEDA Research Activities or TAKEDA
Development Activities. For purposes of clarity, TAKEDA Program
Technology or TAKEDA’s interest in Joint Technology shall not include
TAKEDA Background Technology.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

16

 

     1.113 “TAKEDA Patent Rights” means any Patent Rights Controlled by TAKEDA that
contain one or more claims that cover TAKEDA Technology.

     1.114 “TAKEDA Program Technology” means (a) any Program Technology that is not
ARCHEMIX Program Technology or Joint Technology; and (b) any Program Aptamer-Specific Technology.

     1.115 “TAKEDA Research Activities” means all activities specified to be conducted by
TAKEDA in any Annual Research Plan (or amendment thereto) that are approved by the JPT and JSC.
For purposes of clarity, TAKEDA Research Activities may include the contribution by TAKEDA to the
Research Program of certain disease biology and cellular assay expertise and Technology.

     1.116 “TAKEDA Technology” means, collectively, TAKEDA Background Technology and TAKEDA
Program Technology.

     1.117 “Target” means a protein, cytokine, enzyme, receptor, transducer, transcription
factor, antigen or any other non-nucleic acid molecule.

     1.118 “Target Replacement List” means the list of Targets on Schedule 2B
attached hereto, as amended pursuant to Section 3.5.1.

     1.119 “Technology” means, collectively, inventions, discoveries, improvements, trade
secrets and proprietary methods, whether or not patentable, including, without limitation: (a)
methods of production or use of, and structural and functional information pertaining to, chemical
compounds; and (b) compositions of matter, data, formulations, processes, techniques, know-how and
results (including, without limitation, any negative results).

     1.120 “Terminated Product”means any Product which TAKEDA was Developing or
Commercializing as to which TAKEDA determined to discontinue Development and provided a Product
Termination Notice to ARCHEMIX pursuant to Section 7.1.2(d)(i)

     1.121 “Territory” means all countries and territories of the world.

     1.122 “Third Party” means a Person other than TAKEDA and ARCHEMIX and their respective
Affiliates.

     1.123 “ULEHI” means University License Equity Holdings, Inc., formerly known as UTC.

     1.124 “URC License Agreement” means the Restated Assignment and License Agreement,
dated July 17, 1991, by and between University Research Corporation and Gilead Sciences, Inc. as
successor in interest to NeXstar Pharmaceuticals.

     1.125 “UTC” means University Technology Corporation, the successor to the
University Research Corporation.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

17

 

     1.126 “Valid Claim” means any claim of an issued, unexpired patent that (a) has
not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other
body of competent jurisdiction, (b) has not been permanently revoked, held invalid, or declared
unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that
is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered
unenforceable through disclaimer or otherwise, and (d) is not lost through an interference
proceeding.

     1.127 “Waived Compound” means any Collaboration Aptamer directed against a Waived
Target.

     1.128 “Waived Target” means any Program Target for which TAKEDA has discontinued the
Research Program prior to the designation of an Optimized Lead Compound for such Program Target and
provided a Waived Target Designation Notice to ARCHEMIX pursuant to Section 7.1.2.(c)(i).

     Additional Definitions. In addition, each of the following definitions shall have the
respective meanings set forth in the section of this Agreement indicated below:

	 	 	 
	Definition	 	Section
	Applicable Milestone Payment
	 	7.1.2(d)(ii)(F)
	Applicable Percentage
	 	7.1.2(d)(ii)(F)
	ARCHEMIX Commitment
	 	7.1.2(d)(ii)
	ARCHEMIX Indemnitees
	 	12.2
	Claims
	 	12.1
	Clinical Data
	 	7.1.2(e)(ii)(F)
	Designated Senior Officers
	 	13.1
	Disputed Patent Matter
	 	9.1.1(b)
	Disputed Royalty Matter
	 	5.4.1(i)
	Dispute
	 	13.1(a)
	Disputed Matter
	 	2.1.3(c)
	Exclusive License Notice
	 	7.1.2(f)(ii)
	Failed Target Opportunity Notice
	 	7.1.2(c)(iv)
	[***]% Royalty Reduction
	 	5.4.1(e)
	Filing Party
	 	9.1.4
	[***] Indemnitee
	 	12.3
	Indemnified Party
	 	12.4
	Indemnifying Party
	 	12.4
	Infringement
	 	9.2.1(a)
	Infringement Notice
	 	9.2.1(a)
	Losses
	 	12.1
	Material Use
	 	7.1.2(d)(ii)(F)
	Milestone Payment Due Date
	 	7.1.2(d)(ii)(F)
	Non-Filing Party
	 	9.1.4
	Notice Period
	 	7.1.2(c)(iv)
	Patent Coordinator
	 	8.6
	 
	 	 
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

18

 

	 	 	 
	Definition	 	Section
	Pre-approved Replacement Target
	 	3.5.1(b)
	Proceeding
	 	13.2
	Product Termination Notice
	 	7.1.2(d)(i)
	Quarterly Reconciliation Statement
	 	5.2.1
	Recipient Party
	 	3.7
	Requested Chemistry
	 	5.4.1(d)
	ROFN Notice
	 	7.1.2(c)(iv)
	TAKEDA Indemnitees
	 	12.1
	Term
	 	10.1
	Third Party Chemistry Payments
	 	5.4.1(d)
	Third Party Costs
	 	5.2.4
	Third Party Payments
	 	5.4.1(d)
	Transferring Party
	 	3.7
	Waived Target Designation Notice
	 	7.1.2(c)(i)

2. ADMINISTRATION OF THE COLLABORATION

     2.1 Joint Steering Committee.

          2.1.1 Establishment. Within [***] days from the Effective Date, ARCHEMIX and TAKEDA
shall identify the members of the Joint Steering Committee. Unless otherwise agreed by the
Parties, the term for the JSC shall commence as of the Effective Date and continue until the last
day of the Research Program Term. The JSC shall have and perform the responsibilities set forth in
Section 2.1.4.

          2.1.2 Membership. Each Party shall designate in writing, in its sole discretion,
[***] members to the JSC, which shall be employees of such Party or an Affiliate of such Party.
Unless otherwise agreed by the Parties, one of TAKEDA’s designees shall be designated by TAKEDA as
the Chair. Each Party shall have the right at any time to substitute individuals, on a permanent
or temporary basis, for any of its previously designated representatives to the JSC, by giving
written notice to the other Party.

          2.1.3 Meetings.

                    (a) Schedule of Meetings; Agenda. The
JSC shall establish a schedule of times for regular meetings, taking
into account the planning needs of the Collaboration and its
responsibilities. In urgent cases, special meetings of the JSC may
be convened by any member upon [***] days
(or, if such meeting is proposed to be
conducted by teleconference, upon [***]
days) written notice to the other
members; provided, that, (i) notice of
any such special meeting may be waived at
any time, either before or after such
meeting, and such waiver shall be the
equivalent to the giving of a valid
notice hereunder, and (ii) attendance of
any member at a special meeting shall
constitute a valid waiver of notice from
such member. In no event shall the JSC
meet less frequently than once in each
Fiscal Quarter. Regular and special
meetings of the JSC may be held in person
or by teleconference or videoconference;
provided, that, meetings held in person
shall alternate between the respective
offices of the Parties. The Chair shall
prepare and

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

19

 

circulate to each JSC member an agenda for each JSC meeting not later than one (1) week prior
to such meeting.

                    (b) Quorum; Voting. At each JSC meeting (i) the presence in person of [***] member
designated by each Party shall constitute a quorum and (ii) all members designated by each Party
who are present shall have [***] on all matters before the JSC at such meeting. Alternatively, the
JSC may act by written consent signed by [***] member designated by each Party. Whenever any
action by the JSC is called for hereunder during a time period in which the JSC is not scheduled to
meet, the Chair shall cause the JSC to take the action in the requested time period by calling a
special meeting or by circulating a written consent. Representatives of each Party or of its
Affiliates who are not members of the JSC may attend JSC meetings as non-voting observers with the
consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed.

                    (c) Decisions. The JSC members shall use reasonable efforts to reach unanimous
agreement on any and all matters. Such reasonable efforts shall, if reasonably requested by any
member of the JSC, include the engagement of a mutually acceptable Person who is not affiliated
with either Party and has particular experience or expertise with respect to a particular matter to
advise the JSC, the expense of which engagement shall be borne equally by the Parties. In the
event that, despite such reasonable efforts, agreement on a particular matter cannot be reached by
the JSC within [***] days after the JSC first meets to consider such matter (each such matter, a
“Disputed Matter”), then such Disputed Matter will be decided pursuant to Section 2.1.6 and/or
Section 13.1.

                    (d) Minutes. The JSC shall keep minutes of its meetings that record all decisions and
all actions recommended or taken in reasonable detail. Drafts of the minutes shall be prepared and
circulated to the members of the JSC within a reasonable time after the meeting, not to exceed
[***] business days. The Chair shall have responsibility for the preparation and circulation of
draft minutes. Each member of the JSC shall have the opportunity to provide comments on the draft
minutes. The minutes shall be approved, disapproved and revised as necessary at the next JSC
meeting or within [***] days of the meeting whichever occurs first. Upon approval, final minutes
of each meeting shall be circulated to the members of the JSC by the Chair.

          2.1.4 Responsibilities. The JSC shall be responsible for overseeing the conduct and
progress of and making all significant decisions regarding the scope, content, cost, and timing of
the Research Program. Without limiting the generality of the foregoing, the JSC shall have the
following responsibilities:

                    (a) overseeing the JPT’s performance of its responsibilities;

                    (b) reviewing and approving each Annual Research Plan;

                    (c) reviewing and approving any amendment to an Annual Research Plan approved by the JPT and
submitted to it for its approval;

                    (d) reviewing data, reports or other information submitted to it by the JPT from time to time;

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

20

 

                    (e) resolving all JPT matters that are in dispute;

                    (f) defining the characteristics of the OLSC for each Program Target;

                    (g) reviewing and either approving or rejecting any decision of the JPT to nominate any
Program Aptamer as an Optimized Lead Compound;

                    (h) determining whether a Program Target should be designated as a Failed Target;

                    (i) determining whether a milestone has been achieved under this Agreement for which a
milestone payment is payable;

                    (j) determining the appropriate method of determining royalties for a Combination Product
pursuant to the last sentence of Section 5.4.1(i); and

                    (k) making such other decisions as may be delegated to the JSC pursuant to this Agreement or
by mutual written agreement of the Parties after the Effective Date.

          2.1.5 Interests of the Parties. Notwithstanding any other provisions of this
Agreement, all decisions made and all actions taken by the JSC shall be made or taken in the best
interest of the Collaboration.

          2.1.6 Research Related Dispute Resolution. If a Disputed Matter arises within the JSC
through the course of seeking to make decisions pursuant to Section 2.1.3(c), such Disputed Matter
shall be resolved pursuant to this Section 2.1.6. If the Disputed Matter does not involve an
Excepted Decision or an ARCHEMIX Decision, and except as set forth in the last sentence of this
section, TAKEDA shall have the sole right to make the final decision on such Disputed Matter, but
shall only exercise such right in good faith after full consideration of the positions of both
Parties. Notwithstanding the foregoing, (a) if the Disputed Matter involves an ARCHEMIX Decision,
then ARCHEMIX shall have the sole right to make the final decision on such Disputed Matter but
shall only exercise such right in good faith after full consideration of the positions of both
Parties and (b) if the Disputed Matter involves an Excepted Decision, the Disputed Matter shall be
resolved in accordance with Section 13.1. For purposes of clarity, except with respect to ARCHEMIX
Decisions and Excepted Decisions, TAKEDA shall have the sole and final decision-making authority
regarding all issues with respect to the Development of Optimized Lead Compounds and the
Commercialization of Products and under no circumstances shall the determination of whether TAKEDA
or ARCHEMIX has used or is using Commercially Reasonable Efforts be submitted for resolution under
this Section 2.1.6

     2.2 Joint Project Team.

          2.2.1 Establishment. Within [***] days from the Effective Date, ARCHEMIX and TAKEDA
shall identify the members of the Joint Project Team. Unless otherwise agreed by the Parties, the
term for the JPT shall commence as of the Effective Date and continue until the last day of the
Research Program Term. The JPT shall have and perform the responsibilities set forth in Section
2.2.4.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

21

 

          2.2.2 Membership. Each Party shall designate in writing, in its sole discretion,
[***] members to the JPT which shall be employees of such Party or an Affiliate of such Party.
Unless otherwise agreed by the Parties, one of [***] designees shall be designated by [***] as the
Chair of the JPT. Each Party shall have the right at any time to substitute individuals, on a
permanent or temporary basis, for any of its previously designated representatives to the JPT, by
giving written notice to the other Party.

          2.2.3 Meetings.

                    (a) Schedule of Meetings; Agenda. The JPT shall establish a schedule of times for
regular meetings, in no event less frequently than once per [***], taking into account, without
limitation, the planning needs of the Research Program and its responsibilities. In urgent cases,
special meetings may be convened by any member upon [***] days (or, if such meeting is proposed to
be conducted by teleconference, upon [***] days) written notice to the other members; provided,
that, (i) notice of any such special meeting may be waived at any time, either before or after such
meeting, and such waiver shall be the equivalent to the giving of a valid notice hereunder, and
(ii) attendance of any member at a special meeting shall constitute a valid waiver of notice from
such member. Regular and special meetings of the JPT may be held in person or by teleconference or
videoconference; provided, that, meetings held in person shall alternate between the respective
offices of the Parties. The chair of the JPT shall prepare and circulate to each JPT member an
agenda for each JPT meeting no later than [***] prior to such meeting.

                    (b) Quorum; Voting. At each JPT meeting, (i) the presence in person of at least [***]
members designated by each Party shall constitute a quorum and (ii) all members designated by each
Party who are present shall have [***] on all matters before the JPT at such meeting.
Alternatively, the JPT may act by written consent signed by at least [***] members designated by
each Party. Whenever any action by the JPT is called for hereunder during a time period in which
the JPT is not scheduled to meet, the chair of the JPT shall cause the JPT to take the action in
the requested time period by calling a special meeting or by circulating a written consent.
Representatives of each Party or of its Affiliates who are not members of the JPT (including,
without limitation, the Patent Coordinators) may attend JPT meetings as non-voting observers
without the consent of the other Party.

                    (c) Decisions. The JPT shall resolve all matters before it by unanimous vote of the
JPT. In the event that the JPT is unable to resolve any matter before it, such matter shall be
referred to the JSC for decision, and, in case the JSC is unable to resolve the matter, it shall be
resolved in accordance with Section 2.1.6.

                    (d) Minutes. The JPT shall keep minutes of its meetings that record all decisions and
all actions recommended or taken in reasonable detail. Drafts of the minutes shall be prepared and
circulated to the members of the JPT within a reasonable time after the meeting, not to exceed [***] business days. The chair of the JPT
shall have responsibility for the preparation and circulation of draft minutes. Each member of the
JPT shall have the opportunity to provide comments on the draft minutes. The minutes shall be
approved, disapproved or revised as necessary at the next JPT meeting; and then sent to the JSC
members of each Party who may nullify any decision by the JPT affecting the scope, content, cost,
and timing of the Research

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

22

 

Program. The decisions specified in the JPT minutes shall be deemed ratified if no written
objection is raised within [***] days of the JPT minutes being sent to the JSC members. Upon
approval, final minutes of each meeting shall be circulated to the members of the JPT by the chair
of the JPT.

          2.2.4 Responsibilities. The JPT shall be responsible for overseeing the day-to-day
conduct and progress of the Research Program and the recommendation of Optimized Lead Compounds.
Without limiting the generality of the foregoing, the JPT shall have the following
responsibilities:

                    (a) preparing or directing the preparation of all Annual Research Plans to be submitted to the
JSC for approval by the JSC;

                    (b) preparing or directing the preparation of any amendments to an Annual Research Plan that
the JPT unanimously deems appropriate in furtherance of the objectives of the Research Program as
set forth in the Annual Research Plan, provided, however, that only the JSC may approve an
amendment to an Annual Research Plan submitted to the JSC for approval by the JSC;

                    (c) monitoring the progress of each Annual Research Plan and of each Party’s activities
thereunder;

                    (d) providing a forum for consensual decision making with respect to the Research Program;

                    (e) reviewing data, reports or other information submitted by either Party with respect to
work conducted in the Research Program;

                    (f) preparing for the JSC on at least a semi-annual basis a progress report for the Research
Program in reasonable detail and providing to the JSC such additional information as it may
request;

                    (g) recommending to the JSC amendments to the OLSC as it deems appropriate in furtherance of
the objectives of the Research Program, as set forth in the Annual Research Plan;

                    (h) recommending to the JSC that a Program Target be designated as a Failed Target;

                    (i) nominating Program Aptamers as Optimized Lead Compounds for acceptance by the JSC; and

                    (j) making any other decisions as may be delegated to the JPT by JSC as reflected in the
approved minutes of the JSC.

          2.2.5 Interests of the Parties. Notwithstanding any other provisions of this
Agreement, all decisions made and all actions taken by the JPT shall be made or taken in the best
interest of the Collaboration.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

23

 

3. RESEARCH PROGRAM

     3.1 Objectives of the Research Program. The objectives of the Research Program shall
be the identification of Program Aptamers for nomination by the JPT to the JSC for approval as
Optimized Lead Compounds pursuant to this Agreement. Except for the TAKEDA Research Activities, if
any, which shall be conducted by TAKEDA at its sole expense, ARCHEMIX shall have the primary right
and responsibility to conduct the Research Program.

     3.2 Annual Research Plans

          3.2.1 Annual Research Plans. The initial Annual Research Plan and budget, which
describes the research activities to be carried out by each Party during the first Fiscal Year of
the Research Program Term for the initial Program Targets shall be prepared by the JPT and
submitted to, and approved by, the JSC within [***] days of the Effective Date. For each subsequent
Fiscal Year during the Research Program Term commencing with the second Fiscal Year, an Annual
Research Plan and budget shall be prepared by or at the direction of the JPT and submitted to the
JSC for its approval. The JPT shall manage the preparation of each Annual Research Plan in a
manner designed to obtain JSC approval no later than [***] days prior to the end of the
then-current Fiscal Year. Each Annual Research Plan shall: (a) set forth (i) the research
objectives and activities to be performed for the Fiscal Year covered by the Annual Research Plan
with reasonable specificity, (ii) the research plans and protocols to be employed to complete each
stage of the Research Program, (iii) changes to the OLSC for each Program Target and any other
criteria that the JPT utilizes to evaluate the results of the Research Program in order to nominate
Optimized Lead Compounds for Program Targets, (iv) the Party that shall be responsible for
performing such activities, (v) a timeline and budget for such activities (including any Third
Party Costs), and (vi) with respect to ARCHEMIX Research Activities, the number of FTEs estimated
to be required to perform such activities, and (b) shall be consistent with the other terms of this
Agreement. Without limiting the generality of the foregoing, the objectives of each Annual Research
Plan shall include, as appropriate from time to time during the Research Program Term, conducting
the necessary research activities to identify Program Aptamers or to determine whether Program
Aptamers should be nominated to the JSC as Optimized Lead Compounds. Any Annual Research Plan may
be amended from time to time by the JSC pursuant to Section 2.1.4. Each amendment, modification
and update to the Annual Research Plan shall include the resulting changes to the budget, including
the number of FTEs to be utilized by ARCHEMIX, and shall be set forth in a written document
prepared by, or at the direction of, the JPT and approved by the JSC, shall specifically state that
it is an amendment, modification or update to the Annual Research Plan and shall be attached to the
minutes of the meeting of the JSC at which such amendment, modification or update was approved by
the JSC. Without limiting the nature or frequency of any other amendments, modifications or
updates to the Annual Research Plan that may be approved by the JSC, the Annual Research Plan shall
be updated at least once prior to the end of each Fiscal Year to describe the research activities
to be carried out by each Party during the upcoming Fiscal Year during the Research Program Term in
conducting the Research Program pursuant to this Agreement.

          3.2.2 Minimum Research Commitment. TAKEDA shall at all times during the Research
Program Term provide research support for a number of Program Targets equal to the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

24

 

Minimum Program Target Commitment and ARCHEMIX shall provide sufficient resources to perform
its obligations pursuant to the Annual Research Plan for such Program Targets.

          3.2.3 Minimum FTE Funding Commitment. During the Research Program Term, TAKEDA shall
provide funding equal to at least the Minimum FTE Funding Commitment for as many Program Targets as
are required under the Minimum Program Target Commitment.

     3.3 Conduct of Research Program.

          3.3.1 ARCHEMIX Responsibilities. Except as set forth in Section 3.3.2, ARCHEMIX shall
have the primary right and responsibility for all activities with respect to the Research Program,
including all activities with respect to the identification of Program Aptamers, up through the
identification of an Optimized Lead Compound pursuant to Section 3.6. Without limiting the
foregoing, during the Research Program Term, ARCHEMIX shall (a) conduct the ARCHEMIX Research
Activities using the number of FTEs set forth in the Annual Research Plan, and (b) conduct the
ARCHEMIX Additional Activities as requested by TAKEDA pursuant to Section 4.3 using a standard of
care not less than Commercially Reasonable Efforts. For the first three (3) Program Targets,
ARCHEMIX shall insure that ARCHEMIX Research Activities are initiated at a rate of [***] Program
Target per Fiscal Quarter with [***] Program Target being initiated, to the extent possible, within
[***] days of the Effective Date. Notwithstanding the foregoing, in no event shall ARCHEMIX be
required to initiate ARCHEMIX Research Activities and/or ARCHEMIX Additional Activities for more
than [***] Program Target per [***].

          3.3.2 TAKEDA Responsibilities. During the Research Program Term, TAKEDA shall: (a)
provide ARCHEMIX with such TAKEDA Background Technology, and conduct such TAKEDA Research
Activities, if any, as may be necessary or useful to further the objectives of the Research Program
or as otherwise may be set forth in any Annual Research Plan; (b) pay ARCHEMIX each Quarterly FTE
Payment in accordance with Section 5.2.1 and the R&D Funding to the extent the R&D Funding exceeds
the Quarterly FTE Payments; (c) give ARCHEMIX not less than [***] days’ written notice in the event
that TAKEDA requires a number of FTEs above [***] FTEs in any Fiscal Year; (d) commit such
resources as are reasonably necessary to conduct the TAKEDA Research Activities, if any, set forth
in any Annual Research Plan; and (e) use Commercially Reasonable Efforts to conduct the TAKEDA
Research Activities, if any, set forth in any Annual Research Plan.

          3.3.3 Compliance and Funding. Each Party shall perform its obligations under each
Annual Research Plan in compliance in all material respects with all Applicable Laws. For purposes
of clarity, with respect to each activity performed under an Annual Research Plan that will or
would reasonably be expected to generate data to be submitted to a Regulatory Authority in support
of a Regulatory Filing or Drug Approval Application, the Party performing such activity shall comply in all material respects
with the regulations and guidance of the FDA that constitute Good Laboratory Practice or Good
Manufacturing Practice (or, if and as appropriate under the circumstances, International Conference
on Harmonization (ICH) guidance or other comparable regulation and guidance of any Regulatory
Authority in any country or region in the Territory). Each Party shall be solely responsible for
paying the salaries, benefits and taxes of its employees conducting its activities under Article 3
of this Agreement.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

25

 

          3.3.4 Cooperation. Scientists at ARCHEMIX and TAKEDA shall cooperate in the
performance of the Research Program and, subject to the terms of this Agreement and any
confidentiality obligations to Third Parties, shall exchange such data, information and materials
as are reasonably necessary for the other Party to perform its obligations under any Annual
Research Plan.

     3.4  Records.

          3.4.1  Record Keeping.

                    (a) Research Program Records. Each Party shall maintain complete and accurate records
of its activities in the Research Program in sufficient detail, in good scientific manner and
otherwise in a manner that reflects all work done and results achieved. Subject to Article 6, each
Party shall provide the other Party with access during normal business hours and upon reasonable
advance notice to review such records to the extent reasonably required for the performance of such
other Party’s obligations and/or exercise of such other Party’s rights under this Agreement;
provided, that, the non-reviewing Party may redact information not relevant to the Research Program
prior to such review. Notwithstanding the foregoing, except in conjunction with a Proceeding
pursuant to Section 13.2, TAKEDA shall not have the right to review any records relating to any
Failed Compounds, Waived Compounds or Terminated Products, except for records relating to
activities conducted in the Research Program, in which case TAKEDA shall have the right to review
such records for up to [***] years after the designation of any such Failed Compounds, Waived
Compounds or Terminated Products for purposes of, and in connection with, an audit conducted in
accordance with Section 5.2.3.

                    (b) Record Keeping Policies. Without limiting the generality of Section 3.4.1(a),
each Party agrees to maintain a policy that requires its employees and consultants to record and
maintain all data and information developed during the Research Program.

          3.4.2 Reports. ARCHEMIX and TAKEDA shall keep the JPT regularly informed of the
progress of the Research Program. Without limiting the generality of the foregoing, (a) ARCHEMIX
shall, at each meeting of the JPT, (i) provide reports to the JPT in reasonable detail regarding
the status of its activities under the Research Program, (ii) advise the JPT of its identification
of Program Aptamers and provide the JPT with any supporting data applicable to such Program
Aptamers, (iii) provide the JPT with the results of activities conducted in the Research Program
with respect to each Program Aptamer so as to enable the JPT to determine whether such Program
Aptamer meets the OLSC and should be proposed to the JSC as an Optimized Lead Compound, (iv)
provide the JPT with such additional information that it has in its possession as may be reasonably
requested from time to time by the JPT, and (v) provide TAKEDA, on or before [***] days from the
termination or expiration of the Research Program Term, with a final report regarding all ARCHEMIX
Research Activities conducted by ARCHEMIX during the Research Program Term to the extent not previously included in the reports
described above, and (b) TAKEDA shall, at each meeting of the JPT, (i) provide the JPT with reports
in reasonable detail regarding the status of all TAKEDA Research Activities, if any, and such
additional information that it has in its possession as may be reasonably requested from time to
time by the JPT and (ii) provide ARCHEMIX, on or before [***] days from the termination or
expiration of the Research Program Term, with a final report regarding all

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

26

 

TAKEDA Research Activities, if any, conducted by TAKEDA during the Research Program Term to
the extent not previously included in the reports described above.

     3.5 Selection of Program Targets.

          3.5.1  Selection of Program Targets.

                    (a) Initial Program Targets. The Parties hereby acknowledge and agree that three (3)
Program Targets, as set forth on Schedule 2A, have been designated by the Parties as of the
Effective Date. The Parties further acknowledge and agree that there is a [***]that [***] will
[***] for the [***] and that the Parties shall promptly, but in no event later than [***] months
from the initiation of ARCHEMIX Research Activities against any such Program Target, evaluate the
need to replace each such Program Target with a Pre-approved Replacement Target. For purposes of
clarity, if after [***] months from the initiation of ARCHEMIX Research Activities against a
Program Target no Collaboration Aptamers binding to such Program Target have been identified,
either Party shall have the right to designate such Program Target a Failed Target; provided, that,
if the other Party disagrees with the designation, the Research Activities shall be carried out
with respect to such Program Target for an additional [***] months and if no Aptamers have been
identified upon the expiration of this [***] month period, such Program Target shall be deemed to
have been designated a [***] by the JSC for purposes of this Agreement without any further action
of either Party.

                    (b) Target Replacement List. The Parties hereby acknowledge and agree that three
(3)Targets, as set forth on the Target Replacement List on Schedule 2B, have been
designated by the Parties as replacement Targets as of the Effective Date (each such Target, a
“Pre-approved Replacement Target”). TAKEDA shall have the right at any time during the first two
(2) Fiscal Years of the Research Program Term to request that a Pre-approved Replacement Target on
the Target Replacement List be replaced with another new Pre-approved Replacement Target for any
reason in accordance with Section 3.5.1(c). Upon designation of a Pre-approved Replacement Target
as a Program Target, the Pre-approved Replacement Target will be removed from the Target
Replacement List and no additional Target will be added in its place on the Target Replacement
List.

                    (c) Replacement of Pre-approved Replacement Targets on Target Replacement List. To
the extent TAKEDA has the right to propose that a Target be added to the Target Replacement List as
a replacement for one of the then named Pre-approved Replacement Targets as described in Section
3.5.1(b), TAKEDA shall provide written notice to ARCHEMIX. ARCHEMIX shall accept or reject the
proposed Target within [***] days after receipt of such notice from TAKEDA. A Target proposed by
TAKEDA for inclusion as a Pre-approved Replacement Target on the Target Replacement List shall only
be rejected by ARCHEMIX if: (i) ARCHEMIX is prohibited by an executed contract from licensing
Aptamers against such proposed Target or its [***](s), (ii) ARCHEMIX is in active negotiations with
a Third Party with respect to a license, collaboration or similar agreement relating to Aptamers
against such Target or its [***](s), (iii) ARCHEMIX is actively researching or developing, and has not ceased to research
or develop, for its own benefit, Aptamers against such Target or its [***](s) under an internal
research or development program against such Target; or (iv) ARCHEMIX reasonably believes in good
faith that the conduct of research and/or Development activities with respect to

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

27

 

such Target as contemplated by this Agreement would infringe the Patent Rights or
misappropriate the Technology of a Third Party. Should ARCHEMIX reject a proposed replacement
Target for one of the Pre-approved Replacement Targets on the Target Replacement List under Section
3.5.1(c)(iii), if (i) ARCHEMIX discontinues its internal research for such Target during the
Research Program Term, and (ii) TAKEDA is still able to replace a Pre-approved Replacement Target
at such time, then ARCHEMIX shall notify TAKEDA of the ability to replace one of the Pre-approved
Replacement Targets on Target Replacement List with such previously nominated Target.

                    (d) Replacement of Program Targets. If at any time during the first two (2) full
years of the Research Program Term following the Effective Date, (i) the JSC designates a Program
Target as a Failed Target or (ii) a Program Target becomes a Waived Target, then (A) all activities
under the Research Program with respect to such Failed Target or Waived Target shall cease; and (B)
TAKEDA shall name one of the Pre-approved Replacement Targets from the Target Replacement List as a
Program Target in place of such Failed Target or Waived Target within [***] days of such date and
ARCHEMIX shall begin work to the extent possible on such new Program Target immediately thereafter.

                    (e) Obligations of JPT. As promptly as practicable after designation of a new Program
Target in accordance with Section 3.5.1(d), the JPT shall (i) develop and submit to the JSC for its
approval the OLSC for such new Program Target and (ii) prepare an update to the Annual Research
Plan to (A) include the ARCHEMIX Research Activities to be conducted to identify Program Aptamers
against such new Program Target for potential nomination as an Optimized Lead Compound and (B)
identify any Proprietary Materials, TAKEDA Background Technology and/or TAKEDA Research Activities
that will be provided or conducted by TAKEDA pursuant to Section 3.3.2(a).

          3.5.2 Termination of Replacement Right. Notwithstanding anything to the contrary in
this Agreement, TAKEDA’s right to add Pre-approved Replacement Targets to the Target Replacement
List pursuant to Section 3.5.1(b) and/or replace Program Targets pursuant to Section 3.5.1(d) shall
terminate on the second full year anniversary of the Effective Date of the Agreement.

     3.6 Identification of Optimized Lead Compounds. Within [***] days after its receipt
of each report from ARCHEMIX pursuant to Section 3.4.2 identifying a Program Aptamer as meeting the
applicable OLSC (or which either Party reasonably believes should be an Optimized Lead Compound),
the JPT shall review the data and information and determine whether to nominate the Program Aptamer
to the JSC for designation as an Optimized Lead Compound. If the JPT elects to nominate any such
Program Aptamer as an Optimized Lead Compound, the JPT shall promptly furnish all available
information to the JSC. The JSC shall consider such nomination within [***] days, and if the JSC
agrees that the Program Aptamer meets the OLSC, it shall be designated as such by the JSC and such
Program Aptamer shall be deemed to be an Optimized Lead Compound for purposes of this Agreement. Notwithstanding the above, TAKEDA
shall have the exclusive right to affirmatively designate a given Program Aptamer as an Optimized
Lead Compound at any time for any reason. For purposes of clarity, any decision that a Program
Aptamer does not meet the applicable OLSC and thus should not be

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

28

 

designated an Optimized Lead Compound shall at all times be an Excepted Decision pursuant to
Section 1.38.

     3.7 Supply of Proprietary Materials. From time to time during the Research Program
Term, either Party (the “Transferring Party”) may supply the other Party (the “Recipient Party”)
with Proprietary Materials of the Transferring Party for use in the Research Program. In
connection therewith, each Recipient Party hereby agrees that (a) it shall not use such Proprietary
Materials for any purpose other than exercising its rights or performing its obligations under this
Agreement; (b) it shall use such Proprietary Materials only in compliance with all Applicable Laws;
(c) it shall not transfer any such Proprietary Materials to any Third Party without the prior
written consent of the Transferring Party, except as expressly permitted by this Agreement; (d) the
Recipient Party shall not acquire any right, title or interest in or to such Proprietary Materials
as a result of such supply by the Transferring Party; and (e) upon the expiration or termination of
the Research Program Term, the Recipient Party shall, if and as instructed by the Transferring
Party, either destroy or return any such Proprietary Materials that are not the subject of the
grant of a continuing license hereunder.

     3.8 Research Program Term. The Research Program shall commence on the Effective Date
and shall continue until the last day of the Research Program Term. Notwithstanding the foregoing,
if, upon the expiration of the Research Program Term, ARCHEMIIX has not completed any ARCHEMIX
Research Activities contemplated by the applicable Annual Research Plan, then, subject to TAKEDA
continuing to make the R&D Funding contemplated by Section 5.2.1 with respect to such ARCHEMIX
Research Activities, ARCHEMIX shall continue to conduct such ARCHEMIX Research Activities until the
earlier of (a) the completion of such ARCHEMIX Research Activities and (b) the fifth anniversary of
the Effective Date.

     3.9 Evaluation of Program Aptamers for Satisfaction of OLSC Prior to Expiration of
Research Program Term. Upon the [***] ARCHEMIX [***] in [***] to [***] whether a [***] the
[***], ARCHEMIX [***] TAKEDA [***] a [***] of such [***] to [***] TAKEDA to [***], and, to the
[***] in [***] of such [***] to [***] TAKEDA to [***] whether such [***] the [***]. TAKEDA [***]to
[***] of such [***] of [***] to [***] whether such [***] the [***] to [***] whether such [***] the
[***].

     3.10 Evaluation of Program Aptamers for Satisfaction of OLSC After Expiration of Research
Program Term. To the extent that the Parties are researching a particular Program Target as of
the expiration of the Research Program Term and TAKEDA is evaluating Collaboration Aptamer(s) for
such Program Target pursuant to Section 3.9, then, regardless of the expiration of the Research
Program Term, TAKEDA shall have the time allotted under Section 3.9 to evaluate whether such
Collaboration Aptamer(s) satisfy the OLSC before being required to vote whether such Collaboration
Aptamer(s) satisfy the OLSC. During such time extending beyond the expiration of the Research
Program Term, the Program Target(s) associated with the Collaboration Aptamer(s) under evaluation shall remain Program Target(s) and the Exclusivity Term shall be
extended pursuant to Section 1.40.

4. DEVELOPMENT PROGRAM; COMMERCIALIZATION OF PRODUCTS

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

29

 

     4.1 Objectives of the Development Program. The objectives of the Development
Program shall be the selection and Development of Optimized Lead Compounds and Products Derived
therefrom to enable the Commercialization of such Products in the Field in the Territory.

     4.2 Responsibility for Development and Commercialization of Products. TAKEDA shall
have [***] and [***], consistent with Commercially Reasonable Efforts, for all aspects of the
Development and Commercialization of Products in the Field in the Territory, including, without
limitation, the conduct of: (a) all in vivo efficacy studies and primate PK studies if desired, and
all IND-enabling non-clinical studies that are outside of the Research Program; (b) all activities
related to human clinical trials (including, without limitation, Phase I Clinical Trials, Phase II
Clinical Trials and Phase III Clinical Trials); (c) all activities relating to the manufacture and
supply of Products (including all required process development and scale up work with respect
thereto); and (d) all pre-marketing, marketing, promotion, sales, distribution, import and export
activities (including securing reimbursement, conducting sales and marketing activities and any
post-marketing trials or post-marketing safety surveillance and maintaining databases). Without
limiting the generality of the foregoing, TAKEDA shall have [***] in the exercise of Commercially
Reasonable Efforts, (i) to make all Regulatory Filings for Products and file all Drug Approval
Applications and otherwise seek all Regulatory Approvals for Products, as well as to conduct all
correspondence and communications with Regulatory Authorities regarding such matters, and (ii) to
report all Adverse Events to Regulatory Authorities if and to the extent required by Applicable
Laws. All Regulatory Filings and Regulatory Approvals for Products shall be owned by TAKEDA,
subject to Sections 7.1.2(c) and 10.3.

     4.3 Technical Assistance. During the Term, ARCHEMIX may, upon TAKEDA’s reasonable
request, conduct ARCHEMIX Additional Activities, that may be necessary or useful to assist TAKEDA
or its Affiliates and Sublicensees in the research, Development or Commercialization of Products;
provided, that, ARCHEMIX Additional Activities shall be subject to the payment by TAKEDA of the R&D
Funding applicable thereto pursuant to Section 5.2.1. Unless otherwise agreed to by the Parties,
all ARCHEMIX Additional Activities shall be conducted by ARCHEMIX at its facility. For purpose of
clarity, and notwithstanding Section 1.10(c), ARCHEMIX will endeavour, to the extent that ARCHEMIX
is reasonably capable, to perform ARCHEMIX Additional Activities if such efforts can reasonably be
expected to benefit the Collaboration.

     4.4 Development and Commercialization Obligations.

          4.4.1 Diligence Obligations. With respect to each Aptamer that is designated as an
Optimized Lead Compound, TAKEDA shall exercise Commercially Reasonable Efforts during the Term to
Develop and Commercialize Products Derived from such Optimized Lead Compound in the Field in the
Territory.

          4.4.2 Justification. If ARCHEMIX at any time believes that TAKEDA is not meeting its
diligence obligations pursuant to Section 4.4.1, ARCHEMIX may give written notice to TAKEDA
describing, in as much detail as is reasonably possible, the bases upon which it believes that
TAKEDA is not meeting such diligence obligations. TAKEDA shall provide ARCHEMIX with a written
response within [***] days after such written notice by ARCHEMIX is given, responding to the
allegations raised by ARCHEMIX as to whether TAKEDA is meeting

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

30

 

its diligence obligations. In the event that TAKEDA does not provide a good faith written
response to ARCHEMIX within such [***] day period, then ARCHEMIX shall have the option, in its sole
discretion, to deem TAKEDA to have materially breached this Agreement pursuant to Section 10.2.2,
but only as to the Product(s) and country(ies) in relation to which ARCHEMIX raised the assertion
that TAKEDA has not met its diligence obligations. If TAKEDA provides a good faith written
response to ARCHEMIX within such [***] day period, and if ARCHEMIX nonetheless maintains its
assertion that TAKEDA is not meeting such diligence obligations, such dispute will be resolved
according to Section 13.1. In addition, if the Parties disagree as to whether the written response
provided by TAKEDA constitutes a good faith written response, such dispute will be resolved
according to Section 13.1.

          4.4.3 Uncontrollable Delays. The Parties understand and agree that delays outside the
control of TAKEDA may occur with regard to the Development and/or Commercialization of Products and
that the occurrence of such delays, in and of themselves, shall not be grounds for ARCHEMIX to
claim that TAKEDA has not been using Commercially Reasonable Efforts to avoid the occurrence of
such delays or to reduce the impact of such delays following their occurrence.

          4.4.4 Compliance. TAKEDA shall perform its Development and Commercialization
activities in good scientific manner and in compliance in all material respects with all Applicable
Laws. For purposes of clarity, with respect to each activity that will or would reasonably be
expected to generate data to be submitted to a Regulatory Authority in support of a Regulatory
Filing or Drug Approval Application, TAKEDA shall comply in all material respects with, if and as
applicable, the regulations and guidance of the FDA that constitute Good Laboratory Practice, Good
Manufacturing Practice or Good Clinical Practices, (or, if and as appropriate under the
circumstances, International Conference on Harmonization (ICH) guidance or other comparable
regulation and guidance of any Regulatory Authority in any country or region in the Territory).
Each Party shall be solely responsible for paying the salaries, benefits and taxes of its employees
conducting its activities under Article 4 of this Agreement.

     4.5 Cooperation. Scientists at ARCHEMIX and TAKEDA shall cooperate in the performance
of each Development Program and, subject to the terms of this Agreement and any confidentiality
obligations to Third Parties, shall exchange such data, information and materials as are reasonably
necessary for the other Party to perform its obligations under the Development Program.

     4.6 Exchange of Reports; Information; Updates.

          4.6.1 Preclinical Development of Products. Subject to Section 7.6.1(b), TAKEDA shall
keep ARCHEMIX informed of the progress of its preclinical efforts to Develop Products in the Field
in the Territory by providing ARCHEMIX at least once each Fiscal Quarter with a report in
reasonable detail regarding the status of all preclinical IND-enabling studies and other preclinical activities (including toxicology and
pharmacokinetic studies) for Products.

          4.6.2 Clinical Development of Products. Subject to Section 7.6.1(b), TAKEDA shall
keep ARCHEMIX informed of the progress of its clinical efforts to Develop Products in the Field in
the Territory by providing ARCHEMIX at least [***] with a report in reasonable detail

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

31

 

regarding the status of all Products undergoing clinical Development by TAKEDA in sufficient
detail so as to allow ARCHEMIX to monitor TAKEDA’s satisfaction of its diligence obligations as set
forth in Section 4.4.1. Such reports shall identify the Regulatory Filings and Drug Approval
Applications with respect to such Product that TAKEDA or any of its Affiliates or Sublicensees have
filed, sought or obtained and summarize all clinical and other data, whether positive or negative,
generated by TAKEDA with respect to Products.

          4.6.3 Commercialization Reports. Subject to Section 7.6.1(b), TAKEDA shall keep
ARCHEMIX informed of the progress of its efforts to Commercialize Products in the Field in the
Territory by providing ARCHEMIX at least [***] with a report in reasonable detail regarding the
status of all Products being Commercialized by TAKEDA in sufficient detail so as to allow ARCHEMIX
to monitor TAKEDA’s satisfaction of its diligence obligations as set forth in Section 4.4.

          4.6.4 Adverse Event Reports. In addition to the updates described in Sections 4.6.1
through 4.6.3, TAKEDA shall provide ARCHEMIX with all Adverse Event information relating to
Products as required by the Applicable Law(s) under which such Products are being Developed, such
information to be compiled or prepared by TAKEDA and provided to ARCHEMIX in the normal course of
TAKEDA’s business in connection with the Development of such Products and, in any event, within
time frames consistent with reporting obligations under Applicable Laws. If TAKEDA determines that
any reported Adverse Event is aptamer-specific, TAKEDA shall so notify ARCHEMIX within the earlier
of [***] days or the time frames that are consistent with reporting obligations under Applicable
Laws. In such event, ARCHEMIX may provide such Adverse Event information to the extent reasonably
necessary to licensees of ARCHEMIX who are currently researching, Developing or Commercializing
Aptamers for therapeutic purposes; provided, that, such licensees who are informed by ARCHEMIX (i)
have already agreed to maintain the confidentiality thereof and (ii) have agreed to share Adverse
Event information with ARCHEMIX and licensees of ARCHEMIX. ARCHEMIX will use reasonable efforts to
include in any license agreement with a Third Party to which ARCHEMIX grants a license to research,
Develop and/or Commercialize Aptamers for therapeutic purposes a provision permitting ARCHEMIX to
provide to TAKEDA Adverse Event information obtained from such licensees, subject to TAKEDA’s
confidentiality obligations under this Agreement. Notwithstanding anything to the contrary herein,
ARCHEMIX shall be permitted to provide any Adverse Event information received from TAKEDA to Third
Parties as required by Applicable Laws.

     4.7 Product Recalls. TAKEDA shall decide and have control of whether to conduct a
recall or market withdrawal (except in the event of a recall or market withdrawal mandated by a
Regulatory Authority, in which case it shall be required) or to take other corrective action in any
country and the manner in which any such recall, market withdrawal or corrective action shall be
conducted; provided, that, TAKEDA shall keep ARCHEMIX informed regarding any recall or market withdrawal mandated or requested
by a Regulatory Authority, such information to be compiled or prepared by TAKEDA and provided to
ARCHEMIX in the normal course of TAKEDA’s business and, in any event, within time frames consistent
with reporting obligations under Applicable Laws. TAKEDA shall bear all expenses of any such
recall, market withdrawal or corrective action (including, without limitation, expenses for
notification, destruction and return of the affected Product and any refund to customers of amounts
paid for such Product).

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

32

 

5. PAYMENTS

     5.1 Upfront Technology Access and License Fee. TAKEDA shall pay ARCHEMIX a
non-refundable, non-creditable technology access and license fee in the amount of Six Million
Dollars (US $6,000,000) by wire transfer within [***] days of the Effective Date, according to
instructions that ARCHEMIX shall provide.

     5.2 R&D Funding.

          5.2.1 Payment of R&D Funding. In consideration of the performance by ARCHEMIX of the
ARCHEMIX Research Activities and/or the ARCHEMIX Additional Activities, if any, TAKEDA will pay
ARCHEMIX the greater of (i) the Minimum Funding Commitment set forth in Section 3.2.3 and (ii) the
actual FTEs expended by ARCHEMIX provided such FTEs were authorized by TAKEDA under the Annual
Research Plan or as otherwise authorized in writing by TAKEDA. During the Research Program Term,
TAKEDA shall make the applicable Quarterly FTE Payment upon the initiation of research on the first
Program Target pursuant to Section 3.3.1 and on or prior to the first day of each subsequent Fiscal
Quarter. Within [***] days of the end of each Fiscal Quarter, (i) ARCHEMIX shall provide a report
to the JPT that specifies the actual number of FTEs expended during the period covered therein in
the conduct of (A) ARCHEMIX Research Activities and (B) ARCHEMIX Additional Activities, if any, and
(ii) ARCHEMIX shall provide TAKEDA with a reconciliation statement (“Quarterly Reconciliation
Statement”) that specifies the actual number of FTEs expended during such Fiscal Quarter in the
conduct of (A) ARCHEMIX Research Activities and (B) ARCHEMIX Additional Activities, if any. To the
extent that any Quarterly Reconciliation Statement indicates that ARCHEMIX expended FTEs on
ARCHEMIX Research Activities and ARCHEMIX Additional Activities in excess of the number of FTEs
required by the Minimum Funding Commitment that were authorized by TAKEDA under the Annual Research
Plan or otherwise authorized in writing by TAKEDA, then within [***] days of receipt of such
Quarterly Reconciliation Statement, TAKEDA will compensate ARCHEMIX for such additional FTEs at the
FTE Rate. To the extent that any Quarterly Reconciliation Statement indicates that ARCHEMIX
expended FTEs on ARCHEMIX Research Activities and ARCHEMIX Additional Activities in excess of what
was authorized by TAKEDA under the Annual Research Plan or otherwise authorized in writing by
TAKEDA, TAKEDA shall pay ARCHEMIX for the excess FTEs, not to exceed the [***] of [***] of an FTE
[***] by the [***] in any given [***].

          5.2.2 Credited R&D Funding To the extent that any Quarterly Reconciliation Statement
indicates that the Quarterly FTE Payment in any given Fiscal Quarter exceeds the cost of the FTEs
actually expended by ARCHEMIX for such Fiscal Quarter through no fault of TAKEDA, then TAKEDA shall
have the right to apply such difference towards any amounts due under any [***].

          5.2.3 R&D Funding Audit Rights. ARCHEMIX shall keep complete and accurate books and
financial records pertaining to the number of FTEs utilized in conducting ARCHEMIX Research
Activities and/or ARCHEMIX Additional Activities, if any, which books and financial records shall
be kept in accordance with GAAP and shall be retained by ARCHEMIX for [***] years after the end of
the Fiscal Year to which they pertain. Upon [***] days written notice, TAKEDA shall have the right
to appoint at its expense an independent

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

33

 

certified public accountant reasonably acceptable to ARCHEMIX to audit the financial records
of ARCHEMIX relating to the number of FTEs utilized in conducting the Research Program and/or
ARCHEMIX Additional Activities during any Fiscal Year; provided, that, TAKEDA shall not have the
right to audit any Fiscal Year more than [***] or more than [***] after the end of such Fiscal Year
or to conduct more than [***] such audit in any [***] period. All financial records made available
for audit shall be deemed to be Confidential Information of ARCHEMIX. The results of each audit,
if any, shall be reported in writing to both Parties promptly (but in no event later than [***]
days) after the audit and shall be binding on both Parties. In the event that there was an error
relating to the reported FTEs utilized in conducting the Research Program and/or ARCHEMIX
Additional Activities during any Fiscal Year, (a) if the effect of the error resulted in an
overpayment by TAKEDA, ARCHEMIX shall promptly (but in any event no later than [***] days after
ARCHEMIX’ receipt of the report so concluding), make payment to TAKEDA of the overpayment and (b)
if the effect of the error resulted in an underpayment by TAKEDA, then TAKEDA shall promptly (but
in no event later than [***] days after TAKEDA’s receipt of the report so concluding) make payment
to ARCHEMIX of the underpayment amount. TAKEDA shall bear the full cost of such audit unless such
audit discloses an over reporting by ARCHEMIX of more than [***] percent ([***]%) of the aggregate
amount of FTE Costs reportable in any Fiscal Year, in which case ARCHEMIX shall reimburse TAKEDA
for all reasonable costs incurred by TAKEDA in connection with such audit.

          5.2.4 R&D External Costs. In addition to the funding obligations in Section 5.2.1
above, and without limiting the generality of the provisions of Section 4.2 hereof, TAKEDA shall be
[***] for the payment of all Third Party research and Development activity costs (“Third Party
Costs”), including, without limitation, contract research organizations, contract personnel and
consultant costs and materials cost for large-scale syntheses, incurred by ARCHEMIX to the extent
set forth in an Annual Research Plan or otherwise approved in writing by TAKEDA. TAKEDA shall pay
such Third Party Costs by the last day of the first full month following receipt of the applicable
invoice.

     5.3  Milestone Payments.

          5.3.1  Milestones.

                    (a) Development Milestones. Within [***] days of the occurrence of the following
milestone events, TAKEDA shall make the corresponding non-refundable, non-creditable payments to
ARCHEMIX by wire transfer according to instructions that ARCHEMIX shall provide:

	 	 	 
	Milestone Event	 	Milestone Payment
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

34

 

	 	 	 
	Milestone Event	 	Milestone Payment
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]
	[***]

	 	$[***]

     For purposes of clarity, (a) milestones 1 and 2 shall be paid [***] for each [***] that yields
an [***] and/or for the [***] and (b) milestones 3 through 17 will be paid [***] for each [***],
regardless of the [***] that are [***] under this Agreement.

                    (b) Sales Milestones. In addition to the milestone payments required by Section
5.3.1(a), within [***] days after the occurrence of the following milestone events, TAKEDA shall
make the following [***], non-refundable, non-creditable payments to ARCHEMIX for [***] Product,
regardless of the [***] of Products that are Developed and Commercialized under this Agreement:

	 	 	 
	Milestone Event	 	Milestone Payment
	[***]

	 	$[***]
	[***]

	 	$[***]

          5.3.2 Determination that Milestone Events have Occurred; Invoice for Milestone
Payments. TAKEDA shall provide ARCHEMIX with written notice within [***] days of each
occurrence of a milestone event set forth in Section 5.3.1. In the event that, notwithstanding the
fact that TAKEDA has not given such a notice, ARCHEMIX believes any such milestone event has
occurred, it shall so notify TAKEDA in writing and shall provide to TAKEDA data, documentation or
other information that supports its belief. Any dispute under

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

35

 

this Section 5.3.2 that relates to whether or not a milestone event has occurred shall be
referred to the JSC to be resolved in accordance with Section 2.1.6 and if after the Research Term,
under Section 13.1.

     5.4  Payment of Royalties; Royalty Rates; Accounting and Records.

          5.4.1  Payment of Royalties.

     (a) Royalty Rates in the [***]. TAKEDA shall pay ARCHEMIX the following
non-refundable, non-creditable royalties based on Annual Net Sales of each Product in [***] in each
Fiscal Year (or partial Fiscal Year) commencing with the First Commercial Sale of such Product in
[***] and ending upon the last day of the Royalty Term for such Product in [***], at the following
rates:

	 	 	 
	Annual Net Sales	 	Royalty Rate (%)
	[***]

	 	[***]%
	[***]

	 	[***]%
	[***]

	 	[***]%
	[***]

	 	[***]%
	[***]

	 	[***]%

     The following hypothetical example illustrates the calculation of royalties under Section
5.4.1(a): If, in any Fiscal Year during the Term, Annual Net Sales of a Product are $[***], the
applicable royalty would be $[***], [***]% of Net Sales for Net Sales up to $[***] ($[***]), [***]%
of Net Sales for Net Sales over $[***] and up to $[***] ($[***]) and [***]% of Net Sales for Net
Sales over $[***] ($[***]).

                    (b) Royalty Rates in the ROW. TAKEDA shall pay ARCHEMIX a royalty based on Annual Net
Sales of each Product in each country or countries in the ROW Territory in each Fiscal Year (or
partial Fiscal Year) commencing with the First Commercial Sale of such Product in any country in
the ROW Territory and ending upon the last day of the Royalty Term for such Product in such country
or countries, at a royalty rate equal to [***] percent ([***]%).

                    (c) Royalty Offsets; Requested Chemistry. In the event that TAKEDA, in order to
practice the license granted to it under Section 7.2 of this Agreement in any country in the
Territory, is required to and actually makes milestone and/or royalty payments to any Third Party
(“Third Party Payments”) in order to obtain (i) a license to an issued patent or patents in the
absence of which the oligonucleotide portion of the Product could not legally be imported, sold,
exported, or otherwise exploited in such country and/or (ii) a license to an issued patent or
patents, in the absence of which the Licensed Patent Rights cannot legally be practiced in such
country for using, importing, offering for sale, selling, exporting or otherwise exploiting such
Product, then the royalties payable to ARCHEMIX for such Product under Section 5.4.1(a) and/or (b)
with respect to such country may be reduced by [***] percent ([***]%) of the amount of such Third
Party Payments. Notwithstanding the foregoing, TAKEDA shall be solely responsible for the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

36

 

payment of any Third Party Payments relating to a license that is specific to a particular
Program Target and/or the use of a particular Program Target and, accordingly, the royalties
payable to ARCHEMIX pursuant to Section 5.4.1(a) and/or (b) shall not be reduced by such Third
Party Payments. In the event TAKEDA requests ARCHEMIX to use in the Research Program molecules,
methods and/or processes other than Program Chemistry (“Requested Chemistry”), which TAKEDA has the
right to request in its sole discretion, thereby giving rise to the obligation to pay milestone
and/or royalty payments to a Third Party (“Third Party Chemistry Payments”), then TAKEDA shall be
solely responsible for the payment of such Third Party Chemistry Payments and the royalties payable
to ARCHEMIX pursuant to Section 5.4.1(a) and/or (b) shall not be reduced by such Third Party
Chemistry Payments. For purposes of clarity, any license payments and/or damages relating to the
use of the SELEX Process or the SELEX Technology shall be treated under Section 9.2.2(c).

                    (d) Generic Products. Prior to the expiration of the Royalty Term as to a given
Product, in the event that Third Party(ies) sells Generic Product(s) in a country in which such
Product(s) is then being sold and such [***] is not [***] by a [***]under the [***] in such
country, then, during the period in which unit sales of the Generic Product(s) by such Third
Party(ies) are equal to at least [***] ([***]%) of TAKEDA’s volume-based market share of the
Product(s) in such country (as measured by prescriptions or other similar information available in
such country), the royalties payable with respect to such Product(s) in such country as specified
in Section 5.4.1 shall be reduced by [***] percent ([***]%). Notwithstanding the foregoing,
TAKEDA’s obligation to pay the full amount of royalties payable under Section 5.4.1(a) shall be
reinstated on the first day of the Calendar Quarter immediately following the Calendar Quarter in
which sales of such Generic Product(s) account for less than [***] percent ([***]%) of TAKEDA’s
volume-based market share in such country.

                    (e) Maximum Adjustment of Royalty Rate. Notwithstanding anything to the contrary in
this Agreement, under no circumstances shall the royalty rates in Section 5.4.1 be cumulatively
reduced below [***] percent ([***]%) of the rates set forth therein.

                    (f) Know-How Payments. The Parties hereby acknowledge and agree that any royalties
that are payable for a Product during the Royalty Term for such Product for which no Patent Rights
exist shall be in consideration of (i) the performance by ARCHEMIX of the Research Program
including ARCHEMIX’s expertise in and use of the SELEX Process to identify the Products;
(ii) the disclosure by ARCHEMIX to TAKEDA of results obtained in the Research Program; (iii) the
licenses granted to TAKEDA hereunder with respect to Licensed Technology and Joint Technology that
are not within the claims of any Patent Rights Controlled by ARCHEMIX; (iv) the restrictions on
ARCHEMIX in Section 7.6.1; and (v) the “head start” afforded to TAKEDA by each of the foregoing.

                    (g) Payment Dates and Reports. Royalty payments shall be made by TAKEDA within [***]
days after the end of each [***] commencing with the [***] in which the First Commercial Sale of a
Product occurs. TAKEDA shall also provide, at the same time each such payment is made, a report
showing: (a) the Net Sales of each Product by type of Product and country in the Territory; (b) the
basis for any deductions from gross amounts billed or invoiced to determine Net Sales; (c) the
applicable royalty rates for such Product; (d) the exchange rates used

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

37

 

in calculating any of the foregoing; and (e) a calculation of the amount of royalty due to
ARCHEMIX.

(h) Combination Products. The earned royalty due on a Combination Product shall be
determined pro rata on a Combination Product-by-Combination Product and country-by-country basis,
by multiplying Net Sales of the Combination Product by the fraction A/(A+B), where A is the invoice
price of the Product when sold separately and B is the invoice price of the Supplemental Product
when sold separately by TAKEDA, its Affiliate or its Sublicensee or, if not sold by them, then the
average invoice price when sold separately by Third Parties. If the Supplemental Product in the
Combination Product is not sold separately by any Person, Net Sales shall be calculated by
multiplying actual net revenues derived from sales of the Combination Product by the fraction A/C,
where A is as previously defined and C is the invoice price of the Combination Product sold by
TAKEDA, its Affiliate or its Sublicensee. For purposes of clarity, the average invoice price and
the actual net revenues for any Supplemental Product shall be for a quantity comparable to that
contained in the Combination Product and shall be of the same class, purity and potency as that
contained in the Combination Product. If neither the Product nor the Supplemental Product included
in the Combination Product are sold separately, Net Sales shall be calculated based on the mutual
written agreement of the Parties as to a reasonable allocation between the Product and the
Supplemental Product, taking into account total manufacturing costs, proprietary protection and
relative contribution thereof. If the Parties are unable to reach agreement on an appropriate
method of determining royalties for a Combination Product, (“Disputed Royalty Matter”), such
Disputed Royalty Matter shall be resolved in accordance with Section 13.1.

          5.4.2 Records; Audit Rights. TAKEDA and its Affiliates and Sublicensees shall keep and
maintain for [***] years from the date of each payment of royalties hereunder complete and accurate
records of gross sales and Net Sales by TAKEDA and its Affiliates and Sublicensees of each Product,
in sufficient detail to allow royalties to be determined accurately. ARCHEMIX shall have the right
for a period of [***] years after receiving any such royalty payment to appoint at its expense an
independent certified public accountant reasonably acceptable to TAKEDA to audit the relevant
records of TAKEDA and its Affiliates and Sublicensees to verify that the amount of such payment was
correctly determined. TAKEDA and its Affiliates and Sublicensees shall each make its records
available for audit by such independent certified public accountant during regular business hours
at such place or places where such records are customarily kept, upon [***] days written notice
from ARCHEMIX, solely to verify that royalty payments hereunder were correctly determined. Such
audit right shall not be exercised by ARCHEMIX more than once in any Fiscal Year. All records made
available for audit shall be deemed to be Confidential Information of TAKEDA. The results of each
audit, if any, shall be binding on both Parties. In the event there was an underpayment by TAKEDA
hereunder, TAKEDA shall promptly (but in any event no later than [***] days after TAKEDA’s receipt
of the report so concluding) make payment to ARCHEMIX of any shortfall. ARCHEMIX shall bear the full cost of such audit unless such audit discloses an
underreporting by TAKEDA of more than [***] percent ([***]%) of the aggregate amount of royalties
payable in any Fiscal Year, in which case TAKEDA shall reimburse ARCHEMIX for all costs incurred by
ARCHEMIX in connection with such audit.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

38

 

          5.4.3 Overdue Royalties and Milestones. All royalty payments not made within the
time period set forth in Section 5.4.1(g), including underpayments discovered during an audit, and
all milestone payments not made within the time period specified in Section 5.4.1(a) or (b), shall
bear interest at a rate of [***] percent ([***]%) per month from the due date until paid in full
or, if less, the maximum interest rate permitted by Applicable Laws. Any such overdue royalty or
milestone payment shall, when made, be accompanied by, and credited first to, all interest so
accrued.

          5.4.4 Payments. All payments made by TAKEDA hereunder shall be made by wire transfer
from a banking institution in the United States in United States Dollars in accordance with
instructions given in writing from time to time by ARCHEMIX and shall be free and clear of any
taxes, duties, levies, fees or charges including any withholding taxes.

          5.4.5 Taxes. Any income taxes or other taxes which TAKEDA is required by law to pay
or withhold on behalf of ARCHEMIX with respect to milestones, royalties and any other monies or
other transfer for value payable or provided to ARCHEMIX under this Agreement shall be deducted
from such milestones, royalties and any other monies due to ARCHEMIX under this Agreement. TAKEDA
shall provide ARCHEMIX with documentation of such withholding in a manner that is satisfactory for
purposes of reporting to the U.S. Internal Revenue Service. Payments made by either Party for
goods and services provided by the other Party under this Agreement are exclusive of value added
tax, sales tax or any other similar or substitute tax which will be additionally payable by the
Party receiving the goods or services in the event that value added tax, sales tax or any other
similar or substitute tax applies to any of these payments; provided, that, the Party providing the
goods or services will issue to the other Party an appropriate invoice to support any such charge.
TAKEDA shall submit to ARCHEMIX reasonable proof of payment of the withholding taxes contemplated
by this Section 5.4.5, together with an accounting of the calculations of such taxes, within [***]
days after which such withholding taxes are remitted to the proper authority. The Parties will
cooperate reasonably in completing and filing documents required under the provisions of any
applicable tax laws or under any other Applicable Law, in connection with the making of any
required tax payment or withholding payment, or in connection with any claim to a refund of or
credit for any such payment. The Parties will cooperate to minimize such taxes in accordance with
Applicable Laws.

          5.4.6 Foreign Currency Exchange. All royalties shall be payable in full in the United
States in United States Dollars, regardless of the countries in which sales are made. Any
conversion from a non-U.S. currency to United States Dollars shall be converted as follows:

(A/B), where

A = foreign “Net Sales” (as defined above) in such Fiscal Quarter expressed in such foreign
currency; and

B = foreign exchange conversion rate, expressed in local currency of the foreign country per United
States Dollar (using, as the applicable foreign exchange rate, the average of the daily closing
rates published in the New York edition of The Wall Street Journal under the heading “Money Rates”
or any other mutually agreed upon source, for such Fiscal Quarter).

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.

39

 

6. TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY; NON-SOLICITATION.

     6.1 Confidentiality.

          6.1.1 Confidentiality Obligations. ARCHEMIX and TAKEDA each recognizes that the other
Party’s Confidential Information and Proprietary Materials constitute highly valuable assets of
such other Party. ARCHEMIX and TAKEDA each agrees that, subject to Sections 6.1.2 and 6.2, it will
not disclose, and will cause its Affiliates and sublicensees (or Sublicensees, as the case may be)
not to disclose, any Confidential Information or Proprietary Materials of the other Party and it
will not use, and will cause its Affiliates and sublicensees (or Sublicensees, as the case may be)
not to use, any Confidential Information or Proprietary Materials of the other Party except as
expressly permitted hereunder; provided, that, such obligations shall apply during the Term and for
an additional [***] years thereafter.

          6.1.2 Limited Disclosure. ARCHEMIX and TAKEDA each agrees that disclosure of
Confidential Information or any transfer of Proprietary Materials belonging to the other Party may
be made by the Party to any employee, consultant or Affiliate of such Party to enable such Party to
exercise its rights or to carry out its responsibilities under this Agreement; provided, that, any
such disclosure or transfer shall only be made to Persons who are bound by written obligations as
described in Section 6.1.3. In addition, ARCHEMIX and TAKEDA each agrees that it may disclose
Confidential Information belonging to the other Party (a) on a need-to-know basis to such Party’s
legal and financial advisors, (b) as reasonably necessary in connection with an actual or potential
(i) permitted sublicense of such Party’s rights hereunder that are subject to written obligations
of confidentiality substantially similar to those required hereunder and provided that any
Confidential Information so provided will in no event include information identifying which Program
Targets are subject to this Agreement, (ii) debt or equity financing of such other Party or (iii)
Change of Control; (c) if such Party is ARCHEMIX, to any Third Party that is or may be engaged by
ARCHEMIX to perform services in connection with the Research Program; and (d) for any other purpose
with the other Party’s written consent. In addition, each Party agrees that Confidential
Information or Proprietary Materials may be disclosed (A) as reasonably necessary to file,
prosecute or maintain Patent Rights, or to file, prosecute or defend litigation related to Patent
Rights, in accordance with this Agreement; or (B) as required by Applicable Laws; provided, that,
in the case of any disclosure under this clause (B), the disclosing Party shall (1) if practicable,
provide the non-disclosing Party with reasonable advance notice of and an opportunity to comment on
any such required disclosure and (2) if requested by the non-disclosing Party, cooperate in all
reasonable respects with the non-disclosing Party’s efforts to obtain confidential treatment or a
protective order with respect to any such disclosure, at the non-disclosing Party’s expense.

     6.1.3 Employees and Consultants. ARCHEMIX and TAKEDA each hereby represents that all
of its employees and consultants, and all of the employees and consultants of its Affiliates, who
participate in the activities of the Collaboration or have access to Confidential Information or
Proprietary Materials of the other Party are or will, prior to their participation or access, (a)
be bound by written obligations to maintain such Confidential Information or Proprietary Materials
in confidence and not to use such information except as expressly permitted hereunder, and (b) be
bound by written obligations to assign all Technology and Patent Rights to

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

40

 

the Party that retains such employee or consultant. Each Party agrees to use, and to cause
its Affiliates to use, reasonable efforts to enforce such obligations.

     6.2 Publicity. The Parties acknowledge and agree that the terms of this Agreement
constitute Confidential Information of each Party and may only be disclosed (a) as permitted by
Section 6.1.2, and (b) to investment bankers, investors, and bona fide potential investors, lenders
and potential lenders and other sources and other potential sources of financing, acquirers or
merger partners and potential acquirers or merger partners, Gilead and University License Equity
Holdings, Inc. but only to the extent (i) the identity of which Program Targets are subject to this
Agreement are not disclosed, and (ii) such disclosure is accompanied with confidential obligations
commensurate in scope with the confidentiality obligations set forth hereunder. A copy of this
Agreement may be filed by either Party with the Securities and Exchange Commission if such filing
is required by Applicable Laws; provided, that, in connection with any such filing, such Party
shall endeavour to obtain confidential treatment of economic and trade secret information, and
shall provide the other Party with the proposed confidential treatment request with reasonable time
for such other Party to provide comments, which comments shall be reasonably considered by the
filing Party. Notwithstanding anything to the contrary in Section 6.1, the Parties, upon the
execution of this Agreement, shall jointly issue a press release with respect to this Agreement, in
the form attached here to as Schedule 5, and either Party may make subsequent public
disclosure of the contents of such press release without further approval of the other Party.
After issuance of such press release, except as required by Applicable Laws, neither Party shall
issue a press or news release or make any similar public announcement (it being understood that
publication in scientific journals, presentation at scientific conferences and meetings and the
like are intended to be covered by Section 6.3 and not subject to this Section 6.2) related to the
Research Program or to any Development Program without the prior written consent of the other
Party; provided, that, notwithstanding the foregoing, ARCHEMIX shall be expressly permitted to
publicly announce the occurrence of (i) any of milestone events 3 through 17 under Section 5.3.1;
provided, that, such announcements will not disclose any Program Target without TAKEDA’s prior
written consent, which may be withheld at TAKEDA’s sole discretion, and (ii) any milestone event or
other event the disclosure of which is required by Applicable Laws; provided, that TAKEDA is
provided advance notice and an opportunity to review and comment upon such proposed disclosure.

     6.3 Publications and Presentations. The Parties acknowledge that scientific
publications and presentations must be strictly monitored to prevent any adverse effect from
premature publication or dissemination of results of the activities hereunder. Each Party agrees
that, except as required by Applicable Laws, it shall not publish or present, or permit to be
published or presented, the results of the Research Program without the prior review by and
approval of the other Party. Each Party shall provide to the other Party the opportunity to review
each of the submitting Party’s proposed abstracts, manuscripts or presentations (including, without
limitation, information to be presented verbally) that relate to the Research Program at least
[***] days prior to its intended presentation or submission for publication, and such submitting
Party agrees, upon written request from the other Party given within such [***]day period, not to
submit such abstract or manuscript for publication or to make such presentation until the other
Party is given up to [***] days from the date of such written request to seek appropriate patent
protection for any material in such publication or presentation that it reasonably believes may be
patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by
each Party, the subject matter disclosed in such abstracts, manuscripts

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

41

 

or presentations does not have to be provided again to the other Party for review for a later
submission for publication. Each Party also shall have the right to require that any of its
Confidential Information that is disclosed in any such proposed publication or presentation be
deleted prior to such publication or presentation. In any permitted publication or presentation by
a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be
determined in accordance with customary standards. Subject to the foregoing obligations of this
Section 6.3, TAKEDA may use the results of the Research Program for the purpose and to the extent
necessary to develop and commercialise Products in accordance with this Agreement. Notwithstanding
the foregoing, TAKEDA shall exclusively control all scientific publications and presentations that
contain any data relating to an Optimized Lead Compound or Product. ARCHEMIX agrees that, except
as required by Applicable Laws, it shall not publish or present, or permit to be published or
presented, any data arising out of the Development Program relating to an Optimized Lead Compound
or Product without the prior review and express written approval of TAKEDA which may be withheld at
TAKEDA’s sole discretion.

     6.4 Prohibition on Solicitation. Without the written consent of the other Party,
neither Party nor its Affiliates shall, during the [***] or for [***] year thereafter, solicit
(directly or indirectly) any employee of the other Party or its Affiliates who participated in the
Research Program at any time during the Research Program Term. This provision shall not restrict
either Party or its Affiliates from advertising employment opportunities in any manner that does
not directly target the other Party or its Affiliates.

7. LICENSE GRANTS; ASSIGNMENT; EXCLUSIVITY

     7.1 Research and Development Licenses.

          7.1.1 ARCHEMIX Grants.
—

               (a) Research Program. Subject to the terms and conditions of this Agreement
(including, without limitation, the restrictions set forth in Section 7.5), ARCHEMIX hereby grants
to TAKEDA and its Affiliates a non-exclusive, royalty-free, worldwide license during the Research
Program Term, including the right to grant sublicenses as provided in Section 7.4, under Licensed
Technology and Licensed Patent Rights for the sole purpose of conducting TAKEDA Research Activities
in the Research Program.

               (b) Development Program. Subject to the terms and conditions of this Agreement
(including, without limitation, the restrictions set forth in Section 7.5), ARCHEMIX hereby grants
to TAKEDA and its Affiliates, an exclusive royalty-free, worldwide license during the Term,
including the right to grant sublicenses as provided in Section 7.3, under Licensed Technology and
Licensed Patent Rights for the sole purpose of Developing Products in the Field and in the
Territory.

          7.1.2 TAKEDA Grants.

               (a) Research Program. Subject to the terms and conditions of this Agreement, TAKEDA
hereby grants to ARCHEMIX and its Affiliates a non-exclusive, royalty-free, worldwide license
during the Research Program Term, including the right to grant sublicenses as provided in Section
7.4, under TAKEDA Technology and TAKEDA Patent Rights

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

42

 

and TAKEDA’s interest in Joint Technology and Joint Patent Rights, for the sole purpose of
conducting the Research Program.

               (b) Development Program. Subject to the terms and conditions of this Agreement,
TAKEDA hereby grants to ARCHEMIX and its Affiliates a non-exclusive, royalty-free, worldwide
license during the Term, without the right to grant sublicenses, under TAKEDA Technology and TAKEDA
Patent Rights and TAKEDA’s interest in Joint Technology and Joint Patent Rights), as well as under
the exclusive license granted to TAKEDA by ARCHEMIX pursuant to Section 7.1.1(b), for the sole
purpose of conducting ARCHEMIX Additional Activities in any Development Program.

               (c) Waived Targets; Failed Targets.

                    (i) Designation of Waived Targets. With regard to each Program Target, TAKEDA may
designate such Program Target as a Waived Target and thereby discontinue the Research Program for
such Program Target at any time prior to the designation of a first Optimized Lead Compound for
such Program Target. Such designation shall be made by TAKEDA by providing written notice (the
“Waived Target Designation Notice”) to ARCHEMIX identifying the Program Target that TAKEDA is
designating to become a Waived Target and the effective date of such designation. ARCHEMIX shall
provide written notice confirming such designation within ten (10) days of the Designation Notice.

                    (ii) Designation of Failed Targets. With regard to each Program Target, the JSC may
designate a Program Target as a Failed Target pursuant to Section 2.1.3(c) and thereby discontinue
the Research Program for such Program Target.

                    (iii) Non-exclusive License to ARCHEMIX. Following any Waived Target Designation
Notice by TAKEDA and/or any designation by the JSC of any Program Target as a Failed Target, and
subject to Section 7.1.2(c)(iv), (A) TAKEDA shall be deemed to have granted an [***], non-exclusive
[***] license to ARCHEMIX under all of its right, title and interest in and to all TAKEDA Program
Technology, Patent Rights claiming TAKEDA Program Technology and TAKEDA’s interest in Joint
Technology and Joint Patent Rights that, absent the license granted in this Section 7.1.2(c)(iii),
would be infringed by the researching, developing and/or commercializing of aptamers directed to
the Waived Target or Failed Target for the sole purpose of researching, developing and/or
commercializing aptamers directed to the Waived Target or Failed Target, and (B) ARCHEMIX may, at
its option, continue to research, develop and/or commercialize aptamers to such Waived Target
and/or Failed Target, [***] to TAKEDA.

                    (iv)  Right of First Negotiation. If at any time during period commencing on the date
that any Program Target becomes a Failed Target and continuing until the [***] of such date,
ARCHEMIX determines to [***] an internal research and development program (other than in the
conduct of proof-of-concept development research in animals or humans) to develop Aptamers against
such Failed Target, it shall (A) provide written notice to TAKEDA which shall summarize such
internal research and development program; and (B) on and after the date of such notice, (1)
provide TAKEDA with periodic updates at TAKEDA’s request no more frequently than every [***] months
with respect to the results of such internal

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

43

 

research activities and (2) on the date on which ARCHEMIX [***] to [***] [***] with a Third
Party for a license or collaboration involving such Failed Target, provide TAKEDA with written
notice (the “Failed Target Opportunity Notice”) describing such [***] as well as the then-current
status of its internal research efforts with respect to such Failed Target. TAKEDA shall have
[***] days following the date that the Failed Target Opportunity Notice is given by ARCHEMIX (the
“Notice Period”) to give written notice to ARCHEMIX that it wishes to enter into negotiations with
ARCHEMIX with respect to such Failed Target (an “ROFN Notice”); provided that, if TAKEDA determines
not to give an [***] prior to expiration of the Notice Period, it shall in good faith provide
written notice to ARCHEMIX promptly upon such determination that it declines to enter into
negotiations. If TAKEDA gives a ROFN Notice within the Notice Period that it wishes to enter into
negotiations with ARCHEMIX, the Parties shall negotiate in good faith an agreement with respect to
the grant of rights to TAKEDA with respect to such Failed Target for a period of up to [***] days
from the end of the Notice Period. If the Parties do not agree upon the terms with respect to such
agreement within the [***] day negotiation period, ARCHEMIX shall thereafter have no obligations to
TAKEDA with respect to such Failed Target. For purposes of clarity, after expiration of such
negotiation period, ARCHEMIX shall have the unencumbered right to (inter alia) conduct one or more
research, development and/or commercialization programs itself or together with any Third Party,
and/or negotiate and execute agreements with any Third Party, with respect to the Failed Target.

               (d) Terminated Products.

                    (i) Termination of Product Development. In the event that TAKEDA has satisfied its
diligence obligations under Section 4.4.1 with respect to a Product and nevertheless determines
that it is Commercially Reasonable to cease further Development or Commercialization of such
Product, TAKEDA may designate such Product as a Terminated Product and thereby discontinue
Development or Commercialization of such Product. Such designation shall be by written notice (the
“Product Termination Notice”) to ARCHEMIX identifying the Product that TAKEDA is designating to
become a Terminated Product and the effective date of such designation.

                    (ii) ARCHEMIX’s Use of Terminated Products. With respect to all such Terminated
Products, ARCHEMIX may request in writing within [***] months of the date of the Product
Termination Notice for a given Terminated Product for TAKEDA to transfer the Terminated Product to
ARCHEMIX. Within [***] days of such written request by ARCHEMIX, TAKEDA shall provide ARCHEMIX a
written estimate for the reasonably anticipated costs and expenses (including direct cost
determined on an FTE basis) associated with performing the services described in subsections
(A)-(F) below. Within [***] days of TAKEDA’s written estimate, should ARCHEMIX commit in writing
and in good faith (the “ARCHEMIX Commitment”) to fund such written estimate and continue
Development of such Terminated Product using Commercially Reasonable Efforts, then and only then,
TAKEDA shall take the following actions:

                         (A) Assignment and License. Subject to the terms and conditions of this Agreement, on
the date of receipt of the ARCHEMIX Commitment, TAKEDA shall be deemed to have (1) assigned to
ARCHEMIX all of its right, title and interest in and to all Program Aptamer-Specific Patent Rights
relating solely to any such Terminated Product and (2)

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

44

 

granted to ARCHEMIX an exclusive license in the Field under Patent Rights covering TAKEDA Program
Technology (other than such Program Aptamer-Specific Patent Rights assigned to ARCHEMIX) and
TAKEDA’s interest in Joint Patent Rights to develop any such Terminated Product, subject to the
payment by ARCHEMIX to TAKEDA, for any such Terminated Product, and any Products Derived therefrom,
that are Developed and Commercialized by ARCHEMIX, its Affiliates or sublicensees, of (I) royalty
payments at rates equal to the Applicable Percentage (as defined below) of the rates set forth in
Section 5.4.1, for the remainder of the applicable Royalty Term; provided, however, that TAKEDA
Program Aptamer-Specific Patent Rights shall be further included along with ARCHEMIX Program
Aptamer-Specific Patent Rights within the scope of Royalty Triggering Patent Rights for such
Terminated Product), and (II) the Applicable Milestone Payment on the Milestone Payment Due Date.

                         (B) Regulatory Filings. Upon request of ARCHEMIX at any time after the Product
Termination Notice with respect to each such Terminated Product, TAKEDA shall promptly, and in any
event within [***] days after ARCHEMIX’s request: (I) transfer to ARCHEMIX all of its right, title
and interest in all Regulatory Filings, Drug Approval Applications and Regulatory Approvals then in
its name applicable to such Terminated Product, if any, and all material aspects of Confidential
Information Controlled by it as of the date of the Product Termination Notice relating to such
Regulatory Filings, Drug Approval Applications and Regulatory Approvals; (II) notify the applicable
Regulatory Authorities and take any other action reasonably necessary to effect such transfer;
(III) provide ARCHEMIX with copies all correspondence between TAKEDA and such Regulatory
Authorities relating to such Regulatory Filings, Drug Approval Applications and Regulatory
Approvals; (IV) unless expressly prohibited by any Regulatory Authority, transfer control to
ARCHEMIX of all clinical trials, if any, of such Terminated Product being conducted as of the date
of the Product Termination Notice and continue to conduct such trials for up to [***] months to
enable such transfer to be completed without interruption of any such trial; (V) assign (or cause
its Affiliates to assign) to ARCHEMIX all agreements with any Third Party with respect to the
conduct of clinical trials, if any, for such Terminated Product including, without limitation,
agreements with contract research organizations, clinical sites and investigators, unless expressly
prohibited by any such agreement (in which case TAKEDA shall cooperate with ARCHEMIX in all
reasonable respects to secure the consent of such Third Party to such assignment); (VI) provide
ARCHEMIX with all supplies of such Terminated Products in the possession of TAKEDA or any Affiliate
or contractor of TAKEDA at [***]; and (VII) provide ARCHEMIX with copies of all reports and data
generated or obtained by TAKEDA or its Affiliates pursuant to this Agreement that relate to any
such Terminated Product that have not previously been provided to ARCHEMIX.

                         (C) If TAKEDA has manufactured, is manufacturing or having manufactured any such Terminated
Product or any intermediate thereof as of the date of the Product Termination Notice: (I) TAKEDA
shall, if requested by ARCHEMIX, supply ARCHEMIX with its requirements for all such Terminated
Products and intermediates for up to [***] months following the date of the Product Termination
Notice at a transfer price equal to [***] percent ([***]%) for the supply of such Terminated
Product or intermediate, and (II) within [***] days after ARCHEMIX’s request, TAKEDA shall provide
to ARCHEMIX or its designee all information in its possession with respect to the manufacture of
each such Terminated Product or intermediate.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

45

 

                         (D) ARCHEMIX shall (I) compensate TAKEDA at a mutually agreed upon FTE Rate for the actual
time spent after the Product Termination Notice with respect to such Terminated Product by TAKEDA
personnel fulfilling its obligations under this Section 7.1.2(d)(ii) and (II) reimburse TAKEDA for
all costs and expenses incurred in fulfilling its obligations under this Section 7.1.2(d)(ii).
TAKEDA shall provide ARCHEMIX with an invoice at the end of each Fiscal Quarter with all FTE
funding and expenses accrued during the preceding Fiscal Quarter. ARCHEMIX shall pay such invoices
in full within [***] days. Any dispute arising under this section shall be resolved in accordance
with Section 13.1. Until any dispute is resolved or, in the absence of a dispute, should ARCHEMIX
at any time fail to pay any invoice provided by TAKEDA to ARCHEMIX pursuant to this Section
7.1.2(d)(ii)(D), TAKEDA shall have the right to discontinue any and all of its obligations under
this Section 7.1.2(d)(ii). Following resolution of any dispute, should ARCHEMIX fail to meet its
obligations under this Section 7.1.2(d)(ii)(D) as determined in accordance with Section 13.1, the
assignments and licenses granted under Section 7.1.2(d)(ii)(A) shall revert to TAKEDA.

                         (E) Product Trademarks. In the event that the Terminated Product has already been
Commercialized by TAKEDA, the Parties agree to negotiate in good faith whether and under what
conditions TAKEDA will transfer any Product Trademarks associated with the Terminated Product to
ARCHEMIX.

                         (F) Definitions. For purposes of this Section 7.1.2(d), the following terms shall
have the following definitions:

“Applicable Milestone Payment” shall mean, with respect to each Terminated Product,
an aggregate amount equal to all milestone payments previously made by TAKEDA with respect
to such Terminated Product for (a) milestone events 4 and 5 to the extent ARCHEMIX makes
[***] applicable to such Terminated Product; or (b) milestone events 3 and 4 to the extent
ARCHEMIX makes [***] applicable to such Terminated Product.

“Applicable Percentage” shall mean, with respect to each Terminated Product, (a)
[***] percent ([***]%), to the extent ARCHEMIX makes [***] in the development and
commercialization of such Terminated Product; (b) [***] percent ([***]%), to the extent
ARCHEMIX makes [***] in the development and commercialization of such Terminated Product,
(c) [***] percent ([***]%), if neither of the foregoing (a) nor (b) apply, but ARCHEMIX is
developing and commercializing a Terminated Product that was a Collaboration Aptamer or is
Derived from a Collaboration Aptamer, (d) [***] percent ([***]%), if none of the foregoing
(a), (b) or (c) apply, but ARCHEMIX is developing an aptamer that would infringe any
ARCHEMIX Program Apatamer-Specific Patent Rights or TAKEDA Program Aptamer-Specific Patent
Rights assigned to Archemix pursuant to Section 7.1.2(d)(ii)(A); and (e) [***] percent
([***]%) if none of the foregoing (a), (b), (c) or (d) apply.

“Milestone Payment Due Date” means, with respect to a Terminated Product, (a) to the
extent a Product becomes a Terminated Product prior to the [***], the date of the [***] with
respect to such Terminated Product; (b) to the extent a Product becomes a Terminated Product
after [***] but prior to the [***], the date of the [***] with respect to such

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

46

 

Terminated Product; and (c) to the extent a Product becomes a Terminated Product after [***]
but prior to filing for [***], the date on which such filing for [***] occurs.

“Clinical Data” means all data, results and information produced in the conduct of a
Phase I Clinical Trial (“Phase I Clinical Data”), a Phase II Clinical Trial
(“Phase II Clinical Data”) or a Phase III Clinical Trial (“Phase III Clinical Data)”
conducted by TAKEDA with respect to a Terminated Product.

“Material Use” means, with respect to Clinical Data, the inclusion of, reliance on,
or reference to such Clinical Data in a core report of an NDA filed by ARCHEMIX, as
evidenced by, but not limited to: (a) the use of a bridging study to utilize such Clinical
Data, (b) the elimination for the need to duplicate such Clinical Data, or (iii) the ability
to reduce the number of patients enrolled in a clinical trial due to the use of such
Clinical Data.

                         (E) Further Assurances. Upon ARCHEMIX’s written request, TAKEDA shall execute and
deliver any documents of ownership, assignment or conveyance that are necessary or desirable to
convey the ownership rights granted pursuant to this Section 7.1.2(c).

               (e) License to Aptamers Outside the Collaboration.

                    (i) License Grant. TAKEDA hereby grants to ARCHEMIX and its Affiliates (1) a
non-exclusive, royalty-free, worldwide license, with the right to grant sublicenses, under TAKEDA’s
interest in Program Generic Technology and Program Generic Patent Rights, to research, develop,
have developed, make, have made, use, distribute for sale, sell, offer for sale, import and have
imported Aptamers that do not target a Program Target for any and all uses, except as otherwise
provided herein and (2) a right of first negotiation to obtain an exclusive license on commercially
reasonable terms under TAKEDA’s interest in Program Generic Technology and Program Generic Patent
Rights as described in Section 7.1(e)(ii) below.

                    (ii) Right of First Negotiation. If at any time during the Term, ARCHEMIX desires to
obtain an exclusive license under TAKEDA’s interest in Program Generic Technology and/or Program
Generic Patent Rights, ARCHEMIX shall give written notice to TAKEDA (the “Exclusive License
Notice”), whereupon the Parties shall negotiate in good faith with respect to such license on
commercially reasonable terms for a period of up to [***] days from the date of the Exclusive
License Notice. If the Parties do not agree upon the terms with respect to an exclusive license
within the [***] day negotiation period, TAKEDA shall thereafter have no further obligation to
negotiate with ARCHEMIX with respect to the grant of such exclusive license; provided, that, the
non-exclusive license described in Section 7.1.2(e)(i) shall continue in full force and effect in
accordance with its terms.

     7.2 Commercialization License. Subject to the terms and conditions of this Agreement,
ARCHEMIX hereby grants to TAKEDA and its Affiliates an exclusive, royalty-bearing license during
the Term, including the right to grant sublicenses as provided in Section 7.3, under Licensed
Technology and Licensed Patent Rights for the sole purpose of Commercializing Products in the Field
in the Territory.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

47

 

     7.3 Right to Sublicense. TAKEDA shall have the right to grant sublicenses to
Sublicensees under the licenses granted to it under Section 7.1.1(b) and Section 7.2 with respect
to any Products; provided, that, (i) it shall be a condition of any such sublicense that such
Sublicensee agrees to be bound by all terms of this Agreement applicable to the Development or
Commercialization, as the case may be, of Products in the Field in the Territory (including,
without limitation, Article 6); (ii) TAKEDA shall provide a redacted copy to ARCHEMIX of each such
sublicense within [***] days of its execution [***] the [***] is [***] to [***] to [***]
hereunder; (iii) if TAKEDA grants a sublicense to a Sublicensee, TAKEDA shall be deemed to have
guaranteed that such Sublicensee will fulfil all of TAKEDA’s obligations under this Agreement
applicable to the subject matter of such sublicense; and (iv) TAKEDA shall not be relieved of its
obligations pursuant to this Agreement as a result of such sublicense.

     7.4 Right to Subcontract. Each Party shall have the right to subcontract portions,
but not all, of its research or Development responsibilities to be performed by it under this
Agreement in the normal course of its business, and to grant sublicenses for such activities, to
any Third Party without the prior consent of the other Party; provided, that, (a) such
subcontracting shall not involve the transfer of Confidential Information of the other Party to any
Third Party unless the subcontracted party shall enter into a confidentiality agreement with the
subcontracting Party in accordance with Article 6; (b) the subcontracting Party shall provide
written notice to the other Party of any such proposed subcontract at least [***] days prior to
such execution; (c) if a Party enters into a subcontract as provided in this Section 7.4, such
Party shall be deemed to have guaranteed that such subcontractor will fulfill all of such Party’s
obligations under this Agreement applicable to the subject matter of such subcontract; and (d) such
subcontracting Party shall not be relieved of its obligations pursuant to this Agreement as a
result of such subcontract.

     7.5 No Other Rights. TAKEDA shall have no rights to use or otherwise exploit ARCHEMIX
Technology, ARCHEMIX Patent Rights, or ARCHEMIX Proprietary Materials, and ARCHEMIX shall have no
rights to use or otherwise exploit TAKEDA Technology, TAKEDA Patent Rights or TAKEDA Proprietary
Materials, in each case, except as expressly set forth herein. Without limiting the generality of
the foregoing or Section 11.2, TAKEDA shall have no right under this Agreement to (a) research,
make, use, sell, offer for sale, import or export Diagnostic Products, Radio Therapeutics, or
Aptamer-Antidote Combination Products; (b) use the SELEX Process or the SELEX Technology to the
extent such SELEX Process or SELEX Technology is covered by a Valid Claim of Patent Rights
Controlled by ARCHEMIX or is ARCHEMIX Confidential Information designated as such, and disclosed,
in writing to TAKEDA in the performance of this Agreement, for any reason, including, without
limitation, (i) to research, make, use, sell, offer for sale, import or export any aptamers for
Diagnostic Products, Radio Therapeutics, or Aptamer-Antidote Combination Products or (ii) to
research, make, use, sell, offer for sale, import or export any aptamer (including any Excluded
Aptamer and/or any product containing an Excluded Aptamer); (c) research, make, use, sell, offer
for sale, import or export any aptamers for any in vivo imaging applications; or (d) research,
make, use, sell, offer for sale, import or export any aptamers for any non-therapeutic uses
(including, without limitation, any use as an affinity purification agent).

     7.6 Exclusivity.

          7.6.1 ARCHEMIX.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

48

 

          (a) Exclusivity Obligations. Except as provided in this Section 7.6.1(a) and Section
7.6.1(b), during the Exclusivity Term, ARCHEMIX shall not, and shall cause each of its Affiliates
to not, either on its own, or with, or for the benefit of, any Third Party, research, develop or
commercialize (i) with respect to each Program Target, any aptamer directed and binding to such
Program Target or the [***] therefor identified on Schedule 7 attached hereto, and (ii)
with respect to each Pre-approved Replacement Target, any aptamer directed and binding to such
Pre-approved Replacement Target or the [***] therefor identified on Schedule 7 attached
hereto, except, in each case, for the conduct by ARCHEMIX of Permitted Activities. For purposes of
clarity, the restrictions set forth in this Section 7.6.1(a) shall not apply to (A) Permitted
Activities or (B) the exercise by ARCHEMIX of its rights to develop and commercialize any Waived
Compound, Failed Compound or Terminated Product pursuant to Section 7.1.2(c) or Section 7.1.2(d).
Also for purposes of clarity, if a Pre-approved Replacement Target becomes a Program Target
pursuant to Section 3.5.1(d), the Exclusivity Term applicable to such Pre-approved Replacement
Target shall be the Exclusivity Term applicable to Program Targets.

          (b) Effect of Change of Control. Notwithstanding anything to the contrary in Section
7.6.1(a) above, if at any time during the Exclusivity Term, ARCHEMIX consummates a transaction that
results in a Change of Control of ARCHEMIX and that involves a Third Party that has a Competitive
Program, the existence and continuation of such Competitive Program following the Change of Control
shall not be deemed to be in conflict with, or a breach of, Section 7.6.1(a). In the event that
ARCHEMIX consummates a transaction during the Exclusivity Term that (i) results in a Change of
Control of ARCHEMIX and (ii) involves a Third Party that has a Competitive Program, ARCHEMIX shall
notify TAKEDA in writing within [***] days of the closing of such transaction, which notice shall
(A) identify the Competitive Program and (B) indicate whether or not the Third Party has determined
to discontinue and/or divest itself of such Competitive Program. If ARCHEMIX indicates the
intention of the Third Party to discontinue or divest itself of such Competitive Program, it shall
have a period of up to [***] months of the closing of the transaction to do so. To the extent that
ARCHEMIX indicated in its notice that (i) the Third Party has not made a commitment to discontinue
and/or divest itself of such Competitive Program within [***] months of the closing, (ii) ARCHEMIX
fails to provide such notice or (iii) the Third Party fails to discontinue or divest itself of the
Competitive Program within [***] months as provided above, TAKEDA will thereafter have the option
to (A) designate such Program Target as a Discontinued Competitive Target and direct ARCHEMIX to
discontinue all further work on such designated Discontinued Competitive Target; or (B) to the
extent that TAKEDA is either Developing or Commercializing a Product against a Program Target for
which a Competitive Program exists, limit the scope and content of the reports to ARCHEMIX
otherwise called for under Section 4.6 solely with respect to that Product. For purposes of
clarity, a Discontinued Competitive Target shall never be deemed to be a Failed Target or a Waived
Target and the license grants associated with such Failed Target or Waived Target under Section
7.1.2(c) shall not apply to such Discontinued Competitive Target.

          7.6.2 TAKEDA. During the Exclusivity Term, TAKEDA shall not, and shall cause each of
its Affiliates to not, either on its own, or with, or for the benefit of, any Third Party,
research, develop or commercialize any aptamer binding to a Program Target, except as provided
under this Agreement.

8. INTELLECTUAL PROPERTY RIGHTS

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

49

 

     8.1 ARCHEMIX Intellectual Property Rights. ARCHEMIX shall have sole and exclusive
ownership of all right, title and interest on a worldwide basis in and to any and all ARCHEMIX
Technology and ARCHEMIX Patent Rights.

     8.2 SELEX Process and SELEX Technology Rights. TAKEDA hereby assigns and agrees to
assign to ARCHEMIX all of its right, title and interest on a worldwide basis in and to all Program
Technology and corresponding Patent Rights that are conceived after the Effective Date of this
Agreement that fall within the scope of the SELEX Process and/or the SELEX Technology and/or that
directly relate to the discovery, generation and optimization of Aptamers through (i) the use of
the SELEX Process or (ii) the practice of the SELEX Technology. ARCHEMIX hereby grants to TAKEDA a
non-exclusive, non-transferable, royalty-free license under ARCHEMIX’s interest in such Patent
Rights for any and all uses other than the conduct of the SELEX Process or the practice of the
SELEX Technology or the grant of any sublicense to conduct the SELEX Process or to practice the
SELEX Technology. In the event that a dispute arises between the Parties as to whether certain
Patent Rights of TAKEDA are subject to assignment under this Section 8.2, such dispute shall be
resolved using United States patent law by independent patent counsel mutually acceptable to both
Parties who (and whose firm) is not at the time of the dispute, and was not at any time during the
[***] years prior to such dispute, performing services for either of the Parties, such independent
patent counsel to be selected by the Patent Coordinators. Expenses of such patent counsel shall be
borne equally by the Parties.

     8.3 TAKEDA Intellectual Property Rights. TAKEDA shall have sole and exclusive
ownership of all right, title and interest on a worldwide basis in and to any and all TAKEDA
Technology and TAKEDA Patent Rights.

     8.4 Program Aptamer-Specific Patent Rights. ARCHEMIX hereby assigns and agrees to
assign to TAKEDA all of its right, title and interest on a worldwide basis in and to any and all
Program Aptamer-Specific Technology and corresponding Program Aptamer-Specific Patent Rights.

     8.5 Joint Technology Rights. TAKEDA and ARCHEMIX shall jointly own all Joint
Technology and Joint Patent Rights. Except to the extent (a) exclusively licensed to one Party
under this Agreement, or (b) the practice of such Joint Technology and Joint Patent Rights would
violate an obligation under this Agreement, particularly with regard to Section 7.6 pertaining to
exclusivity, the Parties hereby agree that either Party may use or license or sublicense to
Affiliates or Third Parties all or any portion of its interest in Joint Technology, Joint Patent
Rights or jointly owned Confidential Information or Proprietary Materials for any purposes without
the prior written consent of the other Party, without restriction and without the obligation to
provide compensation to the other Party, except as otherwise provided under this Agreement.

     8.6 Patent Coordinators. ARCHEMIX and TAKEDA shall each appoint a patent coordinator
reasonably acceptable to the other Party (each, a “Patent Coordinator”) to serve as such Party’s
primary liaison with the other Party on matters relating to patent filing, prosecution, maintenance
and enforcement. Each Party may replace its Patent Coordinator at any time by notice in writing to
the other Party. The initial Patent Coordinators shall be:

     For ARCHEMIX: John Harre

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

50

 

     For TAKEDA: [***]

     8.7 Inventorship. All determinations of inventorship under this Agreement with
respect to patent filings shall be made in accordance with the applicable local patent law. In
case of a dispute between ARCHEMIX and TAKEDA over inventorship and, as a result, whether any
particular Technology is ARCHEMIX Technology, TAKEDA Technology or Joint Technology, such dispute
shall be resolved using United States patent law by independent patent counsel mutually acceptable
to both Parties who (and whose firm) is not at the time of the dispute, and was not at any time
during the [***] years prior to such dispute, performing services for either of the Parties, such
independent patent counsel to be selected by the Patent Coordinators. Expenses of such patent
counsel shall be shared equally by the Parties.

     8.8 Technology Disputes. In the case of any dispute regarding whether any particular
Technology is Program Generic Technology or Program Aptamer-Specific Technology or whether any
Program Aptamer-Specific Technology is ARCHEMIX Program Aptamer-Specific Technology or TAKEDA
Program Aptamer-Specific Technology, such dispute shall be resolved using United States patent law
by independent patent counsel selected by the Patent Coordinators and reasonably acceptable to both
Parties who (and whose firm) is not at the time of the dispute, and was not at any time during the
[***] years prior to such dispute, performing services for either of the Parties. Expenses of such
patent counsel shall be shared equally by the Parties.

     8.9 Cooperation. Each Party shall cooperate with the other Party to affect the intent
of this Article 8, including, without limitation, by executing documents and making its employees
and independent contractors available to execute documents as necessary to achieve the foregoing
allocation of ownership rights.

9. FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS

     9.1 Patent Filing, Prosecution and Maintenance.

          9.1.1  ARCHEMIX Prosecution Rights.

               (a) ARCHEMIX Program Technology and Program Generic Patent Rights. ARCHEMIX, at its
sole expense, and acting through patent counsel or agents of its choice, shall be responsible for
Prosecution of (i) Patent Rights covering ARCHEMIX Program Technology; and (ii) Program Generic
Patent Rights. At ARCHEMIX’s request, TAKEDA shall cooperate with ARCHEMIX in all reasonable
respects in connection with the Prosecution of such Patent Rights, including but not limited to
obtaining assignments to reflect chain of title consistent with the terms of this Agreement,
gaining United States patent term extensions, supplementary protection certificates and any other
extensions that are now or become available in the future wherever applicable.

               (b) ARCHEMIX Program Aptamer-Specific Patent Rights.

                    (i) All patent filings relating to ARCHEMIX Program Aptamer-Specific Patent Rights shall be
made in TAKEDA’s name.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

51

 

                    (ii) ARCHEMIX, acting through patent counsel and/or agents of its choice, shall have
responsibility for managing the Prosecution of ARCHEMIX Program Aptamer-Specific Patent Rights.
ARCHEMIX shall use Commercially Reasonable Efforts with regard to such responsibility and shall
cause its appropriate officers, employees and if applicable subcontractors to cooperate in a
sufficient and reasonable manner to the extent necessary to insure that ARCHEMIX satisfies this
responsibility.

                    (iii) From time to time, TAKEDA may request that ARCHEMIX prepare and file one or more patent
applications covering ARCHEMIX Program Aptamer-Specific Technology by providing written notice to
ARCHEMIX. ARCHEMIX shall consider TAKEDA’s request in good faith and in a reasonable matter. In
the event that ARCHEMIX declines to file patents or patent applications with regard to any such
Program Aptamer-Specific Technology, TAKEDA shall have the right to Prosecute patents and patent
applications relating to such Program Aptamer-Specific Technology. In such case, ARCHEMIX shall
cooperate with TAKEDA in good faith and in reasonable manner regarding the Prosecution of such
patents and patent applications.

                    (iv) TAKEDA shall bear [***] (including, without limitation, the [***] of [***] and [***] and
[***]) incurred by ARCHEMIX in the Prosecution of ARCHEMIX Program Aptamer-Specific Patent Rights,
provided that ARCHEMIX shall use Commercially Reasonable Efforts to manage the Prosecution to
insure that such costs and expenses are reasonably consistent with applicable industry standards.

                    (v) If ARCHEMIX consummates a transaction that results in a Change of Control of ARCHEMIX that
involves a Third Party acquirer that has a Competitive Program, then TAKEDA shall have the option
to assume sole and exclusive responsibility for the Prosecution of ARCHEMIX Program
Aptamer-Specific Patent Rights directed to the Program Target for which such Competitive Program
exists.

                    (vi) The Parties will endeavour to make all decisions regarding the Prosecution of ARCHEMIX
Program Aptamer-Specific Patent Rights by mutual agreement, including all initial and subsequent
patent filing and maintenance decisions worldwide. The Parties shall discuss in good faith and
agree upon the content and form of any application for ARCHEMIX Program Aptamer-Specific Patent
Rights and hereby agree that only the application in the form as agreed between the Parties may be
filed with respect to such. In this regard, TAKEDA shall have the full right to reasonably
participate in Prosecution of the ARCHEMIX Program Aptamer-Specific Patent Rights and be
represented by counsel of its choice. TAKEDA shall promptly be provided with a copy of all
relevant correspondences to and from any government patent office in which ARCHEMIX Program
Aptamer-Specific Patent Rights are being pursued.

               (c) ARCHEMIX Background Technology. ARCHEMIX, at its sole expense and acting through
patent counsel or agents of its choice, shall be responsible for the Prosecution of all Patent
Rights covering ARCHEMIX Background Technology.

          9.1.2 TAKEDA’s Prosecution Rights.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

52

 

               (a) TAKEDA Program Technology. TAKEDA, at its sole expense, and acting through patent
counsel or agents of its choice, shall be responsible for the Prosecution of (i) Patent Rights
covering TAKEDA Program Technology including TAKEDA Program Aptamer-Specific Technology but not
ARCHEMIX Program Aptamer-Specific Technology or Program Generic Technology; and (ii) TAKEDA
Background Technology. ARCHEMIX shall cooperate with TAKEDA in all reasonable respects in
connection with the Prosecution of such Patent Rights, including but not limited to obtaining
assignments to reflect chain of title consistent with the terms of this Agreement, gaining United
States patent term extensions, supplementary protection certificates and any other extensions that
are now or become available in the future wherever applicable. For purposes of clarity,
notwithstanding anything to the contrary herein, TAKEDA shall have no right to Prosecute any (1)
Patent Rights related to the SELEX Process or SELEX Technology, (2) Patent
Rights included in the SELEX Portfolio, and (3) Program Generic Patent Rights.

               (b) TAKEDA Background Technology. TAKEDA, at its sole expense and acting through
patent counsel or agents of its choice, shall be responsible for the Prosecution of all Patent
Rights covering TAKEDA Background Technology.

          9.1.3 Joint Prosecution. In the case of Joint Patent Rights, the Parties shall meet
through the JSC and/or the Patent Coordinators to discuss in good faith and agree upon the content
and form of any application for a Joint Patent Right and hereby agree that only the application in
the form as agreed between the Parties may be filed in respect of the Joint Patent Rights. The
Parties shall share the costs equally in respect of the Prosecution of any Joint Patent Right
jointly filed and shall jointly instruct an appropriately qualified patent attorney to Prosecute.
Each Party will have equal control over the Prosecution of the filing such that the patent attorney
will only be able to act on unanimous instructions. In the event that one Party is not interested,
or not willing to equally share the related cost and expense, with respect to any Joint Patent
Rights in a given country, then the other Party shall have the right, at its own cost and expense,
to file for and prosecute such Joint Patent Rights in such country in both Parties’ names.

          9.1.4 Information and Cooperation. Each Party that has responsibility for Prosecuting
any Patent Rights under Section 9.1 (a “Filing Party”) shall (a) regularly provide the other Party
(the “Non-Filing Party”) with copies of all patent applications filed hereunder for Program
Technology and other material submissions and correspondence with the patent offices, in sufficient
time to allow for review and comment by the Non-Filing Party; (b) provide the Non-Filing Party and
its patent counsel with an opportunity to consult with the Filing Party and its patent counsel
regarding the filing and contents of any such application, amendment, submission or response; and
(c) obtain assignments to reflect chain of title consistent with the terms of this Agreement, and
gain United States patent term extensions, supplementary protection certificates and any other
extensions that are now or become available in the future wherever applicable. The advice and
suggestions of the Non-Filing Party and its patent counsel shall be taken into consideration in
good faith by such Filing Party and its patent counsel in connection with such filing. Each Filing
Party shall pursue in good faith all reasonable claims and take such other reasonable actions, as
may be requested by the Non-Filing Party in the prosecution of any Patent Rights under this Section
9.1; provided, however, if the Filing Party incurs any additional expense as a result of any such
request, the Non-Filing Party shall be responsible for the cost and expenses of pursuing any such
additional claim or taking such other activities. In addition, TAKEDA agrees

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

53

 

that if any action taken under Section 9.1 would be detrimental to Patent Rights covering
ARCHEMIX’s Background Technology (including, without limitation, the SELEX Portfolio), ARCHEMIX
shall provide written notice to the Patent Coordinator of TAKEDA and the Patent Coordinators shall,
as promptly as possible thereafter, meet to discuss and resolve such matter and, if they are unable
to resolve such matter, the Parties shall refer such matter to a mutually agreeable outside patent
counsel for resolution.

          9.1.5 Abandonment. If a Filing Party decides to abandon or to allow to lapse any of
the Patent Rights covering any Program Technology for which it has responsibility, it shall inform
the Non-Filing Party of such decision promptly and, in any event, so as to provide the Non-Filing
Party a reasonable amount of time to meet any applicable deadline to establish or preserve such
Patent Rights in such country or region. The Non-Filing Party shall have the right and option to
assume responsibility for continuing the Prosecution of such Patent Rights in such country or
region and paying any required fees to maintain such Patent Rights in such country or region or
defending such Patent Rights, through patent counsel or agents of its choice, which shall be at the
Non-Filing Party’s sole expense. Any change in the Party responsible for Prosecution under this
Section 9.1.5 shall not affect the ownership of any such Patent Rights as a result of its
assumption of any such responsibility. Upon transfer of such responsibility under this Section
9.1.5, the Filing Party shall promptly deliver to the Non-Filing Party copies of all necessary
files related to the Patent Rights with respect to which responsibility has been transferred and
shall take all actions and execute all documents reasonably necessary for the Non-Filing Party to
assume such responsibility. Thereafter, the Filing Party shall cooperate with the Non-Filing Party
(now the prosecuting party) as though consistent with the terms set forth in Section 9.1.4.

     9.2 Legal Actions.

          9.2.1  Third Party Infringement.

               (a) Notice. In the event either Party becomes aware of any possible infringement of
any Patent Rights subject to this Agreement Controlled by either Party where such infringement
relates to the development or commercialization of an aptamer directed to a Program Target for use
in the Field, including the submission by any Third Party of an abbreviated new drug application
under the Hatch-Waxman Act for a Generic Product (each, an “Infringement”), that Party shall
promptly notify the other Party and provide it with all details of such Infringement of which it is
aware (each, an “Infringement Notice”).

               (b) TAKEDA Right to Enforce.

                    (i) Enforcement of Patent Rights Relating To TAKEDA Background Technology. In the
event that any Infringement relates to any Patent Rights covering TAKEDA Background Technology,
TAKEDA shall have the sole right but not the obligation to enforce such claim.

                    (ii) Enforcement of Program Aptamer-Specific Patent Rights. In the event that any
Infringement relates to any Program Aptamer-Specific Patent Rights, TAKEDA shall use Commercially
Reasonable Efforts to enforce such claim, which may include the institution of legal proceedings or
other action. TAKEDA shall keep ARCHEMIX reasonably

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

54

 

informed on a quarterly basis, in person or by telephone, prior to and during any such
enforcement. ARCHEMIX shall assist TAKEDA, upon request, in taking any action to enforce any such
Patent Rights and shall join in any such action if deemed to be a necessary party. TAKEDA shall
incur [***] as a consequence of such litigation or any [***] resulting therefrom, including any
decision [***]. All costs, including, without limitation, attorneys’ fees, relating to such legal
proceedings or other action shall be borne [***]. If TAKEDA does not use Commercially Reasonable
Efforts to abate the Infringement of such Program Aptamer-Specific Patent Rights, within [***] days
from any Infringement Notice (or [***] days in the case of an Infringement resulting from the
submission by any Third Party of an abbreviated new drug application under the Hatch-Waxman Act),
then ARCHEMIX shall have the right and option to do so at its expense. In addition, in the event
TAKEDA initiates but does not continue any action to enforce any such Patent Rights, then ARCHEMIX
shall, with the consent of TAKEDA, such consent not to be unreasonably withheld, have the right and
option to continue to do so at its expense with counsel of its choice. For purposes of clarity,
notwithstanding anything to the contrary herein, TAKEDA shall have no rights to enforce any (1)
ARCHEMIX Patents Rights covering the SELEX Process or SELEX Technology, or (2) the SELEX Portfolio.

               (c) ARCHEMIX Right to Enforce.

                    (i) Enforcement of Patent Rights Relating To ARCHEMIX Background Technology. In the
event that any Infringement relates to any Patent Rights covering ARCHEMIX Background Technology,
ARCHEMIX shall have the sole right but not the obligation to enforce such claim

                    (ii) Enforcement of Patent Rights Relating To Program Technology. In the event that
any Infringement relates to any Patent Right covering Program Technology other than Program
Aptamer-Specific Patent Rights, ARCHEMIX shall use Commercially Reasonable Efforts to enforce such
claim, which may include the institution of legal proceedings or other action. ARCHEMIX shall keep
TAKEDA reasonably informed on a quarterly basis, in person or by telephone, prior to and during any
such enforcement. TAKEDA shall assist ARCHEMIX, upon request, in taking any action to enforce any
such Patent Rights and shall join in any such action if deemed to be a necessary party. ARCHEMIX
shall incur no liability to TAKEDA as a consequence of such litigation or [***]therefrom, [***] any
such [***] or [***]. All costs, including, without limitation, attorneys’ fees, relating to such
legal proceedings or other action shall be borne [***]. If ARCHEMIX does not use Commercially
Reasonable Efforts to abate the Infringement of such Patent Rights within [***] days from any
Infringement Notice (or [***] days in the case of an Infringement resulting from the submission by
any Third Party of an abbreviated new drug application under the Hatch-Waxman Act), then TAKEDA
shall have the right and option to do so at its expense. In addition, in the event ARCHEMIX
initiates but does not continue any action to enforce any such Patent Rights, then TAKEDA shall,
with the consent of ARCHEMIX, such consent not to be unreasonably withheld, have the right and
option to continue to do so at its expense with counsel of its choice.

               (d) Joint Patent Rights. In the event of an Infringement of a Joint Patent Right, the
Parties shall enter into good faith discussions as to whether and how to eliminate the
Infringement. Subject to the foregoing, (i) [***] shall have the first right and option to
eliminate such Infringement by reasonable steps, which may include the institution of legal
proceedings or

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

55

 

other action and (ii) all costs, including without limitation attorneys’ fees, relating to
such legal proceedings or other action shall be borne by [***]. If [***] does not take or initiate
commercially reasonable steps to eliminate the Infringement within [***] days from any Infringement
Notice (or [***] days in the case of an Infringement resulting from the submission by any Third
Party of an abbreviated new drug application under the Hatch-Waxman Act), [***] [***] shall have
the right and option to do so at its expense.

               (e) Representation by Counsel. Each Party shall have the right to be represented by
counsel that it selects in any legal proceedings or other action instituted under this Section
9.2.1 by the other Party.

               (f) Cooperation by the Parties. In any action, suit or proceeding instituted under
any subsection of Section 9.2.1, the Parties shall cooperate with and assist each other in all
reasonable respects. Upon the reasonable request of the Party instituting such action, suit or
proceeding, the other Party shall join such action, suit or proceeding and shall be represented
using counsel of its own choice, at the requesting Party’s expense. If a Party with the right to
initiate legal proceedings under Section 9.2.1 lacks standing to do so and the other Party has
standing to initiate such legal proceedings, then the Party with standing shall initiate such legal
proceedings at the request and expense of the other Party. The Party that is a party to the
action, suit or proceeding shall not admit the invalidity of any patent within the Program
Aptamer-Specific Patent Rights, Licensed Patent Rights, or Joint Patent Rights, nor settle such
action, suit or proceeding in a manner that adversely affects the other Party’s rights under this
Agreement, without the written consent of the other Party, which consent shall not be unreasonably
withheld, delayed or conditioned.

               (g) Allocation of Recoveries Under 9.2.1(b)(ii). Any amounts recovered by the Party
or Parties bringing suit pursuant to actions under Section 9.2.1(b)(ii), whether by settlement or
judgment, shall be allocated in the following order: (i) first, to reimburse TAKEDA and ARCHEMIX
for their reasonable out-of-pocket expenses in making such recovery (which amounts shall be
allocated pro rata if insufficient to cover the totality of such expenses); and (ii) second (A)
with respect to actual damages, then, to TAKEDA and ARCHEMIX in the same proportion as TAKEDA’s
historic Net Sales of the Product or Products affected by the Infringement bears to ARCHEMIX’s
historic royalties hereunder in respect of such Net Sales, in each case as determined in good
faith, and (B) with respect to punitive, special or consequential damages, [***] percent ([***]%)
to TAKEDA.

               (h) Allocation of Recoveries Under 9.2.1(c)(ii). Any amounts recovered by the Party
or Parties bringing suit pursuant to actions under Section 9.2.1(c)(ii), whether by settlement or
judgment, shall be allocated in the following order: (i) first, to reimburse ARCHEMIX and TAKEDA
for their reasonable out-of-pocket expenses in making such recovery (which amounts shall be
allocated pro rata if insufficient to cover the totality of such expenses); and (ii) second (A)
with respect to actual damages, then, to ARCHEMIX and TAKEDA in the same proportion as TAKEDA’s
historic Net Sales of the Product or Products affected by the Infringement bears to ARCHEMIX’s
historic royalties hereunder in respect of such Net Sales, in each case as determined in good
faith, and (B) with respect to punitive, special or consequential damages, [***] percent ([***]%)
to ARCHEMIX.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

56

 

          9.2.2 Defense of Claims.

               (a) Notice. In the event that a Third Party alleges that the conduct of the Research
Program or the Development or Commercialization of an Optimized Lead Compound or Product infringes
the Patent Rights of a Third Party, the Party becoming aware of such allegation shall promptly
notify the other Party hereof, in writing, reasonably detailing the claim.

               (b) Third Party Suit Relating Primarily to Program Targets or Requested Chemistry.

                    (i) In the event that any action, suit or proceeding is brought against either Party or any
Affiliate or sublicensee of either Party alleging the infringement of the Patent Rights of a Third
Party relating specifically to the Program Targets or their uses by reason of activities conducted
pursuant to this Agreement, (A) TAKEDA shall have the right and obligation to defend or otherwise
resolve or settle such action, suit or proceeding at its sole expense; (B) ARCHEMIX or any of its
Affiliates or sublicensees shall have the right to separate counsel at its own expense in any such
action, suit or proceeding and, if such action, suit or proceeding has been brought against
ARCHEMIX or any of its Affiliates or sublicensees, ARCHEMIX may elect to defend itself at its sole
expense; and (C) the Parties shall cooperate with each other in all reasonable respects in any such
action, suit or proceeding. Settlement costs, royalties paid in settlement of any such suit, and
the payment of any damages to the Third Party shall be borne [***].

                    (ii) In the event that any action, suit or proceeding is brought against either Party or any
Affiliate or sublicensee of either Party alleging the infringement, by reason of activities
conducted pursuant to this Agreement, of the Technology or Patent Rights of a Third Party relating
specifically to the use of Requested Chemistry in (A) the Research Program or any Product
independent of any challenge to the right to practice the SELEX Process or SELEX Technology, (B)
the Development or Commercialization of any Product, including, without limitation, the
manufacture, use or sale of such Product, TAKEDA shall have the right and obligation to defend or
otherwise resolve or settle such action, suit or prosecution at its sole expense. Settlement
costs, royalties paid in settlement of any such suit, and the payment of any damages to the Third
Party shall be borne [***].

               (c) Third Party Suit Relating Primarily to the use of the SELEX Process or the SELEX
Technology. In the event that any action, suit or proceeding is brought against either Party
or any Affiliate or sublicensee of either Party alleging the infringement of the Patent Rights of a
Third Party by reason of the use of the SELEX Process or the use of the SELEX Technology (excluding
in either case any action, suit or proceeding based solely on the use of Requested Chemistry) in
the conduct of the Research Program (i) ARCHEMIX shall have the right and obligation to defend or
otherwise resolve or settle such action, suit or proceeding at its sole expense; and (ii) TAKEDA or
any of its Affiliates or Sublicensees shall have the right to separate counsel at its own expense
in any such action, suit or proceeding and, if such action, suit or proceeding has been brought
against TAKEDA or any of its Affiliates or Sublicensees, TAKEDA or its Affiliate or Sublicensee may
elect to defend itself at its sole expense. Settlement

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

57

 

costs, royalties paid in settlement of any such suit, and the payment of any damages to the
Third Party shall be borne [***].

               (d) Cooperation in Defense. The Parties shall cooperate with each other in all
reasonable respects in any action, suit or proceeding under this Section 9.2.2. Each Party shall
provide the other Party with prompt written notice of the commencement of any such suit, action or
proceeding, or allegation of infringement of which such Party becomes aware, and shall promptly
furnish the other Party with a copy of each communication relating to the alleged infringement that
is received by such Party from a third party, provided such provision does not violate or waive
attorney-client privilege.

          9.2.3 Trademark and Copyright Ownership Prosecution, Defense and Enforcement. TAKEDA
shall own and be responsible for the filing, prosecution, maintenance, defense and enforcement of
all Product Trademarks and copyrights created during the Research Program, Development and/or
Commercialization at TAKEDA’s expense.

          9.2.4 Maintenance of Royalty Triggering Patent Rights Schedule by ARCHEMIX. Between
the date of filing of an IND for a Product, and [***] days following the initiation of a Phase I
Clinical Trial for such Product, ARCHEMIX shall provide TAKEDA with a schedule of what ARCHEMIX
considers to be Royalty Triggering Patent Rights. Such schedule shall be updated by ARCHEMIX
within [***] business days following the end of each [***]. At any time, should TAKEDA disagree
with the listing of particular Royalty Triggering Patent Rights as to a given Product, the Parties
will discuss the Patent Rights that are the subject of the disagreement. If the Parties cannot
reach agreement within [***] days after the disagreement is raised by TAKEDA, either Party may
require that the qualification of any given disputed Patent Rights as Royalty Triggering Patent
Rights hereunder be determined by independent patent counsel mutually acceptable to both Parties
who (and whose firm) is not at the time of the dispute, and was not at any time during the [***]
years prior to such dispute, performing services for either of the Parties, such independent patent
counsel to be selected by the Patent Coordinators. Expenses of such patent counsel shall be shared
equally by the Parties.

          9.2.5 Effect of Challenge. In further consideration of ARCHEMIX’s grant of the
licenses and assignments hereunder with regard to Royalty Triggering Patent Rights and except to
the extent the following is unenforceable under the Applicable Laws of a particular jurisdiction
where Royalty Triggering Patent Rights have been issued, in the event that TAKEDA, its Affiliates
and/or Sublicensees (a) initiates a Challenge or directly assists a Third Party in initiating a
Challenge, then, only and specifically as to the Products and country(ies) affected by the
Challenge, (i) during the [***] of such Challenge, the [***] set forth in [***] hereof shall be
[***] by an [***] on the [***]of such [***], and (ii) should the [***] of such Challenge determine
that any [***] that is the subject of the Challenge is [***] or [***] or is [***] by any Products,
the [***] set forth in [***] shall be [***] by an [***]. The following hypothetical example
illustrates the effect on the [***] if TAKEDA initiates or directly assists a Third Party in
initiating a Challenge in the [***] and the Royalty Triggering Patent Rights cover Product X, then,
[***] as to [***]in the [***] shall the [***] be [***] the[***] of such Challenge and by [***]
should the [***] of such Challenge determine that any [***] that is the subject of the Challenge is
[***] or [***] and is [***]; e.g., if, in any Calendar Year during the Term, the [***] is [***] to
be [***] of [***] a [***] during the [***] of any such Challenge the [***] would be

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

58

 

[***] to [***] of [***] and should the [***] of such Challenge determine that any [***] that
is the subject of the Challenge is [valid] or [***] or is [***], the [***] would thereafter be
[***] it were [***] a [***] to [***] of [***] for the [***] of the[***]. The [***] to Product X
shall not be affected in any country other than the [***]. Furthermore, [***] to any other Product
shall not be affected in any country.

10. TERM AND TERMINATION

     10.1 Term. This Agreement shall commence on the Effective Date and shall continue in
full force and effect until the end of the Research Program Term and, if TAKEDA is Developing or
Commercializing a Product as of the end of the Research Program Term, thereafter until the earlier
of (a) when TAKEDA is no longer Developing or Commercializing at least one (1) Product or (b)
expiration of the last to expire Royalty Term for Commercialized Products, unless earlier
terminated in accordance with the provisions of this Article 10 (such period, the “Term”).

     10.2 Termination. This Agreement may be terminated at any time by either Party as
follows:

          10.2.1 Termination by Mutual Agreement. At any time, TAKEDA and ARCHEMIX may mutually
agree to terminate this Agreement by written agreement between the Parties. The Parties agree that
this Section 10.2.1 is not subject to dispute resolution under this Agreement.

          10.2.2 Termination for Breach Prior To Selection of Optimized Lead Compound. Either
Party may terminate this Agreement prior to selection of an Optimized Lead Compound, effective
immediately upon written notice to the other Party, for a material breach by the other Party of any
term of this Agreement that remains uncured for [***] days ([***] days in the event that such
material breach is based on a failure of TAKEDA to make any payment required hereunder) after the
non-breaching Party first gives written notice to the other Party of such breach and its intent to
terminate this Agreement if such breach is not cured. In the event that ARCHEMIX is unable to
provide any of ARCHEMIX Research Activities hereunder as a result of a change in the scope of
rights conveyed to ARCHEMIX under the ARCHEMIX-Gilead License Agreement, then, to the extent such
ARCHEMIX Research Activities are material to the conduct of the Research Program, such occurrence
shall be a material breach of this Agreement by ARCHEMIX. Notwithstanding the foregoing, if the
allegedly breaching Party disputes whether a material breach has occurred or whether it has been
cured, the issue of whether a material breach has in fact occurred or has been cured shall be
resolved pursuant to Section 13.1.

          10.2.3 Termination on Product by Product Basis After Selection of Optimized Lead
Compound. After selection of an Optimized Lead Compound, in the event of a material breach by
either Party, the other Party may terminate this Agreement as to the Product(s) affected by such
breach. Termination under this Section shall be effective immediately upon written notice to the
breaching Party if such breach remains uncured for [***] days ([***] days in the event that such
material breach is based on a failure of TAKEDA to make any payment required hereunder) after the
non-breaching Party first gave written notice to the breaching Party of such breach and its intent
to terminate this Agreement as to such Product(s) if such breach was not cured.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

59

 

Notwithstanding the foregoing, if the allegedly breaching Party disputes whether a material
breach has occurred or whether it has been cured, the issue of whether a material breach has in
fact occurred or has been cured shall be resolved pursuant to Section 13.1.

          10.2.4 Termination for Insolvency. In the event that either Party files for
protection under bankruptcy laws, makes a general assignment for the benefit of creditors, appoints
or suffers appointment of a receiver or trustee over its business, files a petition under any
bankruptcy or insolvency act or has any such petition filed against it which is not dismissed or
stayed within [***] days of the filing thereof, the other Party may terminate this Agreement
effective immediately upon written notice to such Party. In connection therewith, all rights and
licenses granted under this Agreement are, and shall be deemed to be, for purposes of Section
365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property” as
defined under Section 101(35A) of the United States Bankruptcy Code. In addition, to the extent
permitted by Applicable Laws, the Parties agree that, in the event of the commencement of a
proceeding by or against ARCHEMIX under Title 11 of the United States Code, ARCHEMIX agrees,
immediately upon written request of TAKEDA, to provide to TAKEDA all such intellectual property,
including all embodiments thereof. If the trustee in any such proceeding rejects this Agreement,
and if TAKEDA thereupon elects to retain its rights to such intellectual property hereunder,
ARCHEMIX further agrees, immediately upon written request of TAKEDA, to provide to TAKEDA all such
intellectual property, including all embodiments thereof.

     10.3 Consequences of Termination of Agreement. In the event of the termination of
this Agreement pursuant to Section 10.2, the following provisions shall apply, as applicable.

          10.3.1 Termination Pursuant to Section 10.2.2.

               (a) If this Agreement is terminated by TAKEDA pursuant to Section 10.2.2:

                    (i) the Research Program shall terminate without any further obligation of ARCHEMIX and
TAKEDA;

                    (ii) all licenses granted to TAKEDA or ARCHEMIX under Article 7 to any Patent Rights covering
any Collaboration Aptamers as of the effective date of termination, if any, shall immediately
terminate; all such Collaboration Aptamers shall be Failed Compounds, and ARCHEMIX and TAKEDA shall
have no further respective obligations under Section 7.6.1 or 7.6.2;

                    (iii) each Party shall promptly return all Confidential Information and Proprietary Materials
of the other Party that are not subject to a continuing license hereunder; provided, that, each
Party may retain one copy of the Confidential Information of the other Party in its archives solely
for the purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder; and

                    (iv) neither Party shall have the right to research, develop or commercialize such Failed
Compounds

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

60

 

               (b) If this Agreement is terminated by ARCHEMIX pursuant to Section 10.2.2:

                    (i) the Research Program shall terminate without any further obligation of ARCHEMIX and
TAKEDA;

                    (ii) all licenses granted to TAKEDA under Article 7 to any Patent Rights covering
Collaboration Aptamers as of the effective date of termination, if any, shall immediately
terminate; all such Collaboration Aptamers shall be Failed Compounds, and ARCHEMIX and TAKEDA shall
have no further respective obligations under Section 7.6.1 or 7.6.2;

                    (iii) TAKEDA shall be deemed to have (A) assigned to ARCHEMIX all of its right, title and
interest in and to all Program Aptamer-Specific Patent Rights relating solely to any such Failed
Compounds and (B) granted to ARCHEMIX a non-exclusive, royalty-free license under Patent Rights
covering TAKEDA Program Technology (other than such Program Aptamer-Specific Patent Rights assigned
to ARCHEMIX) and TAKEDA’s interest in Joint Patent Rights solely in the Field to develop and
commercialize any such Failed Compound; and

                    (iv) each Party shall promptly return all Confidential Information and Proprietary Materials
of the other Party that are not subject to a continuing license hereunder; provided, that, each
Party may retain one copy of the Confidential Information of the other Party in its archives solely
for the purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder.

Nothing contained herein shall limit either Party’s rights and remedies at law or in equity in the
event of a material breach of this Agreement by the other Party.

          10.3.2 Termination by TAKEDA Pursuant to Section 10.2.3. If this Agreement is
terminated by TAKEDA as to certain Product(s) pursuant to Section 10.2.3 (including, without
limitation, for breach of ARCHEMIX’s exclusivity obligations under Section 7.6.1):

               (a) With respect to the Product(s) materially affected by the breach that gave rise to
TAKEDA’s right to terminate under Section 10.2.2, all milestone, royalty and other payments
applicable to such Products under this Agreement shall be reduced by [***] percent ([***]%) of the
amount such milestone, royalty and other payments would otherwise have been to ARCHEMIX hereunder;

               (b) TAKEDA shall no longer be bound by the obligations of Section 7.6.2 with respect to the
Program Target(s) to which the terminated Product(s) bind; and

               (c) In all other respects, the terms and conditions of this Agreement shall remain in full
force and effect.

Nothing contained herein shall limit TAKEDA’s rights and remedies at law or in equity in the event
of a material breach of this Agreement by ARCHEMIX.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

61

 

          10.3.3 Termination by TAKEDA Pursuant to Section 10.2.4. If this Agreement is
terminated by TAKEDA pursuant to Section 10.2.4, unless prohibited by Applicable Law:

               (a) the license set forth in Section 7.1.1(b) shall survive solely as applied to Products
being Developed by TAKEDA as of the effective date of termination, if any, and the license set
forth in Section 7.2 shall survive solely as applied to Products being Commercialized by TAKEDA as
of the effective date of termination or Derived from Products being Developed by TAKEDA as of the
effective date of termination, if any, subject to TAKEDA’s continued payment of all milestone,
royalty and other payments under and in accordance with this Agreement with respect thereto; and

               (b) each Party shall promptly return all Confidential Information and Proprietary Materials of
the other Party that are not subject to a continuing license hereunder; provided, that, each Party
may retain one copy of the Confidential Information of the other Party in its archives solely for
the purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder.

          10.3.4 Termination by ARCHEMIX Pursuant to Section 10.2.3. If this Agreement is
terminated as to a given Product by ARCHEMIX pursuant to Section 10.2.3 (including, without
limitation, for breach by TAKEDA of its diligence obligations under Section 4.4.1):

          (a) All licenses granted to TAKEDA under Article 7 to such Product as of the effective date of
termination, if any, shall immediately terminate.

          (b) ARCHEMIX shall be entitled to treat such Product as if it were a Terminated Product with
the Parties having the rights and obligations set forth in Section 7.1.2(d), except as follows:

               (i) The royalties, milestones and other payments due to TAKEDA shall be [***] percent ([***]%)
of the amounts provided for under Sections 5.3 and 5.4;

               (ii) There shall be no charge to ARCHEMIX for the fulfillment of TAKEDA’s obligations with
respect to such Product under Section 7.1.2(d)(ii)(A-B); and

               (iii) The supply of Product under Section 7.1.2(d)(ii)(C) by TAKEDA shall be [***] percent
([***]%).

          (c) In all other respects, the terms and conditions of the Agreement shall remain in full
force and effect.

Nothing contained herein shall limit ARCHEMIX’s rights and remedies at law or in equity in the
event of a material breach of this Agreement by TAKEDA.

          10.3.5 Termination by ARCHEMIX Pursuant to Section 10.2.4. If this Agreement is
terminated by ARCHEMIX pursuant to Section 10.2.4, unless prohibited by Applicable Laws, the
provisions of Section 10.3.5 shall apply, except that TAKEDA shall have no obligation to continue
to conduct any clinical trial.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

62

 

     10.4 Surviving Provisions. Termination or expiration of this Agreement for any reason
shall be without prejudice to:

          (a) the rights and obligations of the Parties provided in Section 3.4.1 (Record Keeping),
Section 5.2.3 (R&D Funding Audit Rights), Section 5.4.2 (Records; Audit Rights), Section 9.1.3
(Joint Prosecution), Section 9.2.1(d) (Joint Patent Rights), Section 9.2.2 (Defense of Claim),
Section 10.3 (Consequences of Termination of Agreement), Section 10.4 (Surviving Provisions),
Section 13.2 (Litigation; Jurisdiction), Section 13.4 (Governing Law), Section 13.9 (No Third Party
Beneficiaries), Section 13.15 (Further Assurances), Article 6 (Confidentiality), Article 8
(Intellectual Property Rights), Article 12 (Indemnification) and all other Sections or Articles
referenced in any such Section or Article, including Article 1, all of which shall survive such
termination;

          (b) The rights of the Parties to receive royalties and milestone payments for the duration of
all applicable Royalty Terms, if any; and

          (c) any other rights or remedies provided at law or equity which either Party may otherwise
have.

11. REPRESENTATIONS AND WARRANTIES

     11.1 Mutual Representations and Warranties. ARCHEMIX and TAKEDA each represents and
warrants to the other, as of the Effective Date, as follows:

          11.1.1 Organization. It is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization, and has all requisite power and
authority, corporate or otherwise, to execute, deliver and perform this Agreement.

          11.1.2 Authorization. The execution and delivery of this Agreement and the
performance by it of the transactions contemplated hereby have been duly authorized by all
necessary corporate action and will not violate (a) such Party’s certificate of incorporation or
bylaws, (b) any agreement, instrument or contractual obligation to which such Party is bound in any
material respect, (c) any requirement of any Applicable Law, or (d) any order, writ, judgment,
injunction, decree, determination or award of any court or governmental agency presently in effect
applicable to such Party.

          11.1.3 Binding Agreement. This Agreement is a legal, valid and binding obligation of
such Party enforceable against it in accordance with its terms and conditions.

          11.1.4 No Inconsistent Obligation. It is not under any obligation, contractual or
otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms of
this Agreement or that would impede the diligent and complete fulfillment of its obligations
hereunder.

     11.2 Acknowledgment and Covenants of TAKEDA. TAKEDA acknowledges that the licenses
granted to TAKEDA hereunder are subject to certain limitations and restrictions set forth in the
ARCHEMIX-Gilead License Agreement and the URC License Agreement and agrees that it shall comply
with the terms of the ARCHEMIX-Gilead License Agreement and the URC

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

63

 

License Agreement that ARCHEMIX is subject to thereunder. TAKEDA further acknowledges and
agrees that (a) under the ARCHEMIX-Gilead License Agreement and under the URC License Agreement,
ARCHEMIX’s rights in the SELEX Process or the SELEX Technology as described in the SELEX Portfolio
may revert to Gilead or ULEHI if ARCHEMIX, its Affiliates and all assignees and sublicensees cease
reasonable efforts to develop the commercial applications of products and services utilizing the
SELEX Process or the SELEX Technology; (b) in the event of any termination of the URC License
Agreement, the licenses granted to TAKEDA hereunder shall remain in full force and effect in
accordance with Section 3.4 of the URC License Agreement; provided, that, TAKEDA is not then in
breach of this Agreement and TAKEDA agrees to be bound to ULEHI as the licensor under the terms and
conditions of the URC License Agreement as described in the SELEX Portfolio and reference is
expressly made to ARCHEMIX’s obligations under Section 6, 7, 8, and 10 of URC License Agreement,
(c) in the event of any termination of the ARCHEMIX-Gilead License Agreement, the licenses granted
to TAKEDA hereunder shall remain in full force and effect in accordance with Section 2.3 of the
ARCHEMIX-Gilead License Agreement; provided, that, TAKEDA agrees to comply with such terms,
conditions, agreements and obligations that are consistent with the terms, conditions, agreements
and obligations to which ARCHEMIX was subject under the ARCHEMIX-Gilead Agreement, including,
without limitation, the provisions of Sections 2.1(b), 2.1(c), 2.2, Section 4, Section 5, Section
6.4, Section 7.1(b), Section 8 and Section 9.3, and provided that if the termination of the
ARCHEMIX-Gilead License Agreement arises out of the action or inaction of TAKEDA, Gilead, at its
option, may terminate such license. TAKEDA hereby acknowledges, agrees and covenants that it may
not and will not (a) research, make, use, sell, offer for sale, import or export Diagnostic
Products, Radio Therapeutics, or Aptamer Antidote Combination Products or (b) use the SELEX Process
or the SELEX Technology to the extent such SELEX Process or SELEX Technology is covered by a Valid
Claim of Patent Rights Controlled by ARCHEMIX, or is ARCHEMIX Confidential Information designated
as such, and disclosed, in writing to TAKEDA in the performance of this Agreement, for any reason,
including, without limitation, (i) to research, make, use, sell, offer for sale, import or export
any aptamers for Diagnostic Products, Radio Therapeutics, or Aptamer Antidote Combination Products
or (ii) to research, make, use, sell, offer for sale, import or export any aptamer (including any
Excluded Aptamer and/or any product containing an Excluded Aptamer)

11.3 Representations and Warranties of ARCHEMIX

          11.3.1 Rights to Licensed Technology and Licensed Patent Rights. As of the Effective
Date, to the best of ARCHEMIX’s Knowledge and except as previously disclosed to TAKEDA, (a) all
Licensed Technology and Licensed Patent Rights are Controlled by ARCHEMIX; (b) ARCHEMIX has not
granted to any Third Party any right to use, license or otherwise exploit the Licensed Technology
and Licensed Patent Rights in a manner which would conflict with the exclusive rights granted to
TAKEDA under Section 7.1.1(b); (c) upon the execution by the Parties of this Agreement, TAKEDA
shall have no obligation to make any royalty or other payment to any Third Party as a result of the
grant by ARCHEMIX to TAKEDA of the licenses set forth in Section 7.1.1; (d) there are no judgments,
decrees or orders of any court or administrative agency that affect the use by TAKEDA of Licensed
Technology and Licensed Patent Rights as contemplated by this Agreement; (e) all Licensed Patents
owned by ARCHEMIX consisting of issued patents have not been declared invalid or unenforceable by
any court of competent jurisdiction; and (f) ARCHEMIX is in full compliance with the terms of all
licenses

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

64

 

and other agreements with Third Parties under which it has the right to use any Licensed
Technology and Licensed Patent Rights, all such agreements are in full force and effect, and no
Third Party has given ARCHEMIX written notice that an event has occurred which with notice or lapse
of time would constitute a breach or default or permit termination, modification or acceleration
under any such agreements.

          11.3.2 Non-Infringement by ARCHEMIX. To the best of ARCHEMIX’s Knowledge, as of the
Effective Date, except as previously disclosed to TAKEDA, (i) the practice of the SELEX Process
and use of SELEX Technology as contemplated by this Agreement will not infringe the Patents Rights
or other intellectual property rights of any Third Parties, and (ii) no Third Party has initiated,
or threatened in writing to initiate, any litigation against ARCHEMIX or its Affiliates, including,
without limitation, by initiating any declaratory judgment lawsuit, or by sending a
cease-and-desist letter, alleging that the Licensed Patent Rights are invalid or unenforceable or
that the use of the Licensed Patent Rights or Licensed Technology as contemplated by this Agreement
infringes the Patent Rights of such Third Party.

          11.3.3 Full Disclosure.  As of the Effective Date, ARCHEMIX has provided to
TAKEDA with access to all information in the possession and Control of ARCHEMIX that ARCHEMIX
believes is material to the performance by the Parties of this Agreement.

12. INDEMNIFICATION

     12.1 Indemnification of TAKEDA by ARCHEMIX. ARCHEMIX shall indemnify, defend and hold
harmless TAKEDA, its Affiliates, their respective directors, officers, employees and agents, and
their respective successors, heirs and assigns (collectively, the “TAKEDA Indemnitees”), against
all liabilities, damages, losses and expenses (including, without limitation, reasonable attorneys’
fees and expenses of litigation) (collectively, “Losses”) incurred by or imposed upon the TAKEDA
Indemnitees, or any one of them, as a direct result of claims, suits, actions, demands or judgments
of Third Parties, including, without limitation, intellectual property infringement (except as
otherwise provided in this Agreement), personal injury and product liability claims (collectively,
“Claims”), arising out of (i) ARCHEMIX’s research and development activities under this Agreement,
including claims with respect to ARCHEMIX’s use of the SELEX Process or SELEX Technology in
connection with such activities, and (ii) the development, manufacture, use or sale of any Waived
Compound, Failed Compound or Terminated Product by ARCHEMIX or an assignee or sublicense thereof
(including TAKEDA’s activities under Section 7.1.2(d) and Section 10.3.4); except with respect to
any Claim or Losses that result from a breach of this Agreement by, or the gross negligence or
willful misconduct of, TAKEDA; provided, that, with respect to any Claim for which ARCHEMIX has an
obligation to any TAKEDA Indemnitee pursuant to this Section 12.1 and TAKEDA has an obligation to
any ARCHEMIX Indemnitee pursuant to Section 12.2, each Party shall indemnify each of the other
Party’s Indemnitees for its Losses to the extent of its responsibility, relative to the other
Party, for the facts underlying the Claim.

     12.2 Indemnification of ARCHEMIX by TAKEDA. TAKEDA shall indemnify, defend and hold
harmless ARCHEMIX, its Affiliates, their respective directors, officers, employees and agents, and
their respective successors, heirs and assigns (the “ARCHEMIX Indemnitees”), against any Losses
incurred by or imposed upon the ARCHEMIX Indemnitees, or

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

65

 

any one of them, as a direct result of (i) Claims arising out of the Development or the
Commercialization (including, without limitation, the production, manufacture, promotion, import,
sale or use by any Person) of any Product by TAKEDA or any of its Affiliates, Sublicensees,
distributors or agents, or (ii) Claims that are specific to a particular Program Target and/or the
use of a particular Program Target, except with respect to any Claim that results from a breach of
this Agreement by, or the gross negligence or willful misconduct of, ARCHEMIX; provided, that, with
respect to any Claim for which ARCHEMIX has an obligation to any TAKEDA Indemnitee pursuant to
Section 12.1 and TAKEDA has an obligation to any ARCHEMIX Indemnitee pursuant to this Section 12.2,
each Party shall indemnify each of the other Party’s Indemnitees for its Losses to the extent of
its responsibility, relative to the other Party, for the facts underlying the Claim.

     12.3 Indemnification of [***] and [***] by TAKEDA. If, and solely to the extent,
legally required by the [***] License Agreement, TAKEDA shall indemnify, defend and hold harmless
[***], its Affiliates and [***] and any of their respective directors, officers, employees and
agents (each, a “[***] Indemnitee”), from and against any Losses that are incurred by a [***]
Indemnitee as a result of any Claims, to the extent such Claims arise out of the possession,
research, development, manufacture, use, offer for sale, sale or other commercialization,
distribution, administration, storage or transport, by TAKEDA or its Affiliates or Sublicensees of
(a) any Aptamers or Licensed Products, or (b) any other products, services and activities developed
by TAKEDA relating to the Covered Intellectual Property, including any Licensed Products, Aptamers
or Documentation (as such terms are defined in the [***] License Agreement).

     12.4 Conditions to Indemnification. A Person seeking recovery under this Article 12
(the “Indemnified Party”) in respect of a Claim shall give prompt notice of such Claim to the Party
from which recovery is sought (the “Indemnifying Party”) and, provided that the Indemnifying Party
is not contesting its obligation under this Article 12, shall permit the Indemnifying Party to
control any litigation relating to such Claim and the disposition of such Claim; provided, that,
the Indemnifying Party shall (a) act reasonably and in good faith with respect to all matters
relating to the settlement or disposition of such Claim as the settlement or disposition relates to
such Indemnified Party and (b) not settle or otherwise resolve such claim without the prior written
consent of such Indemnified Party (which consent shall not be unreasonably withheld, conditioned or
delayed). Each Indemnified Party shall cooperate with the Indemnifying Party in its defense of any
such Claim in all reasonable respects and shall have the right to be present in person or through
counsel at all legal proceedings with respect to such Claim.

     12.5 Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT,
NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER
SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE AND NON-INFRINGEMENT.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

66

 

     12.6 No Warranty of Success. Nothing contained in this Agreement shall be construed
as a warranty on the part of either Party that (a) the Research Program will yield any Optimized
Lead Compound or otherwise be successful, (b) any Development Program will yield a Product or
otherwise be successful or (c) the outcome of the Research Program or any Development Program will
be commercially exploitable in any respect.

     12.7 Limited Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT,
NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY SPECIAL,
PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION LOST PROFITS
OR LOST REVENUES, OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, WHETHER
UNDER ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY.

13. MISCELLANEOUS

     13.1 Dispute Resolution. Subject to the exceptions set forth in Sections 2.1.6, 8.2,
8.7, 8.8, 9.1.4 and Section 10.2.1, should a dispute arise under this Agreement, which the Parties
are not initially able to resolve, such dispute shall be referred to the President of ARCHEMIX and
the General Manager of Pharmaceutical Research Division of TAKEDA (the “Designated Senior
Officers”) (or their designees), who shall promptly initiate discussions in good faith to resolve
such dispute. If such dispute is not resolved by the Designated Senior Officers within [***] days
after the date the Designated Senior Officers first met to consider such dispute, such dispute
shall be resolved in accordance with Section 13.2.

     13.2 Litigation; Jurisdiction. Notwithstanding anything to the contrary in this
Agreement, with respect to any suit, action or proceeding brought by either Party which may arise
out of or in connection with this Agreement (a “Proceeding”), each of the Parties hereby (a)
irrevocably submits to the jurisdiction of the state and federal courts in the State of New York
and agrees that all claims in respect of such Proceeding shall be heard and determined in any such
court; (b) waives any defense of inconvenient forum to the maintenance of any such Proceeding and
further agrees not to bring any such Proceeding in any other court; (c) irrevocably consents to the
service of process of any of the aforementioned court in any such Proceeding by the mailing of
copies thereof by certified mail, postage prepaid, to the Party at its address set forth in Section
13.3; and (d) agrees that a final judgment in any such Proceeding shall be conclusive and may be
enforced by suit on the judgment or in any other manner provided by law or at equity.
Notwithstanding anything to the contrary in this Article 13, either Party may seek injunctive
relief in any court in any jurisdiction where appropriate.

     13.3 Notices. All notices and communications shall be in writing and delivered
personally or by courier or mailed via certified mail, return receipt requested, addressed as
follows, or to such other address as may be designated from time to time:

	 	 	 
	If to TAKEDA:

	 	If to ARCHEMIX:
	 
	 	 
	Takeda Pharmaceutical Company Limited

	 	Archemix Corp.
	1-1, Doshomachi 4-chome

	 	300 Third Street

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

67

 

	 	 	 
	Chuo-ku, Osaka 540-8645
	 	 
	Japan

	 	Cambridge, MA 02142
	Tel: [***]

	 	Tel: (617) 621-7700
	Fax: [***]

	 	Fax: (617) 621-9300
	Attention: [***]

	 	Attention: Chief Executive Officer
	[***]

	 	Attention: General Counsel
	 

	 	With a copy to:
	 
	 

	 	Mintz, Levin, Cohn, Ferris, Glovsky
	 

	 	and
Popeo, P.C.

	 

	 	One Financial Center
	 

	 	Boston, Massachusetts 02111
	 

	 	Attention: John J. Cheney, Esq.
	 

	 	Tel: (617) 542-6000
	 

	 	Fax: (617) 542-2241

     In addition, all notices to the JPT or JSC shall be sent to each Party’s designees at such
Party’s address stated above or to such other address as such Party may designate by written notice
given in accordance with this Section 13.3.

     Except as otherwise expressly provided in this Agreement or mutually agreed in writing, any
notice, communication or document (excluding payment) required to be given or made shall be deemed
given or made and effective upon actual receipt or, if earlier, (a) three (3) business days after
deposit with an internationally-recognized overnight express courier with charges prepaid, or (b)
five (5) business days after mailed by certified, registered or regular mail, postage prepaid, in
each case addressed to a Parties at its address stated above or to such other address as such Party
may designate by written notice given in accordance with this Section 13.2.

     13.4 Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the New York, without regard to the application of principles of conflicts of law.

     13.5 Binding Effect. This Agreement shall be binding upon and inure to the benefit of
the Parties and their respective legal representatives, successors and permitted assigns.

     13.6 Headings. Section and subsection headings are inserted for convenience of
reference only and do not form a part of this Agreement.

     13.7 Counterparts. This Agreement may be executed simultaneously in two or more
counterparts, each of which shall be deemed an original and both of which, together, shall
constitute a single agreement.

     13.8 Amendment; Waiver. This Agreement may be amended, modified, superseded or
cancelled, and any of the terms of this Agreement may be waived, only by a written instrument
executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The
delay or failure of either Party at any time or times to require performance of any provisions
shall in no manner affect the rights at a later time to enforce the same. No waiver by either
Party of any

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

68

 

condition or of the breach of any term contained in this Agreement, whether by conduct, or
otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or
continuing waiver of any such condition or of the breach of such term or any other term of this
Agreement.

     13.9 No Third Party Beneficiaries. Except as set forth in Sections 12.1, 12.2 and
12.3, no Third Party (including, without limitation, employees of either Party) shall have or
acquire any rights by reason of this Agreement.

     13.10 Purposes and Scope. The Parties hereto understand and agree that this
Collaboration is limited to the activities, rights and obligations as set forth in this Agreement.
Nothing in this Agreement shall be construed (a) to create or imply a general partnership between
the Parties, (b) to make either Party the agent of the other for any purpose, (c) to alter, amend,
supersede or vitiate any other arrangements between the Parties with respect to any subject matters
not covered hereunder, (d) to give either Party the right to bind the other, (e) to create any
duties or obligations between the Parties except as expressly set forth herein, or (f) to grant any
direct or implied licenses or any other right other than as expressly set forth herein.

     13.11 Assignment and Successors. Neither this Agreement nor any obligation of a Party
hereunder may be assigned by either Party without the consent of the other which shall not be
unreasonably withheld, except that each Party may assign this Agreement and the rights, obligations
and interests of such Party, in whole or in part, to any of its Affiliates, to any purchaser of all
or substantially all of its assets or all or substantially all of its assets to which this
Agreement relates or to any successor corporation resulting from any merger, consolidation, share
exchange or other similar transaction, provided that such Affiliate agrees in writing to be bound
by the terms and conditions of this Agreement.

     13.12 Force Majeure. Neither TAKEDA nor ARCHEMIX shall be liable for failure of or
delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach
of its obligations, if such failure or delay is due to a Force Majeure. In event of such Force
Majeure, the Party affected shall use reasonable efforts to cure or overcome the same and resume
performance of its obligations hereunder.

     13.13 Interpretation. The Parties hereto acknowledge and agree that: (a) each Party
and its counsel reviewed and negotiated the terms and provisions of this Agreement and have
contributed to its revision; (b) the rule of construction to the effect that any ambiguities are
resolved against the drafting Party shall not be employed in the interpretation of this Agreement;
and (c) the terms and provisions of this Agreement shall be construed fairly as to each Party and
not in a favor of or against either Party, regardless of which Party was generally responsible for
the preparation of this Agreement.

     13.14 Integration; Severability. This Agreement is the entire agreement with respect
to the subject matter hereof and supersedes all other agreements and understandings between the
Parties with respect to such subject matter. If any provision of this Agreement is or becomes
invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it
is the intention of the Parties that the remainder of the Agreement shall not be affected.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

69

 

     13.15 Further Assurances. Each of ARCHEMIX and TAKEDA agrees to duly execute and
deliver, or cause to be duly executed and delivered, such further instruments and do and cause to
be done such further acts and things, including, without limitation, the filing of such additional
assignments, agreements, documents and instruments, as the other Party may at any time and from
time to time reasonably request in connection with this Agreement or to carry out more effectively
the provisions and purposes of, or to better assure and confirm unto such other Party its rights
and remedies under, this Agreement.

[Remainder of page intentionally left blank.]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

70

 

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives.

	 	 	 	 	 	 	 
	 	 	ARCHEMIX CORP.
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	TAKEDA PHARMACEUTICAL COMPANY LIMITED.
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

71

 

SCHEDULE 1

OPTIMIZED LEAD COMPOUND SELECTION CRITERIA

[***]

	 	 	 	 	 
	Property	 	Target	 	 
	[***]	 	[***] for [***] is [***].
	 
	 	 	 	 
	[***]

	 	 	 	•     Aptamer [***] in [***] with an [***].

	 

	 	 	 	•     Aptamer [***] in [***] with an [***].

	 
	 	 	 	 
	[***]	 	Aptamer [***] and [***] for the [***].
	 

	 	 	 	•     Aptamer [***] or [***], as [***].

	 

	 	 	 	•     Aptamer [***] with [***]. In the [***], a [***] aptamer will
be [***].

	 
	 	 	 	 
	[***]	 	Aptamer [***] (e.g., [***] in [***] and [***] in [***] upon the
[***].
	[***]	 	Aptamer can be [***] with [***].
	[***]	 	Aptamer can be [***] for [***] as a [***] at [***] without [***]
of [***] and with [***] and [***].
	[***]	 	Aptamer [***] to [***] in [***].
	 

	 	 	 	•     To [***] a [***]

	 

	 	 	 	or
	 

	 	 	 	•     Aptamer is [***] at a [***] (to be [***] in [***]) for a
[***] that would [***] to [***] in [***].

	 
	 	 	 	 
	[***]	 	Aptamer [***] in [***] is [***] for the [***].
	 

	 	 	 	•     [***]

	 

	 	 	 	•     [***]

	 

	 	 	 	•     [***]

	 

	 	 	 	N.B.: [***] for [***] have [***] be [***] for these [***].

[***]

	 	 	 	 	 
	Property	 	Target	 	 
	[***]	 	[***] for [***] is [***].
	 
	 	 	 	 
	[***]

	 	 	 	•     Aptamer [***] as [***] either an [***] or an [***] with an
[***].

	 

	 	 	 	•      Aptamer [***] in a [***] with an [***].

	 
	 	 	 	 
	[***]	 	Aptamer [***] and [***] for the [***].
	 

	 	 	 	•      Aptamer [***] as [***] by [***].

	 

	 	 	 	•     Aptamer [***] with [***] to [***] of [***]; not [***] for [***].

	 
	 	 	 	 
	[***]	 	Aptamer [***] (e.g., [***] in [***] and [***] in [***] upon the
[***].
	 
	 	 	 	 
	[***]	 	Aptamer can be [***] with [***].

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

 

 

	 	 	 	 	 
	Property	 	Target	 	 
	[***]	 	Aptamer can be [***] for [***] as a [***] or [***] at [***] of
[***] and with [***] and [***].
	 
	 	 	 	 
	[***]	 	Aptamer [***] to s[***] in [***].
	 

	 	 	 	•     To [***] a [***]

	 

	 	 	 	or
	 

	 	 	 	•     Aptamer is [***] at a [***] (to be [***] in [***]) for a
[***] that would [***] to [***] in [***].

	 
	 	 	 	 
	[***]	 	Aptamer [***] in [***] is [***] for the [***].
	 

	 	 	 	•     [***]

	 

	 	 	 	•     [***]

	 

	 	 	 	•     [***]

	 

	 	 	 	N.B.: [***] for [***] have [***] be [***] for these [***].

[***]

	 	 	 	 	 
	Property	 	Target	 	 
	[***]	 	[***] for [***] is [***].
	 
	 	 	 	 
	[***]

	 	 	 	•      Aptamer [***] in a [***] with an [***].

	 

	 	 	 	•      Aptamer [***] in [***] with an [***].

	 
	 	 	 	 
	[***]	 	Aptamer [***] and [***] for the [***].
	 

	 	 	 	•     Aptamer [***] to [***] and [***] with [***]

	 

	 	 	 	•     [***] to [***] and [***] is [***] not [***].

	 

	 	 	 	•     Aptamer is [***] for [***] more than [***] to [***].

	 
	 	 	 	 
	[***]	 	Aptamer [***] (e.g., [***] in [***] and [***] in [***] upon the [***].
	 
	 	 	 	 
	[***]	 	Aptamer can be [***] with [***].
	[***]	 	Aptamer can be [***] for [***] as a [***] at [***] without loss of
[***] and with [***] and [***].
	[***]	 	Aptamer [***] to [***] in [***].
	 

	 	 	 	•     To [***] a [***]

	 

	 	 	 	or
	 

	 	 	 	•     Aptamer is [***] at a [***] (to be [***] in [***] for a [***]
that would [***] to [***] in [***].

	 
	 	 	 	 
	[***]	 	Aptamer [***] in [***] is [***] for the [***].
	 

	 	 	 	•     [***]

	 

	 	 	 	•     [***]

	 

	 	 	 	•     [***]

	 

	 	 	 	N.B.: [***] for [***] have [***] be [***] for these [***].

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

2

 

SCHEDULE 2A

PROGRAM TARGETS

	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

Sched. 2A-1 

 

SCHEDULE 2B

TARGET REPLACEMENT LIST

	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

Sched. 2B-1 

 

SCHEDULE 3

LICENSED PATENT RIGHTS (7/17 comments: Can we delete this schedule entirely not to make

possible third party (competitor / generic manufacturers) to evaluate the patent portfolio very

easily ?) (The short answer is “no” — John, let me know if you would like to discuss this

further.)

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

Sched. 3-1 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

2 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

3 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

4 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

5 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

6 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

7 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

8 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

9 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

10 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

11 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

12 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

13 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

14 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	     No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

15 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

16 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

17 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

18 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

19 

 

SCHEDULE 4

EXCLUDED APTAMERS

	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

Sched. 4- 1 

 

SCHEDULE 5

FORM OF PRESS RELEASE

Archemix and Takeda to Enter into Collaboration for Discovery and Development of Aptamer
Therapeutics

CAMBRIDGE, Mass. and OSAKA, Japan – June 11, 2007 – Archemix Corp. (“Archemix”) and Takeda
Pharmaceutical Company Limited (“Takeda”) announced today that both parties have signed a
multi-year, three target agreement that focuses on the discovery, development, and
commercialization of first-in-class aptamer-based therapeutics.

Under the agreement, Archemix will receive an upfront payment of $6 million from Takeda to discover
and generate product candidates to three disease-associated targets identified by Takeda, and
Takeda will be granted an exclusive, worldwide right for research, development, manufacturing and
commercialization for any resulting aptamer-based products. Archemix will also receive committed
research funding and research and clinical development milestone payments for each target selected
for therapeutic development. In addition, Archemix will earn royalties and milestones on worldwide
sales of the developed aptamers commercialized by Takeda. Detailed financial terms were not
disclosed.

“Our alliance with Takeda is the sixth major partnership we have formed over within the past year
and is a major step in the continued validation of aptamer therapeutics,” said Errol De Souza,
Ph.D., President and CEO, Archemix. “Takeda is an excellent partner for Archemix and this
collaboration is a key component of successfully implementing our strategy of forming
collaborations with multi national pharmaceutical companies to rapidly advance aptamer programs
into clinical development.”

“We are very impressed with Archemix’ track record of success in creating therapeutic aptamers,”
said Dr. Shigenori Ohkawa, General manager of Pharmaceutical Research Division, Takeda. “Archemix
is the leader in the discovery of aptamer therapeutics and we believe that, as a class, aptamers
have the potential to create a new paradigm of treatments in a broad spectrum of diseases, and we
believe this collaboration will surely contribute to enhancing our R&D pipeline as source for
future growth of Takeda.”

About Aptamers

Aptamers are single-stranded nucleic acids that form well-defined three dimensional shapes,
allowing them to bind target molecules in a manner that is conceptually similar to antibodies.
Aptamers combine the optimal characteristics of small molecules and antibodies, including high
specificity and affinity, chemical stability, low immunogenicity and the ability to target protein-

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

2 

 

protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized
rather than biologically expressed.

About Archemix

Archemix Corp. is a privately-held biopharmaceutical company developing aptamers as a class of
directed therapeutics for the prevention and treatment of human disease. The company is leveraging
its proprietary drug discovery technology to fuel the growth of its development portfolio, which is
primarily focused on acute cardiovascular and hematology diseases and cancer. Archemix’s broad
product pipeline, being developed both by the company as well as its licensees, includes multiple
investigational compounds at various stages of development, several of which are moving into Phase
2 clinical trials. Archemix’s lead proprietary product, ARC1779, a selective platelet inhibitor,
is anticipated to start a Phase 2a and Phase 1b clinical trial before the end of 2007. Archemix’
leadership position in intellectual property, technology and expertise relating to aptamers has
enabled it to form numerous collaborations with biotechnology and pharmaceutical collaborators,
including Merck Serono, Pfizer Inc., Elan Pharma, Nuvelo, Inc., Antisoma plc., and Regado
Biosciences. For more information, please visit
www.archemix.com.

About Takeda

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on
pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of
the industry, Takeda is committed to striving toward better health for individuals and progress in
medicine by developing superior pharmaceutical products. Takeda is actively dedicated to enhance
its pipeline for future growth through alliance as well as in-house R&D activities. Additional
information about Takeda is available through its corporate website,
www.takeda.com.

	 	 	 
	Contacts:

	 	Archemix Corp.
	 

	 	MEDIA CONTACTS
	 

	 	For Archemix:
	 

	 	Kathryn Morris
	 

	 	Yates and Associates
	 

	 	Tel: 914-204-6412
	 
	 	 
	 

	 	INVESTOR CONTACTS
	 

	 	Lilian Stern
	 

	 	Stern Investor Relations, Inc.
	 

	 	Tel: 212-362-1200
	 

	 	lilian@sternir.com
	 
	 	 
	 

	 	Takeda Pharmaceutical Company Limited
	 

	 	Corporate Communications Dept. (PR/IR)
	 

	 	Mr. Seizo Masuda
	 

	 	Tel: +81-3-3278-2037
	 

	 	Masuda_Seizo@takeda.co.jp

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

3 

 

SCHEDULE 6

PROGRAM CHEMISTRY

	 	 	 
	Modification	 	Anticipated effect
	[***]
	 	[***]
	[***]
	 	[***]
	[***]
	 	[***]
	[***]
	 	[***]
	[***]
	 	[***]
	[***]
	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

Sched. 6- 1 

 

SCHEDULE 7

LIGANDS TO PROGRAM TARGETS/PRE-APPROVED REPLACEMENT TARGETS

	 	 	 
	[***]
	 	[***]
	[***]
	 	[***]
	[***]
	 	[***]
	Pre-approved Replacement Targets
	[***]
	 	[***]
	[***]
	 	[***]
	[***]
	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to
the Company's application requesting confidential treatment under Rule 406 of the Securities Act.

Sched. 7- 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]